Processing 00000000.tx.1: Outbreak of Hepatitis C Virus Infection in Patients With Hematologic Disorders Treated With Intravenous Immunoglobulins: Different Prognosis According to the Immune Status By Giuseppe Rossi, Alessandra Tucci, Elisabetta Cariani, Antonella Ravaggi, Angelo Rossini, and Enrico Radaeli From the Sezione Ematologia, III Laboratorio Analisi, III Divisione Medicina Generale, Spedali Civili, Brescia, Italy.  

Phrase: "Outbreak of Hepatitis C Virus Infection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0012652:outbreak [Phenomenon or Process]

Phrase: "in Patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "With Hematologic Disorders"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0018939:HEMATOLOGIC DISORDERS [Disease or Syndrome]
   861   C0012634:Disorders [Disease or Syndrome]

Phrase: "Treated With Intravenous Immunoglobulins"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   833   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   833   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   770   C0348016:Intravenous [Spatial Concept]
   770   C1522326:Treated [Functional Concept]
   737 E C1292734:TREAT [Functional Concept]
   737 E C1621846:immunoglobulin [Molecular Function]

Phrase: ":"

Phrase: "Different Prognosis According to the Immune Status"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0033325:Prognosis [Health Care Activity]

Phrase: "By Giuseppe Rossi,"

Phrase: "Alessandra Tucci,"

Phrase: "Elisabetta Cariani,"

Phrase: "Antonella Ravaggi,"

Phrase: "Angelo Rossini,"

Phrase: "and"

Phrase: "Enrico Radaeli From the Sezione Ematologia,"

Phrase: "III Laboratorio Analisi,"

Phrase: "III Divisione Medicina Generale,"

Phrase: "Spedali Civili,"

Phrase: "Brescia,"

Phrase: "Italy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]
Processing 00000000.tx.2: ABSTRACT Abstract Introduction Methods Results Discussion References The influence of immunodeficiency on the course of hepatitis C virus (HCV) infection is still debated, although a worsening effect has been suggested. 

Phrase: "ABSTRACT Abstract Introduction Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0557061:Discussion [Therapeutic or Preventive Procedure]
   799   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The influence of immunodeficiency"

Phrase: "on the course"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750729:Course [Temporal Concept]

Phrase: "of hepatitis C virus (HCV) infection"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   923   C0019196:Hepatitis C Infection [Disease or Syndrome]
   861   C0042769:virus infection [Disease or Syndrome]
   812   C0009450:Infection, NOS [Disease or Syndrome]
   756   C0220847:Hepatitis C virus [Virus]
   741 E C0439663:Infected [Functional Concept]
   708   C0019186:Hepatitis virus [Virus]
   701 E C0030657:infectivity [Qualitative Concept]

Phrase: "is"

Phrase: "still"

Phrase: "debated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0870392:debate [Activity]

Phrase: ","

Phrase: "although"

Phrase: "a worsening effect"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1280500:Effect [Qualitative Concept]
   861   C2348382:Effect [Qualitative Concept]

Phrase: "has"

Phrase: "been"

Phrase: "suggested."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]
Processing 00000000.tx.3: We compared the characteristics of hepatitis C in two groups of hematologic patients with different levels of immunocompetence who acquired the same virus strain after treatment with contaminated intravenous immunoglobulins (IVIG). 

Phrase: "We"

Phrase: "compared"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1707455:Compared [Activity]

Phrase: "the characteristics of hepatitis C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1521970:Characteristics [Qualitative Concept]

Phrase: "in two groups"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1552839:groups [Idea or Concept]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "of hematologic patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "with different levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "of immunocompetence"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0020987:Immunocompetence [Cell Function]
   928 E C1512656:Immunocompetent [Clinical Attribute]

Phrase: "who"

Phrase: "acquired"
Meta Candidates (Total=8; Excluded=6; Pruned=0; Remaining=2)
  1000   C0439661:Acquired [Temporal Concept]
  1000   C3245488:acquired [Intellectual Product]
   966 E C1706701:Acquire [Activity]
   928 E C1517378:Gain [Quantitative Concept]
   907 E C0205217:Increased [Quantitative Concept]
   907 E C0442805:Increase [Functional Concept]
   907 E C0442808:Increasing [Functional Concept]
   907 E C1301820:Obtain [Functional Concept]

Phrase: "the same virus strain after treatment"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0080194:Strain [Injury or Poisoning]
   753   C0456178:strain [Intellectual Product]
   753   C1518614:Strain [Organism]
   753   C2987481:Strain [Mental Process]

Phrase: "with contaminated intravenous immunoglobulins (IVIG)."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   901   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   827   C0348016:Intravenous [Spatial Concept]
   793 E C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.4: Indications for IVIG therapy were idiopathic thrombocytopenic purpura (ITP) in six patients and hypogammaglobulinemia in 7 patients with various hematologic disorders, who were defined immunodeficient (ID). 

Phrase: "Indications for IVIG therapy"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0392360:Indications [Idea or Concept]
   726 E C3146298:Indication [Functional Concept]

Phrase: "were"

Phrase: "idiopathic thrombocytopenic purpura (ITP) in six patients"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   790   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   790   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   753   C0034150:Purpura [Disease or Syndrome]
   753   C0332240:Idiopathic [Functional Concept]
   753   C3463943:Purpura [Eukaryote]

Phrase: "and"

Phrase: "hypogammaglobulinemia in 7 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0086438:Hypogammaglobulinaemia [Disease or Syndrome]

Phrase: "with various hematologic disorders,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0018939:HEMATOLOGIC DISORDERS [Disease or Syndrome]
   827   C0012634:Disorders [Disease or Syndrome]

Phrase: "who"

Phrase: "were"

Phrase: "defined"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1704788:Defined [Conceptual Entity]
  1000   C3539106:Defined [Intellectual Product]

Phrase: "immunodeficient (ID)."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021051:Immunodeficient [Disease or Syndrome]
Processing 00000000.tx.5: Infection rate was 100%. 

Phrase: "Infection rate"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   861   C0009450:Infection, NOS [Disease or Syndrome]
   861   C0871208:Rate [Activity]
   861   C1521828:Rate [Quantitative Concept]
   789 E C0439663:Infected [Functional Concept]
   750 E C0030657:infectivity [Qualitative Concept]

Phrase: "was"

Phrase: "100%."
Processing 00000000.tx.6: Five ID patients never developed HCV antibodies despite serum HCV-RNA positivity. 

Phrase: "Five ID patients never developed HCV antibodies"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   849   C0166049:Hepatitis C Virus Antibodies [Immunologic Factor]
           Hepatitis C Antibodies
   832 E C0201487:Hepatitis C Virus Antibody [Laboratory Procedure]
   829   C0019161:Hepatitis Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   791   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   758 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "despite serum HCV-RNA positivity."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   734   C0369335:Hepatitis C virus RNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   727   C0439178:% Positive [Quantitative Concept]
   727   C1446409:Positive [Qualitative Concept]
   727   C1514241:Positive [Finding]
   727   C2825490:Positive [Qualitative Concept]
   700   C0019169:Serum hepatitis virus [Virus]
   700   C0855840:hepatitis c rna [Laboratory Procedure]
Processing 00000000.tx.7: The same HCV genotype was shown in 10 patients tested. 

Phrase: "The same HCV genotype"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   937   C1148363:Hepatitis C virus genotype [Finding]
   937   C1533728:Hepatitis C virus genotype [Laboratory Procedure]
   804   C0017431:Genotype [Organism Attribute]
   717   C0220847:Hepatitis C virus [Virus]

Phrase: "was"

Phrase: "shown in 10 patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0030705:Patients [Patient or Disabled Group]
   737   C1547282:Show [Intellectual Product]

Phrase: "tested."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392366:tested [Intellectual Product]
   966 E C0022885:Test [Laboratory Procedure]
   966 E C0039593:Test [Functional Concept]
Processing 00000000.tx.8: Moreover, E1-E2 gene partial nucleotide sequencing, performed in four patients, showed identical or closely related amino acid sequences, thus strongly supporting the hypothesis of a common source of infection. 

Phrase: "Moreover,"

Phrase: "E1-E2 gene partial nucleotide sequencing,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   858   C1294197:Gene Sequencing [Laboratory Procedure]
   827   C0004793:nucleotide sequencing [Nucleotide Sequence]
   799   C1553778:Sequencing [Intellectual Product]
   799   C1561491:Sequencing [Functional Concept]

Phrase: "performed in four patients,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0205450:Four [Quantitative Concept]
   770   C0884358:Performed [Functional Concept]
   737 E C2947996:Perform [Pharmacologic Substance]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "identical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205280:Identical [Qualitative Concept]

Phrase: "or"

Phrase: "closely"

Phrase: "related"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0439849:Related [Qualitative Concept]
  1000   C0445223:Related [Finding]
   966 E C0163712:Relate [Organic Chemical]

Phrase: "amino acid sequences,"
Meta Candidates (Total=11; Excluded=5; Pruned=0; Remaining=6)
  1000   C0002518:Sequences, Amino Acid [Amino Acid Sequence]
   901   C0002520:Amino acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   901   C2917660:Amino Acid [Pharmacologic Substance]
   827   C0001128:Acid [Chemical]
   827   C0162326:Sequences [Nucleotide Sequence]
   827   C0202406:Acid [Laboratory Procedure]
   793 E C0004793:Sequence [Nucleotide Sequence]
   793 E C0162327:Sequence [Nucleotide Sequence]
   793 E C1519249:Sequence [Functional Concept]
   743 E C1548958:Sequential [Idea or Concept]
   743 E C1705294:Sequential [Qualitative Concept]

Phrase: "thus strongly"

Phrase: "supporting"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0183683:Support [Medical Device]
   966   C1521721:Support [Conceptual Entity]

Phrase: "the hypothesis of a common source of infection."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C1512571:Hypothesis [Idea or Concept]
Processing 00000000.tx.9: Clinical acute infection did not differ significantly between the two groups, but subsequent liver failure developed in five of the seven ID patients and in none of the ITP patients (P = .04). 

Phrase: "Clinical acute infection"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   913   C0275521:Clinical infection [Disease or Syndrome]
   901   C0275518:Acute infection [Disease or Syndrome]
   827   C0009450:Infection, NOS [Disease or Syndrome]
   755 E C0439663:Infected [Functional Concept]
   716 E C0030657:infectivity [Qualitative Concept]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "differ"

Phrase: "significantly between the two groups,"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   760   C0205448:Two [Quantitative Concept]
   760   C0441833:Group [Idea or Concept]
   760   C0687744:group [Population Group]
   760   C1257890:Group [Population Group]
   760   C1552516:Group [Health Care Related Organization]
   760   C1552839:groups [Idea or Concept]
   760   C1705428:Group [Conceptual Entity]
   760   C1705429:Group [Population Group]

Phrase: "but"

Phrase: "subsequent liver failure"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0085605:Liver Failure [Disease or Syndrome]
   827   C0231174:Failure [Functional Concept]
   827   C0680095:failure [Individual Behavior]

Phrase: "developed in five of the seven ID patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   744   C0021051:Immunodeficient [Disease or Syndrome]
   744   C0030705:Patients [Patient or Disabled Group]
   744   C0205451:Five [Quantitative Concept]
   744   C0205453:Seven [Quantitative Concept]

Phrase: "and in none of the ITP patients"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   790   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   764   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   764   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   742   C0030705:Patients [Patient or Disabled Group]
   742   C0034150:Purpura [Disease or Syndrome]
   742   C0332240:Idiopathic [Functional Concept]
   742   C0456148:None [Quantitative Concept]
   742   C0549184:None [Quantitative Concept]
   742   C1515981:And [Idea or Concept]
   742   C3463943:Purpura [Eukaryote]

Phrase: "(P = .04"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.10: Liver biopsy, performed in three cases, documented HCV as the only cause of liver damage. 

Phrase: "Liver biopsy,"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
  1000   C0193388:Liver Biopsy [Diagnostic Procedure]
   861   C0005558:Biopsy [Diagnostic Procedure]
   861   C0023884:Liver [Body Part, Organ, or Organ Component]
   861   C0220797:biopsy [Functional Concept]
   861   C0736268:LIVER [Body Part, Organ, or Organ Component]
   861   C1278929:Liver [Body Part, Organ, or Organ Component]
   861   C2346688:LIVER [Food]
   805 E C0205054:Hepatic [Body Location or Region]

Phrase: "performed in three cases,"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   770   C0205449:Three [Quantitative Concept]
   770   C0868928:Cases [Functional Concept]
   770   C0884358:Performed [Functional Concept]
   770   C1533148:Cases [Quantitative Concept]
   737 E C1706255:CASE [Medical Device]
   737 E C1706256:Case [Conceptual Entity]
   737 E C2947996:Perform [Pharmacologic Substance]

Phrase: "documented HCV as the only"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   814   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   778   C0019196:Hepatitis C [Disease or Syndrome]
   774   C0019186:Hepatitis virus [Virus]
   774   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   748   C0019158:Hepatitis [Disease or Syndrome]
   748   C0019159:hepatitis [Disease or Syndrome]
   748   C0042776:Virus [Virus]
   748   C0319157:virus [Virus]
   748   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "cause of liver damage."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   833   C0151763:Liver damage [Pathologic Function]
   770   C0010957:Damage [Injury or Poisoning]
   770   C0015127:cause [Functional Concept]
   770   C0023884:Liver [Body Part, Organ, or Organ Component]
   770   C0736268:LIVER [Body Part, Organ, or Organ Component]
   770   C1278929:Liver [Body Part, Organ, or Organ Component]
   770   C1524003:Cause [Conceptual Entity]
   770   C1883709:Damage [Functional Concept]
   770   C2346688:LIVER [Food]
   715 E C0205054:Hepatic [Body Location or Region]
Processing 00000000.tx.11: Six ID patients died, with liver disease being the primary cause of death in four cases and a contributory cause in two cases. 

Phrase: "Six ID patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "died"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
  1000   C0011065:Died [Organism Function]
  1000   C1546956:Died [Finding]
   928 E C0231800:Expired [Organ or Tissue Function]
   928 E C1704631:Expire [Idea or Concept]
   907 E C0184532:dying [Organism Function]
   907 E C1553404:terminated [Idea or Concept]
   907 E C2348570:Terminated [Functional Concept]

Phrase: ","

Phrase: "with liver disease"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
  1000   C0023895:Liver disease [Disease or Syndrome]
   861   C0012634:Disease [Disease or Syndrome]
   861   C0023884:Liver [Body Part, Organ, or Organ Component]
   861   C0736268:LIVER [Body Part, Organ, or Organ Component]
   861   C1278929:Liver [Body Part, Organ, or Organ Component]
   861   C2346688:LIVER [Food]
   805 E C0205054:Hepatic [Body Location or Region]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "being"

Phrase: "the primary cause of death"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   926   C3262229:Primary Cause of Death [Finding]
   926   C3537403:Primary cause of death [Finding]
   862   C0007465:Cause of Death [Finding]
           Death Cause
   862   C0804771:Cause of death [Clinical Attribute]
   760   C0015127:cause [Functional Concept]
   760   C0205225:Primary [Qualitative Concept]
   760   C0439631:Primary [Therapeutic or Preventive Procedure]
   760   C1524003:Cause [Conceptual Entity]

Phrase: "in four cases"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0868928:Cases [Functional Concept]
   861   C1533148:Cases [Quantitative Concept]
   827 E C1706255:CASE [Medical Device]
   827 E C1706256:Case [Conceptual Entity]

Phrase: "and"

Phrase: "a contributory cause in two cases."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0015127:cause [Functional Concept]
   753   C1524003:Cause [Conceptual Entity]
Processing 00000000.tx.12: Their median survival after IVIG was 12 months, significantly worse than that of ITP patients (P = .0028). 

Phrase: "Their median survival after IVIG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0038952:Survival [Activity]
   753   C0220921:survival [Functional Concept]

Phrase: "was"

Phrase: "12 months,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "significantly worse than that of ITP patients"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   742   C0332271:worse [Qualitative Concept]
   742   C1279889:Worse [Finding]
   742   C1457868:Worse [Qualitative Concept]
   708 E C0205169:Bad [Qualitative Concept]
   708 E C0231218:Ill [Sign or Symptom]

Phrase: "(P = .0028"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.13: We conclude that immunodeficiency markedly worsens the course of IVIG-acquired HCV infection in hematologic patients.  

Phrase: "We"

Phrase: "conclude"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0917903:conclude [Biomedical or Dental Material,Organic Chemical]

Phrase: "that immunodeficiency markedly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0021051:IMMUNO-DEFICIENCY [Disease or Syndrome]

Phrase: "worsens"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332271:worsen [Qualitative Concept]
  1000   C1279889:worsen [Finding]

Phrase: "the course of IVIG-acquired HCV infection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C0750729:Course [Temporal Concept]

Phrase: "in hematologic patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.14: INTRODUCTION Abstract Introduction Methods Results Discussion References HEPATITIS C VIRUS (HCV) infection is a known complication of transfusions of blood products, including intravenous immunoglobulins (IVIG). 

Phrase: "INTRODUCTION Abstract Introduction Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0557061:Discussion [Therapeutic or Preventive Procedure]
   799   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "HEPATITIS C VIRUS"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   913   C0019186:Hepatitis virus [Virus]
   901   C0019196:Hepatitis C [Disease or Syndrome]
   827   C0019158:Hepatitis [Disease or Syndrome]
   827   C0019159:hepatitis [Disease or Syndrome]
   827   C0042776:Virus [Virus]
   827   C0319157:virus [Virus]
   827   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "(HCV"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   913   C0019186:Hepatitis virus [Virus]
   901   C0019196:Hepatitis C [Disease or Syndrome]
   827   C0019158:Hepatitis [Disease or Syndrome]
   827   C0019159:hepatitis [Disease or Syndrome]
   827   C0042776:Virus [Virus]
   827   C0319157:virus [Virus]
   827   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: ")"

Phrase: "infection"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0009450:Infection, NOS [Disease or Syndrome]
   928 E C0439663:Infected [Functional Concept]
   888 E C0030657:infectivity [Qualitative Concept]

Phrase: "is"

Phrase: "a known complication of transfusions of blood products,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   807   C0274435:Complication of blood transfusion [Pathologic Function]
           blood complication transfusion
   744   C0009566:Complication [Pathologic Function]
   744   C2362589:Complication [Idea or Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "intravenous immunoglobulins"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]

Phrase: "(IVIG"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]

Phrase: ")."
Processing 00000000.tx.15: The clinical course and the prognosis of posttransfusion HCV hepatitis, as well as the pathogenetic mechanisms of hepatocellular damage, including the role of the immune system, are still debated.1-4 Several reports have suggested a worsening effect of immunodeficiency, either congenital, human immunodeficiency virus (HIV)-linked, or pharmacologically mediated,5-8 on the severity of hepatitis C. 

Phrase: "The clinical course"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0449259:Clinical course [Temporal Concept]
   861   C0205210:Clinical [Qualitative Concept]
   861   C0750729:Course [Temporal Concept]

Phrase: "and"

Phrase: "the prognosis of posttransfusion HCV hepatitis,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   744   C0033325:Prognosis [Health Care Activity]

Phrase: "as well as"

Phrase: "the pathogenetic mechanisms of hepatocellular damage,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0441712:Mechanisms [Functional Concept]
   719 E C1706376:Mechanism [Manufactured Object]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "the role of the immune system,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "are"

Phrase: "still"

Phrase: "debated.1-4 Several reports"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   804   C0684224:Reports [Intellectual Product]
   804   C0700287:reports [Health Care Activity]
   771 E C3273238:Report [Intellectual Product]

Phrase: "have"

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "a worsening effect of immunodeficiency,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C1280500:Effect [Qualitative Concept]
   760   C2348382:Effect [Qualitative Concept]

Phrase: "either congenital, human immunodeficiency virus (HIV)-linked,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   766   C1517892:Link [Intellectual Product]
   766   C1704666:Link [Intellectual Product]

Phrase: "or"

Phrase: "pharmacologically"

Phrase: "mediated"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0086597:mediated [Social Behavior]
  1000   C0127400:Mediated [Organic Chemical,Pharmacologic Substance]

Phrase: ","

Phrase: "5-8 on the severity of hepatitis C."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   770   C0019196:Hepatitis C [Disease or Syndrome]
   770   C0220847:Hepatitis C [Virus]
   744   C0019158:Hepatitis [Disease or Syndrome]
   744   C0019159:hepatitis [Disease or Syndrome]
   744   C0439084:>5 [Quantitative Concept]
   744   C0439793:Severity [Qualitative Concept]
   744   C0728893:+5 [Quantitative Concept]
   744   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   744   C2983285:Severity [Intellectual Product]
Processing 00000000.tx.16: We had the opportunity of observing a group of patients with different hematologic disorders, in which infection with the same strain of HCV was accidentally transmitted through the administration of a preparation of anti-HCV antibody-screened IVIG that was associated with reports of acute hepatitis C outbreak.9 Because our patients had different degrees of immunocompetence, we could comparatively analyze the effects of an impaired immune system on the clinical course of hepatitis C. 

Phrase: "We"

Phrase: "had"

Phrase: "the opportunity of observing"

Phrase: "a group of patients"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0441835:a group [Classification]
   770   C0441833:Group [Idea or Concept]
   770   C0687744:group [Population Group]
   770   C1257890:Group [Population Group]
   770   C1552516:Group [Health Care Related Organization]
   770   C1705428:Group [Conceptual Entity]
   770   C1705429:Group [Population Group]

Phrase: "with different hematologic disorders,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0018939:HEMATOLOGIC DISORDERS [Disease or Syndrome]
   827   C0012634:Disorders [Disease or Syndrome]

Phrase: "in which infection"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0009450:Infection, NOS [Disease or Syndrome]
   928 E C0439663:Infected [Functional Concept]
   888 E C0030657:infectivity [Qualitative Concept]

Phrase: "with the same strain"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0080194:Strain [Injury or Poisoning]
   861   C0456178:strain [Intellectual Product]
   861   C1518614:Strain [Organism]
   861   C2987481:Strain [Mental Process]

Phrase: "of HCV"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   913   C0019186:Hepatitis virus [Virus]
   901   C0019196:Hepatitis C [Disease or Syndrome]
   827   C0019158:Hepatitis [Disease or Syndrome]
   827   C0019159:hepatitis [Disease or Syndrome]
   827   C0042776:Virus [Virus]
   827   C0319157:virus [Virus]
   827   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "was"

Phrase: "accidentally"

Phrase: "transmitted through the administration of a preparation"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   748   C0001554:Administration [Occupational Activity]
   748   C0242781:Transmitted [Pathologic Function]
   748   C0332289:transmitted [Functional Concept]
   748   C0455052:Preparation [Health Care Activity]
   748   C1521797:Transmitted [Natural Phenomenon or Process]
   748   C1521827:Preparation [Functional Concept]
   748   C1533734:Administration [Therapeutic or Preventive Procedure]

Phrase: "of anti-HCV antibody-screened IVIG"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   812   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   793   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   793   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   793   C0348016:Intravenous [Spatial Concept]
   760 E C1621846:immunoglobulin [Molecular Function]

Phrase: "that"

Phrase: "was"

Phrase: "associated with reports of acute hepatitis C outbreak.9"
Meta Candidates (Total=16; Excluded=3; Pruned=0; Remaining=13)
   790   C0400914:Acute hepatitis C [Disease or Syndrome]
   764   C0019196:Hepatitis C [Disease or Syndrome]
   764   C0220847:Hepatitis C [Virus]
   764   C0267797:Acute hepatitis [Disease or Syndrome]
   764   C0332281:Associated with [Qualitative Concept]
           Associated
   742   C0012652:outbreak [Phenomenon or Process]
   742   C0019158:Hepatitis [Disease or Syndrome]
   742   C0019159:hepatitis [Disease or Syndrome]
   742   C0205178:acute [Temporal Concept]
   742   C0684224:Reports [Intellectual Product]
   742   C0700287:reports [Health Care Activity]
   742   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   708 E C0750490:Associate [Idea or Concept]
   708 E C1706221:Associate [Professional or Occupational Group]
   708 E C3273238:Report [Intellectual Product]

Phrase: "Because"

Phrase: "our patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "had"

Phrase: "different degrees of immunocompetence,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0449286:degrees [Quantitative Concept]
   770   C0542560:degrees [Intellectual Product]
   737 E C0441889:Degree [Qualitative Concept]
   737 E C1561545:degree [Quantitative Concept]
   737 E C2348088:Degree [Quantitative Concept]

Phrase: "we"

Phrase: "could"

Phrase: "comparatively"

Phrase: "analyze"

Phrase: "the effects of an impaired immune system"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   748   C1280500:effects [Qualitative Concept]
   714 E C2348382:Effect [Qualitative Concept]

Phrase: "on the clinical course"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0449259:Clinical course [Temporal Concept]
   861   C0205210:Clinical [Qualitative Concept]
   861   C0750729:Course [Temporal Concept]

Phrase: "of hepatitis C."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0019196:Hepatitis C [Disease or Syndrome]
  1000   C0220847:Hepatitis C [Virus]
   861   C0019158:Hepatitis [Disease or Syndrome]
   861   C0019159:hepatitis [Disease or Syndrome]
   861   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.17: We found that in hematologic patients with coexisting immunodeficiency, IVIG-induced HCV infection can frequently lead to irreversible liver failure, which markedly worsens their prognosis.  

Phrase: "We"

Phrase: "found"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0150312:Found [Quantitative Concept]
   966 E C0243095:Find [Finding]

Phrase: "that in hematologic patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0018943:Hematologic [Biomedical Occupation or Discipline]
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0205488:Haematologic [Functional Concept]

Phrase: "with coexisting immunodeficiency,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0021051:IMMUNO-DEFICIENCY [Disease or Syndrome]

Phrase: "IVIG-induced HCV infection"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   861   C0858744:induced infection [Disease or Syndrome]
   852   C0019196:Hepatitis C Infection [Disease or Syndrome]
   818   C0042769:virus infection [Disease or Syndrome]
   795   C0009450:Infection, NOS [Disease or Syndrome]
   724 E C0439663:Infected [Functional Concept]

Phrase: "can"

Phrase: "frequently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332183:Frequently [Temporal Concept]

Phrase: "lead to irreversible liver failure,"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   806   C0085605:Liver Failure [Disease or Syndrome]
   760   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   760   C0023884:Liver [Body Part, Organ, or Organ Component]
   760   C0231174:Failure [Functional Concept]
   760   C0680095:failure [Individual Behavior]
   760   C0736268:LIVER [Body Part, Organ, or Organ Component]
   760   C1278929:Liver [Body Part, Organ, or Organ Component]
   760   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   760   C1522538:Lead [Functional Concept]
   760   C2346688:LIVER [Food]
   760   C2348269:Lead [Element, Ion, or Isotope]
   760   C3275067:LEAD [Therapeutic or Preventive Procedure]
   704 E C0205054:Hepatic [Body Location or Region]

Phrase: "which markedly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0522501:Markedly [Qualitative Concept]

Phrase: "worsens"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332271:worsen [Qualitative Concept]
  1000   C1279889:worsen [Finding]

Phrase: "their prognosis."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0033325:Prognosis [Health Care Activity]
Processing 00000000.tx.18: PATIENTS AND METHODS Abstract Introduction Methods Results Discussion References During January and February 1994, a preparation of commercially available IVIG (Gammagard; Baxter Hyland Division, Rome, Italy) was available for use in our hematologic unit. 

Phrase: "PATIENTS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "AND"

Phrase: "METHODS Abstract Introduction Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0557061:Discussion [Therapeutic or Preventive Procedure]
   799   C2584313:Discussion [Social Behavior]

Phrase: "References During January"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1514811:Reference [Idea or Concept]
   790   C1706462:Reference [Conceptual Entity]

Phrase: "and"

Phrase: "February 1994,"

Phrase: "a preparation of commercially available IVIG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0455052:Preparation [Health Care Activity]
   748   C1521827:Preparation [Functional Concept]

Phrase: "(Gammagard"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086333:Gammagard [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "; Baxter Hyland Division,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C1293097:Division [Therapeutic or Preventive Procedure]
   827   C2919030:Division [Organization]
   827   C2919031:Division [Activity]

Phrase: "Rome,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0035831:Rome [Geographic Area]

Phrase: "Italy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]

Phrase: ")"

Phrase: "was"

Phrase: "available for use"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0470187:Available [Functional Concept]

Phrase: "in our hematologic unit."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0439148:Unit [Quantitative Concept]
   861   C1519795:Unit [Quantitative Concept]
   861   C1704753:Unit [Manufactured Object]
   861   C1880519:Unit [Quantitative Concept]
Processing 00000000.tx.19: The preparation was withdrawn worldwide on February 21, 1994 after reports of acute hepatitis C outbreaks both in Europe and the United States. 

Phrase: "The preparation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0455052:Preparation [Health Care Activity]
  1000   C1521827:Preparation [Functional Concept]

Phrase: "was"

Phrase: "withdrawn"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0424092:Withdrawn [Finding]
  1000   C2349954:Withdrawn [Activity]
  1000   C2825032:Withdrawn [Mental or Behavioral Dysfunction]

Phrase: "worldwide on February 21,"

Phrase: "1994 after reports of acute hepatitis C outbreaks"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   800   C0400914:Acute hepatitis C [Disease or Syndrome]
   770   C0019196:Hepatitis C [Disease or Syndrome]
   770   C0220847:Hepatitis C [Virus]
   770   C0267797:Acute hepatitis [Disease or Syndrome]
   744   C0012652:Outbreaks [Phenomenon or Process]
   744   C0019158:Hepatitis [Disease or Syndrome]
   744   C0019159:hepatitis [Disease or Syndrome]
   744   C0205178:acute [Temporal Concept]
   744   C0220888:outbreaks [Functional Concept]
   744   C0684224:Reports [Intellectual Product]
   744   C0700287:reports [Health Care Activity]
   744   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   711 E C3273238:Report [Intellectual Product]

Phrase: "both in Europe"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0015176:Europe [Geographic Area]
   790   C0238767:Both [Spatial Concept]
   790   C1706086:Both [Qualitative Concept]

Phrase: "and"

Phrase: "the United States."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0041703:United States [Geographic Area]
   861   C1301808:states [Geographic Area]
   827   C0166872:unite [Biomedical or Dental Material]
   827 E C1442792:State [Functional Concept]
   827 E C3148680:State [Geographic Area]
Processing 00000000.tx.20: Fourteen of the the 310 patients admitted to the unit during that period were treated with IVIG. 

Phrase: "Fourteen of the"

Phrase: "the 310 patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "admitted to the unit"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0184666:admitted [Health Care Activity]
   770   C0439148:Unit [Quantitative Concept]
   770   C1519795:Unit [Quantitative Concept]
   770   C1704753:Unit [Manufactured Object]
   770   C1880519:Unit [Quantitative Concept]

Phrase: "during"

Phrase: "that period"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0439531:/period [Temporal Concept]
  1000   C1948053:Period [Temporal Concept]
   928 E C0332182:Periodic [Temporal Concept]
   928 E C1706381:PERIODIC [Intellectual Product]
   900 E C0031084:Periodicities [Temporal Concept]

Phrase: "were"

Phrase: "treated with IVIG."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   833   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   833   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   770   C0348016:Intravenous [Spatial Concept]
   770   C1522326:Treated [Functional Concept]
   737 E C1292734:TREAT [Functional Concept]
   737 E C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.21: One had known serum anti-HCV antibody (Ab) positivity and was not further considered. 

Phrase: "One"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205447:One [Quantitative Concept]

Phrase: "had"

Phrase: "known serum anti-HCV antibody (Ab) positivity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   776   C0741132:antibody positive [Laboratory or Test Result]
   721   C0439178:% Positive [Quantitative Concept]
   721   C1446409:Positive [Qualitative Concept]
   721   C1514241:Positive [Finding]
   721   C2825490:Positive [Qualitative Concept]

Phrase: "and"

Phrase: "was"

Phrase: "not further"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C1517331:Further [Spatial Concept]
   861   C1518422:Not [Functional Concept]
   827 E C0205108:far [Spatial Concept]

Phrase: "considered."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]
Processing 00000000.tx.22: The 13 patients with negative (no. 10) or unknown (no. 3) serum anti-HCV Ab status at the time of IVIG infusion are the subject of the present report. 

Phrase: "The 13 patients with negative"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0030705:Patients [Patient or Disabled Group]

Phrase: "("

Phrase: "no. 10"

Phrase: ")"

Phrase: "or"

Phrase: "unknown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439673:Unknown [Qualitative Concept]

Phrase: "("

Phrase: "no. 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")"

Phrase: "serum anti-HCV Ab status at the time"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   799   C2708504:Hepatitis C virus status [Clinical Attribute]
   799   C2708505:Hepatitis C virus status [Finding]
   777   C0458071:Hepatitis C status [Finding]
   739   C0449438:Status [Qualitative Concept]

Phrase: "of IVIG infusion"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C0021440:Intravenous infusion [Therapeutic or Preventive Procedure]
   913   C1272892:Intravenous infusion [Biomedical or Dental Material]
   913   C1621368:Intravenous Infusion [Functional Concept]
   827   C0574032:Infusion [Therapeutic or Preventive Procedure]
   827   C1827465:Infusion [Functional Concept]
   734   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "are"

Phrase: "the subject of the present report."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0681850:Subject [Group]
   753   C1550501:{Subject} [Idea or Concept]
   753   C1706203:Subject [Idea or Concept]
   753   C2349001:Subject [Human]
   753   C2697811:Subject [Functional Concept]
Processing 00000000.tx.23: Indications for IVIG therapy were idiopathic thrombocytopenic purpura (ITP) in six patients and hypogammaglobulinemia in seven patients, who were defined as immunodeficient (ID), being affected either by chronic lymphoproliferative disorders (no. 5), common variable immunodeficiency (no. 1), or graft-versus-host disease after allogeneic marrow transplantation (no.1). 

Phrase: "Indications for IVIG therapy"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0392360:Indications [Idea or Concept]
   726 E C3146298:Indication [Functional Concept]

Phrase: "were"

Phrase: "idiopathic thrombocytopenic purpura"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   901   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   901   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   827   C0034150:Purpura [Disease or Syndrome]
   827   C0332240:Idiopathic [Functional Concept]
   827   C3463943:Purpura [Eukaryote]

Phrase: "(ITP"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   901   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   901   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   827   C0034150:Purpura [Disease or Syndrome]
   827   C0332240:Idiopathic [Functional Concept]
   827   C3463943:Purpura [Eukaryote]

Phrase: ")"

Phrase: "in six patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "hypogammaglobulinemia in seven patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0086438:Hypogammaglobulinaemia [Disease or Syndrome]

Phrase: "who"

Phrase: "were"

Phrase: "defined as immunodeficient"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0021051:Immunodeficient [Disease or Syndrome]
   790   C1704788:Defined [Conceptual Entity]
   790   C3539106:Defined [Intellectual Product]

Phrase: "(ID"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021051:Immunodeficient [Disease or Syndrome]

Phrase: ")"

Phrase: ","

Phrase: "being"

Phrase: "affected"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0392760:Affected [Functional Concept]
  1000   C1314939:Affected [Functional Concept]
   966 E C0001721:Affect [Mental Process]

Phrase: "either by chronic lymphoproliferative disorders"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C0024314:Lymphoproliferative Disorders [Neoplastic Process]
   797   C0008679:chronic disorders [Disease or Syndrome]
   760   C0012634:Disorders [Disease or Syndrome]
   760   C0205191:chronic [Temporal Concept]

Phrase: "("

Phrase: "no. 5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "common variable immunodeficiency"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0009447:Common Variable Immunodeficiency [Disease or Syndrome]
   827   C0021051:IMMUNO-DEFICIENCY [Disease or Syndrome]
   827   C0205214:Common [Quantitative Concept]
   827   C0439828:Variable [Qualitative Concept]
   827   C1522138:Common [Functional Concept]
   827   C3245511:common [Intellectual Product]

Phrase: "("

Phrase: "no. 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: ")"

Phrase: ","

Phrase: "or"

Phrase: "graft-versus-host disease after allogeneic marrow transplantation"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   833   C0018133:Graft-Versus-Host Disease [Disease or Syndrome]
   833   C2984293:Graft-versus-host disease [Functional Concept]
   767   C0002136:allogeneic disease [Disease or Syndrome]
   767   C0450127:Allogeneic graft [Biomedical or Dental Material]
   744   C0012634:Disease [Disease or Syndrome]
   744   C0181074:{Graft} [Biomedical or Dental Material]
   744   C0332835:Graft [Tissue]
   744   C1167395:Host [Organism]
   744   C1961139:Graft, NOS [Therapeutic or Preventive Procedure]

Phrase: "(no.1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1298908:no [Idea or Concept]
   861   C1549444:No [Idea or Concept]

Phrase: ")."
Processing 00000000.tx.24: The clinical characteristics of the patients are detailed in Table 1. 

Phrase: "The clinical characteristics of the patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0683325:clinical characteristics [Clinical Attribute]
   767   C0815172:patient characteristics [Clinical Attribute]
   753   C1521970:Characteristics [Qualitative Concept]

Phrase: "are"

Phrase: "detailed in Table 1."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   770   C0039224:Table [Manufactured Object]
   770   C1522508:Detailed [Qualitative Concept]
   770   C1706073:Table [Medical Device]
   770   C1706074:Table [Intellectual Product]
   737 E C1561567:detail [Functional Concept]
Processing 00000000.tx.25: Because the original batches of IVIG suspected for HCV contamination were not available, virologic tests were performed only on the serum of patients treated with IVIG.  

Phrase: "Because"

Phrase: "the original batches of IVIG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1550176:Batch [Idea or Concept]
   753   C1948031:Batch [Quantitative Concept]

Phrase: "suspected for HCV contamination"
Meta Candidates (Total=16; Excluded=1; Pruned=0; Remaining=15)
   833   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   790   C0019196:Hepatitis C [Disease or Syndrome]
   783   C0019186:Hepatitis virus [Virus]
   783   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   753   C0019158:Hepatitis [Disease or Syndrome]
   753   C0019159:hepatitis [Disease or Syndrome]
   753   C0042776:Virus [Virus]
   753   C0259846:contamination [Human-caused Phenomenon or Process]
   753   C0319157:virus [Virus]
   753   C0332147:Suspected [Qualitative Concept]
   753   C0750491:Suspected [Idea or Concept]
   753   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   753   C1881659:CONTAMINATION [Event]
   753   C2349974:Contamination [Idea or Concept]
   719 E C1571873:Suspect [Idea or Concept]

Phrase: "were"

Phrase: "not available, virologic tests"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   812   C0022885:Tests [Laboratory Procedure]
   812   C0392366:Tests [Intellectual Product]
   779 E C0039593:Test [Functional Concept]

Phrase: "were"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: "only on the serum of patients"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0205171:Only [Quantitative Concept]
   753   C0229671:Serum [Body Substance]
   753   C1546774:Serum [Intellectual Product]
   753   C1550100:Serum [Body Substance]
   753   C1720467:Only [Intellectual Product]

Phrase: "treated with IVIG."
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   833   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   833   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   770   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   770   C0348016:Intravenous [Spatial Concept]
   770   C1522326:Treated [Functional Concept]
   737 E C1292734:TREAT [Functional Concept]
   737 E C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.26: View this table: [in this window] [in a new window]  Table 1. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 1."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.27: Characteristics of Patients Receiving IVIG Serological tests. 

Phrase: "Characteristics of Patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   841   C0815172:patient characteristics [Clinical Attribute]
   790   C1521970:Characteristics [Qualitative Concept]

Phrase: "Receiving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1514756:Receive [Qualitative Concept]

Phrase: "IVIG Serological tests."
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   861   C0036743:Serological Tests [Laboratory Procedure]
   858   C0850992:immunoglobulin tests [Laboratory Procedure]
   812   C0022885:Tests [Laboratory Procedure]
   812   C0205473:Serological [Functional Concept]
   812   C0392366:Tests [Intellectual Product]
   779 E C0039593:Test [Functional Concept]
   741 E C0036745:Serology [Biomedical Occupation or Discipline]
   741 E C0220911:serology [Functional Concept]
Processing 00000000.tx.28: Anti-HCV Ab was assayed in duplicate by an enzyme-linked immunosorbent assay (ELISA) (Ortho Diagnostic Systems, Raritan, NJ). 

Phrase: "Anti-HCV Ab"
Meta Candidates (Total=19; Excluded=0; Pruned=0; Remaining=19)
   937   C0166049:Hepatitis C virus antibody [Immunologic Factor]
           Hepatitis C antibody
   937   C0201487:Hepatitis C Virus Antibody [Laboratory Procedure]
   902   C0051967:anti-c antibody [Immunologic Factor]
   897   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   884   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   875   C0019161:Hepatitis antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   853   C0019186:Hepatitis virus [Virus]
   853   C0432624:Anti C [Amino Acid, Peptide, or Protein,Immunologic Factor]
   853   C0432626:Anti c [Amino Acid, Peptide, or Protein,Immunologic Factor]
   840   C0019196:Hepatitis C [Disease or Syndrome]
   804   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   804   C0019158:Hepatitis [Disease or Syndrome]
   804   C0019159:hepatitis [Disease or Syndrome]
   804   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   804   C0042776:Virus [Virus]
   804   C0319157:virus [Virus]
   804   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "was"

Phrase: "assayed in duplicate"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   790   C0205173:Duplicate [Functional Concept]
   790   C3539942:Duplicate [Intellectual Product]
   756   C0005507:Assay [Laboratory Procedure]
   756   C0243073:assay [Qualitative Concept]
   756   C1510438:Assay [Laboratory Procedure]

Phrase: "by an enzyme-linked immunosorbent assay (ELISA)"
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
  1000   C0014441:Enzyme-Linked Immunosorbent Assay [Laboratory Procedure]
   902   C2717977:Enzyme Assay [Laboratory Procedure]
   812   C0005507:Assay [Laboratory Procedure]
   812   C0014442:Enzyme [Enzyme,Organic Chemical]
   812   C0021075:immunosorbent [Indicator, Reagent, or Diagnostic Aid]
   812   C0243073:assay [Qualitative Concept]
   812   C1510438:Assay [Laboratory Procedure]
   779   C1517892:Link [Intellectual Product]
   779   C1704666:Link [Intellectual Product]
   729 E C0014445:enzymes [Functional Concept]

Phrase: "(Ortho Diagnostic Systems,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   793   C0449913:System [Functional Concept]
   793   C1553451:System [Manufactured Object]
   793   C1704459:System [Medical Device]
   743 E C0205373:Systemic [Functional Concept]

Phrase: "Raritan,"

Phrase: "NJ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0027971:NJ [Geographic Area]

Phrase: ")."
Processing 00000000.tx.29: The determination of antibodies against specific viral antigens was carried out with second- or third-generation Recombinant Immunoblot Assay (RIBA) (Ortho Diagnostic Systems). 

Phrase: "The determination of antibodies"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C1148554:determination [Laboratory Procedure]

Phrase: "against specific viral antigens"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   913   C0456981:Specific antigens [Immunologic Factor]
   901   C0003342:Antigens, Viral [Immunologic Factor]
   827   C0003320:Antigens [Immunologic Factor]
   827   C0521026:Viral [Functional Concept]
   721 E C2698667:ANTIGENICITY [Regulation or Law]

Phrase: "was"

Phrase: "carried"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0206243:carried [Activity]
  1000   C0699809:carried [Finding]

Phrase: "out with second-"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   790   C0205436:Second [Quantitative Concept]
   790   C0439787:Out [Spatial Concept]
   790   C0457385:Second [Temporal Concept]
   790   C0565930:/second [Quantitative Concept]
   790   C0849355:Out [Qualitative Concept]
   790   C1561503:second [Idea or Concept]
   790   C1705190:Second [Qualitative Concept]
   718 E C0027627:secondary [Neoplastic Process]
   718 E C0175668:Secondary [Temporal Concept]

Phrase: "or"

Phrase: "third-generation Recombinant Immunoblot Assay (RIBA)"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   840   C0020985:Immunoblot assay [Laboratory Procedure]
           Immunoblot
   804   C0005507:Assay [Laboratory Procedure]
   804   C0243073:assay [Qualitative Concept]
   804   C1510438:Assay [Laboratory Procedure]
   804   C1514798:recombinant [Organism]

Phrase: "(Ortho Diagnostic Systems"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   793   C0449913:System [Functional Concept]
   793   C1553451:System [Manufactured Object]
   793   C1704459:System [Medical Device]
   743 E C0205373:Systemic [Functional Concept]

Phrase: ")."
Processing 00000000.tx.30: RNA extraction and amplification by the polymerase chain reaction (PCR). 

Phrase: "RNA extraction"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0185115:Extraction [Therapeutic or Preventive Procedure]
   861   C0684295:extraction [Laboratory Procedure]

Phrase: "and"

Phrase: "amplification by the polymerase chain reaction (PCR)."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1517480:Amplification [Molecular Biology Research Technique]
   753   C1521871:Amplification [Phenomenon or Process]
   753   C1705759:Amplification [Cell or Molecular Dysfunction]
Processing 00000000.tx.31: Total RNA was isolated from 100 L of serum with RNAzol B (Cinna-Biotecx, Houston, TX), following the manufacturer's instructions. 

Phrase: "Total RNA"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "was"

Phrase: "isolated from 100 L of serum"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   753   C0205409:Isolated [Functional Concept]
   753   C0229671:Serum [Body Substance]
   753   C1546774:Serum [Intellectual Product]
   753   C1548221:Isolated [Idea or Concept]
   753   C1550100:Serum [Body Substance]
   719 E C0370215:Isolate [Substance]
   719 E C1875400:ISOLATE [Pharmacologic Substance]

Phrase: "with RNAzol B (Cinna-Biotecx,"

Phrase: "Houston,"

Phrase: "TX"

Phrase: ")"

Phrase: ","

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "the manufacturer's instructions."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0302828:instructions [Intellectual Product]
   861   C1442085:Instructions [Idea or Concept]
   861   C3263700:Instructions [Clinical Attribute]
   827 E C0039401:Instruction [Educational Activity]
Processing 00000000.tx.32: Reverse transcription and nested PCR of the 5' untranslated region (5'UTR) and E1-E2 region were performed as previously described.10,11 Determination of HCV genotypes. 

Phrase: "Reverse transcription"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0035380:Reverse Transcription [Genetic Function]
   861   C0040649:Transcription [Genetic Function]
   861   C1555029:Reverse [Idea or Concept]

Phrase: "and"

Phrase: "nested PCR of the 5' untranslated region"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   818   C0242574:Nested Polymerase Chain Reaction [Molecular Biology Research Technique]
   790   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   742   C0337112:Chain [Manufactured Object]
   742   C0443286:Reaction [Functional Concept]
   742   C1114821:Reaction [Clinical Attribute]
   742   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   742   C1524075:Chain [Idea or Concept]

Phrase: "(5'UTR)"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0600493:5' UTR [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   861   C0600680:UTR [Nucleic Acid, Nucleoside, or Nucleotide]
   861   C1420099:UTR [Gene or Genome]
   861   C1540171:UTR [Gene or Genome]

Phrase: "and"

Phrase: "E1-E2 region"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0017446:Region [Geographic Area]
   827   C0205147:Region [Spatial Concept]
   755 E C0205276:Regional [Spatial Concept]
   755 E C1947913:Regional [Spatial Concept]

Phrase: "were"

Phrase: "performed as previously"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   790   C0884358:Performed [Functional Concept]
   756 E C2947996:Perform [Pharmacologic Substance]

Phrase: "described.10,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1552738:described [Idea or Concept]

Phrase: "11 Determination of HCV genotypes."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   868   C1533728:Hepatitis C virus genotype determination [Laboratory Procedure]
   757   C1285573:Genotype determination [Laboratory Procedure]
   748   C1148554:determination [Laboratory Procedure]
Processing 00000000.tx.33: The determination of HCV genotypes was performed by differential hybridization of the 5'UTR PCR products on microtiter plates11,12 using probes specific for genotypes 1-4 located at nucleotides -171--155: genotype 1 (5'-GAATTGCCAGGACGACC-3' ), genotype 2 (5'-GAATTGCCGGGAAGACT-3' ), genotype 3 (5'-GAATCGCTGGGGTGACC-3' ), and genotype 4 (5'-GAATCGCCGGGATGACC-3' ). 

Phrase: "The determination of HCV genotypes"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   868   C1533728:Hepatitis C virus genotype determination [Laboratory Procedure]
   757   C1285573:Genotype determination [Laboratory Procedure]
   748   C1148554:determination [Laboratory Procedure]

Phrase: "was"

Phrase: "performed by differential hybridization of the 5'UTR PCR products"
Meta Candidates (Total=18; Excluded=2; Pruned=0; Remaining=16)
   770   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   753   C1550369:Performed By [Qualitative Concept]
   736   C0020202:Hybridisation [Genetic Function]
   736   C0337112:Chain [Manufactured Object]
   736   C0443199:Differential [Qualitative Concept]
   736   C0443286:Reaction [Functional Concept]
   736   C0600680:UTR [Nucleic Acid, Nucleoside, or Nucleotide]
   736   C0884358:Performed [Functional Concept]
   736   C1114821:Reaction [Clinical Attribute]
   736   C1300517:Hybridization [Laboratory Procedure]
   736   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   736   C1420099:UTR [Gene or Genome]
   736   C1514468:Products [Entity]
   736   C1524075:Chain [Idea or Concept]
   736   C1540171:UTR [Gene or Genome]
   736   C1705242:Differential [Qualitative Concept]
   703 E C1704444:Product [Quantitative Concept]
   703 E C2947996:Perform [Pharmacologic Substance]

Phrase: "on microtiter plates11,"

Phrase: "12"

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "probes"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0182400:Probe [Medical Device]
  1000   C1704681:Probe [Gene or Genome]
  1000   C2347609:Probe [Chemical Viewed Functionally]
  1000   C3536729:Probe [Manufactured Object]

Phrase: "specific for genotypes 1-4"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0205369:Specific [Qualitative Concept]
   760   C1552740:specific [Intellectual Product]

Phrase: "located at nucleotides -171"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0028630:Nucleotides [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "--"

Phrase: "155"

Phrase: ":"

Phrase: "genotype 1"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017431:Genotype [Organism Attribute]

Phrase: "(5'-GAATTGCCAGGACGACC-3'"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439084:>5 [Quantitative Concept]
   827   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "genotype 2"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017431:Genotype [Organism Attribute]

Phrase: "(5'-GAATTGCCGGGAAGACT-3'"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439084:>5 [Quantitative Concept]
   827   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "genotype 3"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017431:Genotype [Organism Attribute]

Phrase: "(5'-GAATCGCTGGGGTGACC-3'"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439084:>5 [Quantitative Concept]
   827   C0728893:+5 [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "and"

Phrase: "genotype 4"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017431:Genotype [Organism Attribute]

Phrase: "(5'-GAATCGCCGGGATGACC-3'"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439084:>5 [Quantitative Concept]
   827   C0728893:+5 [Quantitative Concept]

Phrase: ")."
Processing 00000000.tx.34: Cloning and nucleotide sequence analysis. 

Phrase: "Cloning"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0009015:Cloning [Research Activity]

Phrase: "and"

Phrase: "nucleotide sequence analysis."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   901   C0162801:Sequence Analysis [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0002778:Analysis [Laboratory Procedure]
   827   C0936012:Analysis [Research Activity]
   827   C1524024:analysis [Functional Concept]
   734   C0004793:Nucleotide Sequence [Nucleotide Sequence]
Processing 00000000.tx.35: The PCR products of the E1-E2 region, including the hypervariable region 1 (HVR1) (nucleotides 498-1671), were cloned in the Bluescript plasmid vector (Stratagene, La Jolla, CA). 

Phrase: "The PCR products of the E1-E2 region,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   739   C1514468:Products [Entity]
   706 E C1704444:Product [Quantitative Concept]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "the hypervariable region 1 (HVR1)"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0017446:Region [Geographic Area]
   827   C0205147:Region [Spatial Concept]
   755 E C0205276:Regional [Spatial Concept]
   755 E C1947913:Regional [Spatial Concept]

Phrase: "(nucleotides 498-1671"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0028630:Nucleotides [Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: ")"

Phrase: ","

Phrase: "were"

Phrase: "cloned in the Bluescript plasmid vector"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   790   C1514152:Plasmid Vector [Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0009013:cloned [Cell]
   753   C0032136:Plasmid [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0086022:Vector [Nucleic Acid, Nucleoside, or Nucleotide]
   753   C0442335:Vector [Spatial Concept]
   753   C1705099:Vector [Idea or Concept]
   719 E C1522642:Clone [Tissue]

Phrase: "(Stratagene,"

Phrase: "La Jolla,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1555265:La Jolla [Population Group]

Phrase: "CA)."
Processing 00000000.tx.36: Six independent clones were isolated from each PCR product. 

Phrase: "Six independent clones"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0009013:Clones [Cell]
   793 E C1522642:Clone [Tissue]
   743 E C1704387:Clonal [Qualitative Concept]
   721 E C0796368:clonality [Diagnostic Procedure]

Phrase: "were"

Phrase: "isolated from each PCR product."
Meta Candidates (Total=12; Excluded=2; Pruned=0; Remaining=10)
   814   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   748   C0205409:Isolated [Functional Concept]
   748   C0337112:Chain [Manufactured Object]
   748   C0443286:Reaction [Functional Concept]
   748   C1114821:Reaction [Clinical Attribute]
   748   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   748   C1514468:product [Entity]
   748   C1524075:Chain [Idea or Concept]
   748   C1548221:Isolated [Idea or Concept]
   748   C1704444:Product [Quantitative Concept]
   714 E C0370215:Isolate [Substance]
   714 E C1875400:ISOLATE [Pharmacologic Substance]
Processing 00000000.tx.37: Partial nucleotide sequence analysis was performed on single-stranded DNA using the Sequenase Images kit (United States Biochemical, Cleveland, OH). 

Phrase: "Partial nucleotide sequence analysis"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0162801:Sequence Analysis [Laboratory Procedure,Molecular Biology Research Technique]
   812   C0002778:Analysis [Laboratory Procedure]
   812   C0936012:Analysis [Research Activity]
   812   C1524024:analysis [Functional Concept]

Phrase: "was"

Phrase: "performed on single-stranded DNA"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
   862   C0012935:DNA, Single-Stranded [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   770   C1979975:Single strand [Qualitative Concept]
   760   C0012854:DNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   760   C0037179:Single [Population Group]
   760   C0087136:single [Finding]
   760   C0205171:Single [Quantitative Concept]
   760   C0884358:Performed [Functional Concept]
   726 E C2947996:Perform [Pharmacologic Substance]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the Sequenase Images kit (United States Biochemical, Cleveland,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   795   C0454845:Cleveland [Geographic Area]

Phrase: "OH"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0220853:OH- [Element, Ion, or Isotope]

Phrase: ")."
Processing 00000000.tx.38: Sequence data were analyzed and compared with reference sequences13 using the computer program PC/GENE (Intelligenetics, Geel, Belgium).  

Phrase: "Sequence data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]

Phrase: "were"

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: "and"

Phrase: "compared with reference sequences13"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C1514811:Reference [Idea or Concept]
   770   C1706462:Reference [Conceptual Entity]
   770   C1707455:Compared [Activity]

Phrase: "using"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C1524063:Using [Functional Concept]
   966 E C0042153:use [Functional Concept]
   966 E C0457083:Use [Functional Concept]
   966 E C1947944:Use [Intellectual Product]

Phrase: "the computer program PC/GENE"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1418288:PC gene [Gene or Genome]
   812   C0017337:Gene [Gene or Genome]

Phrase: "(Intelligenetics,"

Phrase: "Geel,"

Phrase: "Belgium"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0004950:Belgium [Geographic Area]

Phrase: ")."
Processing 00000000.tx.39: RESULTS Abstract Introduction Methods Results Discussion References Rate of HCV infection. 

Phrase: "RESULTS Abstract Introduction Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   799   C0557061:Discussion [Therapeutic or Preventive Procedure]
   799   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Rate of HCV infection."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0871208:Rate [Activity]
   753   C1521828:Rate [Quantitative Concept]
Processing 00000000.tx.40: Infection by HCV after IVIG therapy was documented in 100% (13 of 13) of patients. 

Phrase: "Infection by HCV"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   844   C0019196:Hepatitis C Infection [Disease or Syndrome]
   811   C0019160:Hepatitis Virus, Infectious [Virus]
   811   C0376325:Infectious hepatitis virus [Virus]
   797   C0042769:virus infection [Disease or Syndrome]
   762   C0019159:Hepatitis, Infectious [Disease or Syndrome]
   760   C0009450:Infection, NOS [Disease or Syndrome]

Phrase: "after IVIG therapy"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C0455142:Intravenous therapy [Therapeutic or Preventive Procedure]
   884   C0021022:Immunoglobulin Therapy [Therapeutic or Preventive Procedure]
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C1363945:Therapy [Finding]
   734   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "was"

Phrase: "documented in 100%"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C1301725:Documented [Health Care Activity]
   790   C1609436:documented [Idea or Concept]
   756 E C1301746:document [Intellectual Product]
   756 E C1547673:Document [Intellectual Product]

Phrase: "(13 of 13"

Phrase: ")"

Phrase: "of patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.41: Among six ITP patients, five showed seroconversion from anti-HCV Ab negativity to anti-HCV Ab positivity 2 to 12 months after IVIG (Table 2). 

Phrase: "Among six ITP patients,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0030705:Patients [Patient or Disabled Group]
   717   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]

Phrase: "five"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205451:Five [Quantitative Concept]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "seroconversion from anti-HCV Ab negativity"

Phrase: "to anti-HCV Ab positivity 2"
Meta Candidates (Total=24; Excluded=0; Pruned=0; Remaining=24)
   877   C0166049:Hepatitis C virus antibody [Immunologic Factor]
           Hepatitis C antibody
   877   C0201487:Hepatitis C Virus Antibody [Laboratory Procedure]
   863   C0051967:anti-c antibody [Immunologic Factor]
   861   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   845   C0019161:Hepatitis antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   845   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   829   C0019186:Hepatitis virus [Virus]
   829   C0432624:Anti C [Amino Acid, Peptide, or Protein,Immunologic Factor]
   829   C0432626:Anti c [Amino Acid, Peptide, or Protein,Immunologic Factor]
   818   C0019196:Hepatitis C [Disease or Syndrome]
   795   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   795   C0019158:Hepatitis [Disease or Syndrome]
   795   C0019159:hepatitis [Disease or Syndrome]
   795   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   795   C0042776:Virus [Virus]
   795   C0319157:virus [Virus]
   795   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   782   C0741132:antibody positive [Laboratory or Test Result]
   724   C0439178:% Positive [Quantitative Concept]
   724   C1446409:Positive [Qualitative Concept]
   724   C1514241:Positive [Finding]
   724   C2825490:Positive [Qualitative Concept]

Phrase: "to 12 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "after IVIG"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]

Phrase: "(Table 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.42: One patient had unknown anti-HCV Ab status before IVIG, but had evidence of acute hepatitis 5 months after IVIG, and of anti-HCV Ab positivity 10 months after IVIG, respectively (Table 3). 

Phrase: "One patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "had"

Phrase: "unknown anti-HCV Ab status before IVIG,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   799   C2708504:Hepatitis C virus status [Clinical Attribute]
   799   C2708505:Hepatitis C virus status [Finding]
   777   C0458071:Hepatitis C status [Finding]
   739   C0449438:Status [Qualitative Concept]

Phrase: "but"

Phrase: "had"

Phrase: "evidence of acute hepatitis 5 months"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "after IVIG,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]

Phrase: "and of anti-HCV Ab positivity 10 months"
Meta Candidates (Total=25; Excluded=1; Pruned=0; Remaining=24)
   806   C0166049:Hepatitis C virus antibody [Immunologic Factor]
           Hepatitis C antibody
   806   C0201487:Hepatitis C Virus Antibody [Laboratory Procedure]
   782   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   775   C0051967:anti-c antibody [Immunologic Factor]
   760   C0019196:Hepatitis C [Disease or Syndrome]
   757   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   757   C0019161:Hepatitis antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   757   C0019186:Hepatitis virus [Virus]
   757   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   757   C0368815:antibody c [Amino Acid, Peptide, or Protein,Immunologic Factor]
   757   C0432624:Anti C [Amino Acid, Peptide, or Protein,Immunologic Factor]
   757   C0432626:Anti c [Amino Acid, Peptide, or Protein,Immunologic Factor]
   739   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   739   C0019158:Hepatitis [Disease or Syndrome]
   739   C0019159:hepatitis [Disease or Syndrome]
   739   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   739   C0042776:Virus [Virus]
   739   C0319157:virus [Virus]
   739   C0439231:months [Temporal Concept]
   739   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   739   C1515981:And [Idea or Concept]
   724   C0741132:antibody positive [Laboratory or Test Result]
   706 E C0439507:/month [Temporal Concept]

Phrase: "after IVIG,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]

Phrase: "respectively"

Phrase: "(Table 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.43: Among seven ID patients, anti-HCV Ab negativity was shown in all cases, five before and two shortly after IVIG. 

Phrase: "Among seven ID patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "anti-HCV Ab negativity"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   734   C0166049:Hepatitis C virus antibody [Immunologic Factor]
           Hepatitis C antibody
   734   C0201487:Hepatitis C Virus Antibody [Laboratory Procedure]
   727   C0205160:Negative [Qualitative Concept]
   727   C1513916:Negative [Finding]
   727   C2825415:Negative [Conceptual Entity]
   727   C2825491:Negative [Qualitative Concept]
   712   C0051967:anti-c antibody [Immunologic Factor]
   709   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "was"

Phrase: "shown in all cases,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   770   C0868928:Cases [Functional Concept]
   770   C1533148:Cases [Quantitative Concept]
   737   C1547282:Show [Intellectual Product]
   737 E C1706255:CASE [Medical Device]
   737 E C1706256:Case [Conceptual Entity]

Phrase: "five before"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205451:Five [Quantitative Concept]

Phrase: "and"

Phrase: "two shortly after IVIG."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   806   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   760   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   760   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   760   C0205448:Two [Quantitative Concept]
   760   C0348016:Intravenous [Spatial Concept]
   726 E C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.44: Only two patients had evidence of seroconversion to anti-HCV Ab positivity, 2 and 5 months after IVIG, respectively. 

Phrase: "Only two patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "had"

Phrase: "evidence of seroconversion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   882   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "to anti-HCV Ab positivity,"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   791   C0741132:antibody positive [Laboratory or Test Result]
   734   C0166049:Hepatitis C virus antibody [Immunologic Factor]
           Hepatitis C antibody
   734   C0201487:Hepatitis C Virus Antibody [Laboratory Procedure]
   727   C0439178:% Positive [Quantitative Concept]
   727   C1446409:Positive [Qualitative Concept]
   727   C1514241:Positive [Finding]
   727   C2825490:Positive [Qualitative Concept]
   712   C0051967:anti-c antibody [Immunologic Factor]
   709   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]

Phrase: "and"

Phrase: "5 months after IVIG,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0439231:months [Temporal Concept]
   726 E C0439507:/month [Temporal Concept]

Phrase: "respectively."
Processing 00000000.tx.45: The other five patients, who remained anti-HCV Ab negative up to 12 months after IVIG, had evidence of acute hepatitis a median of 3 months after IVIG (Table 3) and serum HCV-RNA positivity was detected in all patients 1.5 to 12 months after IVIG (Table 2). 

Phrase: "The"

Phrase: "other five patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "who"

Phrase: "remained"

Phrase: "anti-HCV Ab negative up to 12 months"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   757   C0855852:negative antibody [Laboratory or Test Result]
   739   C0205160:Negative [Qualitative Concept]
   739   C1513916:Negative [Finding]
   739   C2825415:Negative [Conceptual Entity]
   739   C2825491:Negative [Qualitative Concept]

Phrase: "after IVIG,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]

Phrase: "had"

Phrase: "evidence of acute hepatitis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: "a median of 3 months"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0549183:Median [Spatial Concept]
   760   C0876920:Median [Quantitative Concept]
   760   C2347635:Median [Quantitative Concept]
   760   C2348144:Median [Quantitative Concept]
   760   C2939193:Median [Spatial Concept]

Phrase: "after IVIG"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]

Phrase: "(Table 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")"

Phrase: "and"

Phrase: "serum HCV-RNA positivity"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   734   C0369335:Hepatitis C virus RNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   727   C0439178:% Positive [Quantitative Concept]
   727   C1446409:Positive [Qualitative Concept]
   727   C1514241:Positive [Finding]
   727   C2825490:Positive [Qualitative Concept]
   700   C0019169:Serum hepatitis virus [Virus]
   700   C0855840:hepatitis c rna [Laboratory Procedure]

Phrase: "was"

Phrase: "detected in all patients 1.5"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0442726:Detected [Finding]
   753   C1511790:Detected [Therapeutic or Preventive Procedure]

Phrase: "to 12 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "after IVIG"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]

Phrase: "(Table 2"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.46: In one case (FF ), HCV-RNA was also tested before IVIG and found negative. 

Phrase: "In one case"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0868928:Case [Functional Concept]
   861   C1706255:CASE [Medical Device]
   861   C1706256:Case [Conceptual Entity]

Phrase: "(FF"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C3539653:FF [Idea or Concept]

Phrase: ")"

Phrase: ","

Phrase: "HCV-RNA"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0369335:Hepatitis C virus RNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   923   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   923   C0855840:hepatitis c rna [Laboratory Procedure]
   875   C0019186:Hepatitis virus [Virus]
   861   C0019196:Hepatitis C [Disease or Syndrome]
   861   C0035691:Virus-RNA [Virus]
   861   C0035736:virus RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0019158:Hepatitis [Disease or Syndrome]
   812   C0019159:hepatitis [Disease or Syndrome]
   812   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0042776:Virus [Virus]
   812   C0319157:virus [Virus]
   812   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "was"

Phrase: "also"

Phrase: "tested before IVIG"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   833   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   786   C0850992:immunoglobulin test [Laboratory Procedure]
   770   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   770   C0348016:Intravenous [Spatial Concept]
   770   C0392366:tested [Intellectual Product]
   737 E C0022885:Test [Laboratory Procedure]
   737 E C0039593:Test [Functional Concept]
   737 E C1621846:immunoglobulin [Molecular Function]

Phrase: "and"

Phrase: "found negative."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0205160:Negative [Qualitative Concept]
   861   C1513916:Negative [Finding]
   861   C2825415:Negative [Conceptual Entity]
   861   C2825491:Negative [Qualitative Concept]
Processing 00000000.tx.47: Moreover, in two (AA and BF ) of the remaining four ID patients, the demonstration of the same type of viral sequences by molecular studies of the HVR1 region (Fig 1) strongly supported their HCV-naive status before IVIG.  

Phrase: "Moreover,"

Phrase: "in two"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205448:Two [Quantitative Concept]

Phrase: "(AA"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1235746:Aa [Plant]
  1000   C1882141:aa [Qualitative Concept]

Phrase: "and"

Phrase: "BF ) of the remaining four ID patients,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0006409:BF [Geographic Area]
   748   C1824728:BF [Gene or Genome]

Phrase: "the demonstration of the same type of viral sequences"

Phrase: "by molecular studies"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0947630:studies [Laboratory Procedure]
   861   C1521991:Molecular [Qualitative Concept]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]
   789 E C0567416:Molecule [Substance]

Phrase: "of the HVR1 region"

Phrase: "(Fig 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")"

Phrase: "strongly"

Phrase: "supported"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521721:Supported [Conceptual Entity]
   966 E C0183683:Support [Medical Device]

Phrase: "their HCV-naive status before IVIG."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   810   C2708504:Hepatitis C virus status [Clinical Attribute]
   810   C2708505:Hepatitis C virus status [Finding]
   784   C0458071:Hepatitis C status [Finding]
   742   C0449438:Status [Qualitative Concept]
Processing 00000000.tx.48: View this table: [in this window] [in a new window]  Table 2. 

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.49: Virologic Data  View this table: [in this window] [in a new window]  Table 3. 

Phrase: "Virologic Data"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "this table"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0039224:Table [Manufactured Object]
  1000   C1706073:Table [Medical Device]
  1000   C1706074:Table [Intellectual Product]

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Table 3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]
Processing 00000000.tx.50: Clinical Data View larger version (25K): [in this window] [in a new window]  Fig 1. 

Phrase: "Clinical Data"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1516606:Clinical Data [Intellectual Product]
   861   C1511726:Data [Idea or Concept]
   861   C3245479:data [Medical Device]

Phrase: "View"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0449911:View [Spatial Concept]

Phrase: "larger version"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0333052:Version [Functional Concept]
   861   C2607870:Version [Spatial Concept]

Phrase: "(25K"

Phrase: ")"

Phrase: ":"

Phrase: "["

Phrase: "in this window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0557702:Window [Manufactured Object]
  1000   C1272706:Window [Temporal Concept]
  1000   C1704674:Window [Manufactured Object]

Phrase: "]"

Phrase: "["

Phrase: "in a new window"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0557702:Window [Manufactured Object]
   861   C1272706:Window [Temporal Concept]
   861   C1704674:Window [Manufactured Object]

Phrase: "]  Fig 1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]
Processing 00000000.tx.51: Deduced amino acid sequence of the E1-E2 region (residues 337-410). 

Phrase: "Deduced amino acid sequence of the E1-E2 region"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   790   C0002518:Amino Acid Sequence [Amino Acid Sequence]
   764   C0002520:Amino acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   764   C2917660:Amino Acid [Pharmacologic Substance]
   742   C0001128:Acid [Chemical]
   742   C0004793:Sequence [Nucleotide Sequence]
   742   C0162326:Sequence [Nucleotide Sequence]
   742   C0162327:Sequence [Nucleotide Sequence]
   742   C0202406:Acid [Laboratory Procedure]
   742   C1519249:Sequence [Functional Concept]
   726   C1515860:Acidic Region [Amino Acid Sequence]

Phrase: "(residues 337-410"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   793   C1709915:Residue [Conceptual Entity]
   793   C1882936:RESIDUE [Phenomenon or Process]
   743 E C1609982:Residual [Qualitative Concept]

Phrase: ")."
Processing 00000000.tx.52: The initials of patients and the number of each clone are indicated on the left. 

Phrase: "The initials of patients"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   770   C1555582:Initials [Idea or Concept]
   737 E C0205265:Initial [Temporal Concept]
   737 E C1279901:Initial [Qualitative Concept]
   737 E C1705685:INITIAL [Functional Concept]

Phrase: "and"

Phrase: "the number of each clone"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0237753:*Number [Quantitative Concept]
   760   C0449788:Number [Quantitative Concept]

Phrase: "are"

Phrase: "indicated on the left."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0205091:Left [Spatial Concept]
   770   C1444656:Indicated [Finding]
   770   C1552822:left [Functional Concept]
Processing 00000000.tx.53: The horizontal line indicates the HVR1 region. 

Phrase: "The horizontal line"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205132:Line [Spatial Concept]
   861   C1550648:Line [Substance]
   861   C1552960:Line [Quantitative Concept]

Phrase: "indicates"

Phrase: "the HVR1 region."
Processing 00000000.tx.54: The residues specific for genotypes 1a or 1b (clones LM 5, LM 8, and LM 3)13 are underlined. 

Phrase: "The residues"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   966   C1709915:Residue [Conceptual Entity]
   966   C1882936:RESIDUE [Phenomenon or Process]
   916 E C1609982:Residual [Qualitative Concept]

Phrase: "specific for genotypes 1a"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0205369:Specific [Qualitative Concept]
   770   C1552740:specific [Intellectual Product]

Phrase: "or"

Phrase: "1b"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450345:1B [Intellectual Product]

Phrase: "(clones LM 5,"
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   827   C0009013:Clones [Cell]
   827   C1261082:LM [Body Part, Organ, or Organ Component]
   827   C1551056:lm [Quantitative Concept]
   827   C2981682:LM [Quantitative Concept]
   793 E C1522642:Clone [Tissue]
   743 E C1704387:Clonal [Qualitative Concept]
   721 E C0796368:clonality [Diagnostic Procedure]

Phrase: "LM 8,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1261082:LM [Body Part, Organ, or Organ Component]
   861   C1551056:lm [Quantitative Concept]
   861   C2981682:LM [Quantitative Concept]

Phrase: "and"

Phrase: "LM 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C1261082:LM [Body Part, Organ, or Organ Component]
   861   C1551056:lm [Quantitative Concept]
   861   C2981682:LM [Quantitative Concept]

Phrase: ")"

Phrase: "13"

Phrase: "are"

Phrase: "underlined."
Processing 00000000.tx.55: Source of HCV infection. 

Phrase: "Source of HCV infection."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   820   C0449426:Source of infection [Finding]
           infection source
   753   C0449416:Source [Finding]
   753   C1705919:Source [Idea or Concept]
Processing 00000000.tx.56: The IVIG origin of HCV infection was supported by clinical follow-up as well as by virologic studies (Tables 2 and 3). 

Phrase: "The IVIG origin of HCV infection"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   742   C0079946:origin [Classification]
   742   C0439659:Origin [Temporal Concept]
   742   C1550512:origin [Intellectual Product]
   712   C0729552:Genital infection [Disease or Syndrome]

Phrase: "was"

Phrase: "supported by clinical follow-up"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
   806   C0589120:Follow-up [Finding]
   806   C1522577:follow-up [Health Care Activity]
   806   C1704685:FOLLOW-UP [Intellectual Product]
   806   C3274571:FOLLOW-UP [Health Care Activity]
   760   C0205210:Clinical [Qualitative Concept]
   760   C0332283:follow [Temporal Concept]
   760   C1521721:Supported [Conceptual Entity]
   760   C1719822:Follow [Intellectual Product]
   726 E C0183683:Support [Medical Device]

Phrase: "as well as by virologic studies"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
   753   C0205170:Well [Qualitative Concept]
   753   C0205466:virologic [Functional Concept]
   753   C0947630:studies [Laboratory Procedure]
   753   C3146287:Well [Manufactured Object]
   719 E C0557651:Study [Manufactured Object]
   719 E C2603343:Study [Research Activity]

Phrase: "(Tables 2"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   861   C0039224:tables [Manufactured Object]
   861   C1706074:Tables [Intellectual Product]
   827 E C1706073:Table [Medical Device]

Phrase: "and"

Phrase: "3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]

Phrase: ")."
Processing 00000000.tx.57: At the time of IVIG infusion, alanine aminotransferase (ALT) levels were normal in all patients except in one (VE), whose levels were less than 100 U/dL. 

Phrase: "At the time"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0040223:Time [Temporal Concept]
  1000   C3541383:Time [Temporal Concept]
   944 E C0442043:Temporal [Spatial Concept]
   944 E C2362314:Temporal [Temporal Concept]
   916 E C1632851:Times [Quantitative Concept]

Phrase: "of IVIG infusion,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C0021440:Intravenous infusion [Therapeutic or Preventive Procedure]
   913   C1272892:Intravenous infusion [Biomedical or Dental Material]
   913   C1621368:Intravenous Infusion [Functional Concept]
   827   C0574032:Infusion [Therapeutic or Preventive Procedure]
   827   C1827465:Infusion [Functional Concept]
   734   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "alanine aminotransferase"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0001899:Alanine Aminotransferase [Amino Acid, Peptide, or Protein,Enzyme]
  1000   C0057041:Alanine amino transferase [Amino Acid, Peptide, or Protein,Enzyme]
   861   C0001898:Alanine [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   861   C0002594:Aminotransferase [Amino Acid, Peptide, or Protein,Enzyme]

Phrase: "(ALT) levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "were"

Phrase: "normal in all patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   819   C0848894:normal patients [Finding]
   770   C0205307:Normal [Qualitative Concept]
   770   C0439166:% normal [Quantitative Concept]
   770   C2347086:% Normal [Quantitative Concept]

Phrase: "except"

Phrase: "in one (VE"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0042469:VE [Geographic Area]

Phrase: ")"

Phrase: ","

Phrase: "whose levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0441889:Levels [Qualitative Concept]
   966 E C0456079:Level [Classification]
   966 E C1547707:Level [Geographic Area]
   966 E C2946261:Level [Pharmacologic Substance]

Phrase: "were"

Phrase: "less than 100 U/dL."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0439092:Less Than [Intellectual Product]
           less
   806   C1532632:U/dL [Quantitative Concept]
   806   C1880520:U/dL [Quantitative Concept]
   760   C0547044:Less [Qualitative Concept]
   760   C3642216:/dL [Quantitative Concept]
Processing 00000000.tx.58: A median of 3 months after IVIG therapy, a greater than fivefold ALT increase over baseline levels was detected in 11 of 11 evaluable patients. 

Phrase: "A median of 3 months"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0549183:Median [Spatial Concept]
   760   C0876920:Median [Quantitative Concept]
   760   C2347635:Median [Quantitative Concept]
   760   C2348144:Median [Quantitative Concept]
   760   C2939193:Median [Spatial Concept]

Phrase: "after IVIG therapy,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C0455142:Intravenous therapy [Therapeutic or Preventive Procedure]
   884   C0021022:Immunoglobulin Therapy [Therapeutic or Preventive Procedure]
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C1363945:Therapy [Finding]
   734   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "a greater than fivefold ALT increase"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0439093:Greater Than [Quantitative Concept]
   753   C0443228:greater [Quantitative Concept]
   753   C1704243:Greater [Quantitative Concept]
   719 E C0549177:Great [Quantitative Concept]

Phrase: "over baseline levels"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   861   C0168634:baseline [Biomedical or Dental Material]
   861   C0441889:Levels [Qualitative Concept]
   861   C1442488:Baseline [Quantitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "was"

Phrase: "detected in 11 of 11 evaluable patients."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C2986511:evaluable patients [Patient or Disabled Group]
   748   C0030705:Patients [Patient or Disabled Group]
   748   C0442726:Detected [Finding]
   748   C1511790:Detected [Therapeutic or Preventive Procedure]
   748   C1516986:Evaluable [Disease or Syndrome]
Processing 00000000.tx.59: In two patients (GA, SG), ALT levels were not monitored shortly after IVIG, but abnormal ALT levels and seroconversion to HCV-Ab positivity were documented 5 and 10 months after IVIG treatment, respectively. 

Phrase: "In two patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "(GA,"

Phrase: "SG"

Phrase: ")"

Phrase: ","

Phrase: "ALT levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "were"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "monitored"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   966   C0030695:monitor [Health Care Activity]
   966   C0150369:monitor [Health Care Activity]
   966   C0181904:Monitor [Medical Device]
   966   C0596972:Monitor [Medical Device]
   966   C1521743:Monitor [Professional or Occupational Group]
   966   C1704646:Monitor [Manufactured Object]

Phrase: "shortly after IVIG,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   833   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   770   C0348016:Intravenous [Spatial Concept]
   737 E C1621846:immunoglobulin [Molecular Function]

Phrase: "but"

Phrase: "abnormal ALT levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]

Phrase: "and"

Phrase: "seroconversion to HCV-Ab positivity"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   713   C0166049:Antibody to hepatitis C virus [Immunologic Factor]

Phrase: "were"

Phrase: "documented"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C1301725:Documented [Health Care Activity]
  1000   C1609436:documented [Idea or Concept]
   966 E C1301746:document [Intellectual Product]
   966 E C1547673:Document [Intellectual Product]

Phrase: "5"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]

Phrase: "and"

Phrase: "10 months after IVIG treatment,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   753   C0439231:months [Temporal Concept]
   719 E C0439507:/month [Temporal Concept]

Phrase: "respectively."
Processing 00000000.tx.60: Transfusions of packed red blood cells (RBCs) and/or platelet concentrates were given after IVIG therapy and before the onset of hepatitis to two ITP and four ID patients (Table 1). 

Phrase: "Transfusions of packed red blood cells (RBCs)"
Meta Candidates (Total=16; Excluded=3; Pruned=0; Remaining=13)
   988   C0199962:Transfusion of packed red blood cells [Therapeutic or Preventive Procedure]
           blood cells packed red transfusion
       E   Red Blood Cell Transfusion
   890   C0086252:Transfusion of red blood cells [Therapeutic or Preventive Procedure]
           blood cells red transfusions
   855   C0178192:Transfusion of packed cells [Therapeutic or Preventive Procedure]
           blood cell packed transfusions
           Packed cell transfusion
   804   C0565531:blood cell transfusions [Therapeutic or Preventive Procedure]
   783   C0005841:Blood Transfusions [Therapeutic or Preventive Procedure]
           Transfusions
   767 E C0455012:Blood Transfusion [Therapeutic or Preventive Procedure]
       E   Transfusion
   753   C0199960:transfusions [Functional Concept]
   753   C1879316:Transfusions [Therapeutic or Preventive Procedure]
   716   C2316467:Packed red blood cells [Pharmacologic Substance]

Phrase: "and/or"

Phrase: "platelet concentrates"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   966   C1547251:Platelet Concentrate [Intellectual Product]
   966   C2362067:Platelet concentrate [Pharmacologic Substance]
   861   C0005821:Platelet [Cell]
   827   C1880310:Concentrate [Manufactured Object]
   827   C2003864:Concentrate [Substance]
   777 E C1963076:Platelets [Finding]

Phrase: "were"

Phrase: "given after IVIG therapy"
Meta Candidates (Total=14; Excluded=2; Pruned=0; Remaining=12)
   806   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   797   C0455142:Intravenous therapy [Therapeutic or Preventive Procedure]
   790   C0021022:Immunoglobulin Therapy [Therapeutic or Preventive Procedure]
   760   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   760   C0039798:therapy [Functional Concept]
   760   C0087111:Therapy [Therapeutic or Preventive Procedure]
   760   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   760   C0348016:Intravenous [Spatial Concept]
   760   C1363945:Therapy [Finding]
   760   C1442162:GIVEN [Conceptual Entity]
   760   C1550718:given [Idea or Concept]
   760   C3244317:given [Intellectual Product]
   726 E C1621846:immunoglobulin [Molecular Function]
   726 E C1947971:Give [Functional Concept]

Phrase: "and before the onset of hepatitis"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0019158:Hepatitis [Disease or Syndrome]
   753   C0019159:hepatitis [Disease or Syndrome]
   753   C0332162:Onset [Qualitative Concept]
   753   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   753   C1515981:And [Idea or Concept]

Phrase: "to two ITP"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   861   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   861   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   812   C0034150:Purpura [Disease or Syndrome]
   812   C0332240:Idiopathic [Functional Concept]
   812   C3463943:Purpura [Eukaryote]

Phrase: "and"

Phrase: "four ID patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "(Table 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.61: However, none of the patients was transfused from the same blood donor. 

Phrase: "However,"

Phrase: "none of the patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0456148:None [Quantitative Concept]
   770   C0549184:None [Quantitative Concept]

Phrase: "was"

Phrase: "transfused from the same blood donor."
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   790   C0005795:Blood donor [Population Group]
   790   C1313951:Blood donor [Finding]
   753   C0005767:Blood [Tissue]
   753   C0005768:blood [Body Substance]
   753   C0013018:Donor [Population Group]
   753   C0040288:Donor [Population Group]
   753   C0229664:Blood [Body Substance]
   753   C0445247:Same [Qualitative Concept]
   753   C1527169:Donor NOS [Finding]
   753   C1549003:Transfused [Idea or Concept]
Processing 00000000.tx.62: HCV genotype determination, performed on 10 patients (6 ID and 4 ITP), detected genotype 1 in all cases. 

Phrase: "HCV genotype determination,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C1533728:Hepatitis C virus genotype determination [Laboratory Procedure]
           Hepatitis C virus genotype
   840   C1285573:Genotype determination [Laboratory Procedure]
   804   C1148554:determination [Laboratory Procedure]
   771   C1148363:Hepatitis C virus genotype [Finding]
   717   C0220847:Hepatitis C virus [Virus]

Phrase: "performed on 10 patients"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0884358:Performed [Functional Concept]
   737 E C2947996:Perform [Pharmacologic Substance]

Phrase: "(6 ID"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0021051:Immunodeficient [Disease or Syndrome]

Phrase: "and"

Phrase: "4 ITP"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   861   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   861   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   812   C0034150:Purpura [Disease or Syndrome]
   812   C0332240:Idiopathic [Functional Concept]
   812   C3463943:Purpura [Eukaryote]

Phrase: ")"

Phrase: ","

Phrase: "detected genotype 1 in all cases."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   753   C0017431:Genotype [Organism Attribute]
   753   C0442726:Detected [Finding]
   753   C0868928:Cases [Functional Concept]
   753   C1511790:Detected [Therapeutic or Preventive Procedure]
   753   C1533148:Cases [Quantitative Concept]
   719 E C1706255:CASE [Medical Device]
   719 E C1706256:Case [Conceptual Entity]
Processing 00000000.tx.63: The E1-E2 region was successfully amplified from 4 of 5 available samples obtained from ID patients 3 to 4 months after infusion of IVIG. 

Phrase: "The E1-E2 region"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0017446:Region [Geographic Area]
   827   C0205147:Region [Spatial Concept]
   755 E C0205276:Regional [Spatial Concept]
   755 E C1947913:Regional [Spatial Concept]

Phrase: "was"

Phrase: "successfully"

Phrase: "amplified from 4 of 5 available samples"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0470187:Available [Functional Concept]
           Availability of
   714   C0370003:Sample [Substance]
   714   C2347026:Sample [Conceptual Entity]

Phrase: "obtained from ID patients 3"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0021051:Immunodeficient [Disease or Syndrome]
   760   C0030705:Patients [Patient or Disabled Group]
   760   C1301820:Obtained [Functional Concept]
   726 E C1706701:Obtain [Activity]
   715   C0596032:acquired immunodeficiency [Finding]

Phrase: "to 4 months"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "after infusion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0574032:Infusion [Therapeutic or Preventive Procedure]
  1000   C1827465:Infusion [Functional Concept]

Phrase: "of IVIG."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.64: The alignment of deduced amino acid sequences showed common features in all patients (Fig 1). 

Phrase: "The alignment of deduced amino acid sequences"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   757   C0080143:Sequence Alignment [Molecular Biology Research Technique]
   748   C1706765:Alignment [Quantitative Concept]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "common features in all patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   726   C1521970:Feature [Qualitative Concept]
   726   C1706388:Feature [Conceptual Entity]
   726   C2346469:Feature [Qualitative Concept]
   726   C2348519:Feature [Qualitative Concept]

Phrase: "(Fig 1"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0349966:Fig [Food]
   861   C1337208:FIG [Food]

Phrase: ")."
Processing 00000000.tx.65: In 3 cases all sequences were identical or closely related to each other, whereas in 1 patient (LM), two molecular species were detected, one of which was common to the remaining patients. 

Phrase: "In 3 cases"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   861   C0868928:Cases [Functional Concept]
   861   C1533148:Cases [Quantitative Concept]
   827 E C1706255:CASE [Medical Device]
   827 E C1706256:Case [Conceptual Entity]

Phrase: "all"

Phrase: "sequences"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0004793:Sequence [Nucleotide Sequence]
  1000   C0162326:Sequence [Nucleotide Sequence]
  1000   C0162327:Sequence [Nucleotide Sequence]
  1000   C1519249:Sequence [Functional Concept]

Phrase: "were"

Phrase: "identical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205280:Identical [Qualitative Concept]

Phrase: "or"

Phrase: "closely"

Phrase: "related to each other,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0439849:Related [Qualitative Concept]
   770   C0445223:Related [Finding]
   737 E C0163712:Relate [Organic Chemical]

Phrase: "whereas in 1 patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030705:*^patient [Patient or Disabled Group]

Phrase: "(LM"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1261082:LM [Body Part, Organ, or Organ Component]
  1000   C1551056:lm [Quantitative Concept]
  1000   C2981682:LM [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "two molecular species"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C1705920:Species [Conceptual Entity]

Phrase: "were"

Phrase: "detected"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0442726:Detected [Finding]
  1000   C1511790:Detected [Therapeutic or Preventive Procedure]

Phrase: ","

Phrase: "one of which"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205447:One [Quantitative Concept]

Phrase: "was"

Phrase: "common to the remaining patients."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0205214:Common [Quantitative Concept]
   760   C1522138:Common [Functional Concept]
   760   C3245511:common [Intellectual Product]
Processing 00000000.tx.66: Amino acid sequences of the C terminus of E1 region indicated that the HCV isolate detected in all patients belonged to genotype 1a. 

Phrase: "Amino acid sequences of the C terminus of E1 region"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   782   C0002518:Sequences, Amino Acid [Amino Acid Sequence]
   760   C0002520:Amino acid [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   760   C2917660:Amino Acid [Pharmacologic Substance]
   739   C0001128:Acid [Chemical]
   739   C0162326:Sequences [Nucleotide Sequence]
   739   C0202406:Acid [Laboratory Procedure]
   722   C1515860:Acidic Region [Amino Acid Sequence]
   706 E C0004793:Sequence [Nucleotide Sequence]
   706 E C0162327:Sequence [Nucleotide Sequence]
   706 E C1519249:Sequence [Functional Concept]

Phrase: "indicated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1444656:Indicated [Finding]

Phrase: "that"

Phrase: "the HCV isolate"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0370215:Isolate [Substance]
   812   C1875400:ISOLATE [Pharmacologic Substance]
   756   C0220847:Hepatitis C virus [Virus]
   708   C0019186:Hepatitis virus [Virus]

Phrase: "detected in all patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0442726:Detected [Finding]
   770   C1511790:Detected [Therapeutic or Preventive Procedure]

Phrase: "belonged to genotype 1a."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0017431:Genotype [Organism Attribute]
   770   C0450344:1A [Intellectual Product]
   770   C1553633:1a [Medical Device]
Processing 00000000.tx.67: By contrast, the sequence isolated only from patient LM shared homology with genotype 1b. 

Phrase: "By contrast,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1979874:Contrast [Qualitative Concept]

Phrase: "the sequence"
Meta Candidates (Total=6; Excluded=2; Pruned=0; Remaining=4)
  1000   C0004793:Sequence [Nucleotide Sequence]
  1000   C0162326:Sequence [Nucleotide Sequence]
  1000   C0162327:Sequence [Nucleotide Sequence]
  1000   C1519249:Sequence [Functional Concept]
   928 E C1548958:Sequential [Idea or Concept]
   928 E C1705294:Sequential [Qualitative Concept]

Phrase: "isolated"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0205409:Isolated [Functional Concept]
  1000   C1548221:Isolated [Idea or Concept]
   966 E C0370215:Isolate [Substance]
   966 E C1875400:ISOLATE [Pharmacologic Substance]

Phrase: "only from patient LM"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   770   C0030705:*^patient [Patient or Disabled Group]
   770   C0205171:Only [Quantitative Concept]
   770   C1261082:LM [Body Part, Organ, or Organ Component]
   770   C1551056:lm [Quantitative Concept]
   770   C1720467:Only [Intellectual Product]
   770   C2981682:LM [Quantitative Concept]

Phrase: "shared"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0237876:shared [Social Behavior]
  1000   C1522138:Shared [Functional Concept]

Phrase: "homology with genotype 1b."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C1334043:Homology [Gene or Genome]
   770   C2697616:Homology [Qualitative Concept]
Processing 00000000.tx.68: This patient was anti-HCV Ab-negative before IVIG and received 1 U of packed RBCs during splenectomy after IVIG. 

Phrase: "This patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "was"

Phrase: "anti-HCV Ab-negative before IVIG"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   762   C0855852:negative antibody [Laboratory or Test Result]
   742   C0205160:Negative [Qualitative Concept]
   742   C1513916:Negative [Finding]
   742   C2825415:Negative [Conceptual Entity]
   742   C2825491:Negative [Qualitative Concept]

Phrase: "and"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "1 U of packed RBCs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   757   C0301863:"U" cell [Cell]

Phrase: "during splenectomy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0037995:Splenectomy [Therapeutic or Preventive Procedure]

Phrase: "after IVIG."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.69: However, 2 of the 3 patients who showed complete homology of all HVR1 sequences of E2 gene also had received multiple transfusions. 

Phrase: "However,"

Phrase: "2 of the 3 patients"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   797   C1519042:2-3 [Research Activity]
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0740116:+2 [Quantitative Concept]
   760   C2827735:2+ [Quantitative Concept]
   760   C2981700:2+ [Classification]

Phrase: "who"

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "complete homology of all HVR1 sequences of E2 gene also"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   751   C0314644:Homology region [Genetic Function]
   736   C1334043:Homology [Gene or Genome]
           Gene Homolog
   736   C2697616:Homology [Qualitative Concept]
   734   C0162775:Sequence Homology [Quantitative Concept]

Phrase: "had"

Phrase: "received multiple transfusions."
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   827   C0005841:Transfusions [Therapeutic or Preventive Procedure]
   827   C0199960:transfusions [Functional Concept]
   827   C1879316:Transfusions [Therapeutic or Preventive Procedure]
   793 E C0455012:Transfusion [Therapeutic or Preventive Procedure]
   743 E C1549003:Transfused [Idea or Concept]
Processing 00000000.tx.70: The clinical course of HCV hepatitis in the double-infected patient (LM) was mild. 

Phrase: "The clinical course of HCV hepatitis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0449259:Clinical course [Temporal Concept]
   744   C0205210:Clinical [Qualitative Concept]
   744   C0750729:Course [Temporal Concept]

Phrase: "in the double-infected patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:*^patient [Patient or Disabled Group]

Phrase: "(LM)"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C1261082:LM [Body Part, Organ, or Organ Component]
  1000   C1551056:lm [Quantitative Concept]
  1000   C2981682:LM [Quantitative Concept]

Phrase: "was"

Phrase: "mild."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2945599:Mild [Qualitative Concept]
Processing 00000000.tx.71: Clinical course. 

Phrase: "Clinical course."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0449259:Clinical course [Temporal Concept]
   861   C0205210:Clinical [Qualitative Concept]
   861   C0750729:Course [Temporal Concept]
Processing 00000000.tx.72: Clinical or laboratory features of acute hepatitis developed in all 11 evaluable patients (Table 3). 

Phrase: "Clinical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205210:Clinical [Qualitative Concept]

Phrase: "or"

Phrase: "laboratory"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0022877:Laboratory [Manufactured Object,Organization]
  1000   C3244292:laboratory [Functional Concept]

Phrase: "features of acute hepatitis"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   833   C0267797:Acute hepatitis [Disease or Syndrome]
   770   C0019158:Hepatitis [Disease or Syndrome]
   770   C0019159:hepatitis [Disease or Syndrome]
   770   C0205178:acute [Temporal Concept]
   770   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   770   C1521970:Feature [Qualitative Concept]
   770   C1706388:Feature [Conceptual Entity]
   770   C2346469:Feature [Qualitative Concept]
   770   C2348519:Feature [Qualitative Concept]

Phrase: "developed in all 11 evaluable patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C2986511:evaluable patients [Patient or Disabled Group]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C1516986:Evaluable [Disease or Syndrome]

Phrase: "(Table 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.73: Liver failure, defined as a reduction of prothrombin activity below 50% and/or of albumin concentration below 2.5 g/dL and/or an irreversible elevation of bilirubin level greater than 10 mg/dL, developed in five patients, while ALT levels never exceeded 1,000 IU/mL. 

Phrase: "Liver failure,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0085605:Liver Failure [Disease or Syndrome]
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "defined as a reduction of prothrombin activity"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   778   C0200396:Prothrombin.activity [Laboratory Procedure]
   778   C3274435:Prothrombin Activity [Laboratory Procedure]
   774   C2267000:Reduction Activity [Molecular Function]
   748   C0033706:Prothrombin [Amino Acid, Peptide, or Protein,Biologically Active Substance,Pharmacologic Substance]
   748   C0205177:Activity [Functional Concept]
   748   C0301630:Reduction [Natural Phenomenon or Process]
   748   C0392756:Reduction [Qualitative Concept]
   748   C0439167:% activity [Quantitative Concept]
   748   C0441610:Reduction [Therapeutic or Preventive Procedure]
   748   C0441655:Activity [Activity]
   748   C1561536:*Activity [Idea or Concept]
   748   C1704788:Defined [Conceptual Entity]
   748   C2828369:Prothrombin [Organic Chemical,Pharmacologic Substance]
   748   C3539106:Defined [Intellectual Product]

Phrase: "below 50%"

Phrase: "and/or of albumin concentration"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   806   C0486291:Albumin concentration [Laboratory or Test Result]
   806   C1706528:And/Or [Conceptual Entity]
   760   C0001924:Albumin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   760   C0086045:Concentration [Mental Process]
   760   C1446561:Concentration [Quantitative Concept]
   760   C1515981:And [Idea or Concept]

Phrase: "below 2.5 g/dL"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439267:g/dL [Quantitative Concept]
   812   C3642216:/dL [Quantitative Concept]

Phrase: "and/or"

Phrase: "an irreversible elevation of bilirubin level"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0439775:Elevation [Therapeutic or Preventive Procedure]
   753   C0702240:Elevation [Spatial Concept]

Phrase: "greater than 10 mg/dL,"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   806   C0439093:Greater Than [Quantitative Concept]
   760   C0443228:greater [Quantitative Concept]
   760   C1704243:Greater [Quantitative Concept]
   726 E C0549177:Great [Quantitative Concept]

Phrase: "developed in five patients,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0205451:Five [Quantitative Concept]

Phrase: "while"

Phrase: "ALT levels never"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]

Phrase: "exceeded"

Phrase: "1,000 IU/mL."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439458:IU/mL [Quantitative Concept]
   812   C0439526:/mL [Quantitative Concept]
Processing 00000000.tx.74: A liver biopsy was performed in three patients. 

Phrase: "A liver biopsy"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
  1000   C0193388:Liver Biopsy [Diagnostic Procedure]
   861   C0005558:Biopsy [Diagnostic Procedure]
   861   C0023884:Liver [Body Part, Organ, or Organ Component]
   861   C0220797:biopsy [Functional Concept]
   861   C0736268:LIVER [Body Part, Organ, or Organ Component]
   861   C1278929:Liver [Body Part, Organ, or Organ Component]
   861   C2346688:LIVER [Food]
   805 E C0205054:Hepatic [Body Location or Region]

Phrase: "was"

Phrase: "performed in three patients."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0205449:Three [Quantitative Concept]
   770   C0884358:Performed [Functional Concept]
   737 E C2947996:Perform [Pharmacologic Substance]
Processing 00000000.tx.75: Liver histology showed moderately aggressive chronic hepatitis in one ITP patient with chronic ALT elevation as well as in one ID patient with low-grade non-Hodgkin's lymphoma. 

Phrase: "Liver histology"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0019638:Histology [Biomedical Occupation or Discipline]
   861   C0205462:histology [Functional Concept]
   861   C0344441:Histology [Laboratory Procedure]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "moderately aggressive chronic hepatitis in one ITP patient"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   799   C0272293:Chronic idiopathic thrombocytopenic purpura [Disease or Syndrome]
           Chronic thrombocytopenic purpura
   782   C0520463:Aggressive chronic hepatitis [Disease or Syndrome]
   760   C0019189:Hepatitis, Chronic [Disease or Syndrome]
   757   C0332213:Chronic aggressive [Functional Concept]
   739   C0019158:Hepatitis [Disease or Syndrome]
   739   C0019159:hepatitis [Disease or Syndrome]
   739   C0205191:chronic [Temporal Concept]
   739   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   730   C0030781:PELIOSIS HEPATITIS [Disease or Syndrome]

Phrase: "with chronic ALT elevation"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0439775:Elevation [Therapeutic or Preventive Procedure]
   827   C0702240:Elevation [Spatial Concept]

Phrase: "as well as in one ID patient"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0021051:Immunodeficient [Disease or Syndrome]
   748   C0030705:*^patient [Patient or Disabled Group]
   748   C0205170:Well [Qualitative Concept]
   748   C0205447:One [Quantitative Concept]
   748   C3146287:Well [Manufactured Object]

Phrase: "with low-grade non-Hodgkin's lymphoma."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   911   C0079747:Lymphoma, Low-Grade [Neoplastic Process]
   884   C0024305:Lymphoma, Non-Hodgkin [Neoplastic Process]
   884   C2700512:LYMPHOMA, NON-HODGKIN [Gene or Genome]
   884   C3539720:Non-Hodgkin Lymphoma [Intellectual Product]
   840   C0019829:Hodgkin Lymphoma [Neoplastic Process]
   840   C3541281:Hodgkin Lymphoma [Intellectual Product]
   804   C0024299:Lymphoma [Neoplastic Process]
   804   C1518422:Non [Functional Concept]
Processing 00000000.tx.76: In this patient hepatic infiltration by lymphoma was excluded by immunohistochemistry. 

Phrase: "In this patient hepatic infiltration"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0332448:Infiltration [Pathologic Function]
   827   C0702249:Infiltration [Therapeutic or Preventive Procedure]
   827   C1523986:Infiltration [Functional Concept]

Phrase: "by lymphoma"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0024299:Lymphoma [Neoplastic Process]

Phrase: "was"

Phrase: "excluded by immunohistochemistry."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0021044:Immunohistochemistry [Laboratory Procedure]
   790   C1554077:Excluded [Idea or Concept]
   790   C2828389:Excluded [Activity]
   756 E C0332196:Exclude [Functional Concept]
Processing 00000000.tx.77: In the single marrow transplanted ID patient histology showed acute HCV hepatitis excluding the possibility of hepatic graft-versus-host disease. 

Phrase: "In the single marrow"
Meta Candidates (Total=7; Excluded=4; Pruned=0; Remaining=3)
   861   C0086590:Marrow [Food]
   861   C0376152:Marrow [Body Part, Organ, or Organ Component]
   861   C1546708:Marrow [Intellectual Product]
   805 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   805 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   805 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   777 E C0330477:Marrows [Plant]

Phrase: "transplanted"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0040732:transplanted [Therapeutic or Preventive Procedure]
  1000   C0332835:transplanted [Tissue]
  1000   C0700106:Transplanted [Functional Concept]

Phrase: "ID patient histology"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0019638:Histology [Biomedical Occupation or Discipline]
   827   C0205462:histology [Functional Concept]
   827   C0344441:Histology [Laboratory Procedure]

Phrase: "showed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "acute HCV hepatitis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   717   C0220847:Hepatitis C virus [Virus]
   717   C0400914:Acute hepatitis C [Disease or Syndrome]

Phrase: "excluding"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0332196:Exclude [Functional Concept]
   966   C2828389:Exclude [Activity]

Phrase: "the possibility of hepatic graft-versus-host disease."
Processing 00000000.tx.78: Liver biopsy was not performed in four ID patients because of coagulation defects. 

Phrase: "Liver biopsy"
Meta Candidates (Total=8; Excluded=1; Pruned=0; Remaining=7)
  1000   C0193388:Liver Biopsy [Diagnostic Procedure]
   861   C0005558:Biopsy [Diagnostic Procedure]
   861   C0023884:Liver [Body Part, Organ, or Organ Component]
   861   C0220797:biopsy [Functional Concept]
   861   C0736268:LIVER [Body Part, Organ, or Organ Component]
   861   C1278929:Liver [Body Part, Organ, or Organ Component]
   861   C2346688:LIVER [Food]
   805 E C0205054:Hepatic [Body Location or Region]

Phrase: "was"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "performed in four ID patients"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   760   C0021051:Immunodeficient [Disease or Syndrome]
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0205450:Four [Quantitative Concept]
   760   C0884358:Performed [Functional Concept]
   726 E C2947996:Perform [Pharmacologic Substance]

Phrase: "because of coagulation defects."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0005779:Coagulation defects [Disease or Syndrome]
   861   C0243067:defects [Functional Concept]
   827 E C1457869:Defect [Functional Concept]
   827 E C1861101:DEFECT [Disease or Syndrome]
Processing 00000000.tx.79: At the present time, seven patients, six ITP and one ID, are still alive 27 months after infected IVIG infusion. 

Phrase: "At the present time,"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   861   C0040223:Time [Temporal Concept]
   861   C3541383:Time [Temporal Concept]
   805 E C0442043:Temporal [Spatial Concept]
   805 E C2362314:Temporal [Temporal Concept]
   777 E C1632851:Times [Quantitative Concept]

Phrase: "seven patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "six ITP"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   923   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   861   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   861   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   812   C0034150:Purpura [Disease or Syndrome]
   812   C0332240:Idiopathic [Functional Concept]
   812   C3463943:Purpura [Eukaryote]

Phrase: "and"

Phrase: "one"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205447:One [Quantitative Concept]

Phrase: "ID,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021051:Immunodeficient [Disease or Syndrome]

Phrase: "are"

Phrase: "still alive 27 months after infected IVIG infusion."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   742   C0439231:months [Temporal Concept]
   708 E C0439507:/month [Temporal Concept]
Processing 00000000.tx.80: Six of them have mild chronic HCV hepatitis without showing signs of liver failure. 

Phrase: "Six of them"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205452:Six [Quantitative Concept]

Phrase: "have"

Phrase: "mild chronic HCV hepatitis without showing signs of liver failure."
Processing 00000000.tx.81: Six ID patients died 4.5 to 17 months after IVIG, 1 to 14 months (median, 2.5 months) after the development of hepatitis. 

Phrase: "Six ID patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "died"
Meta Candidates (Total=7; Excluded=5; Pruned=0; Remaining=2)
  1000   C0011065:Died [Organism Function]
  1000   C1546956:Died [Finding]
   928 E C0231800:Expired [Organ or Tissue Function]
   928 E C1704631:Expire [Idea or Concept]
   907 E C0184532:dying [Organism Function]
   907 E C1553404:terminated [Idea or Concept]
   907 E C2348570:Terminated [Functional Concept]

Phrase: "4.5 to 17 months"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   806   C0450367:4 5 [Quantitative Concept]
   760   C0439231:months [Temporal Concept]
   726 E C0439507:/month [Temporal Concept]

Phrase: "after IVIG,"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]

Phrase: "1 to 14 months"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   802   C1442451:1 Month [Temporal Concept]
   770   C0439231:months [Temporal Concept]
   770   C2827734:1+ [Quantitative Concept]
   770   C2981698:1+ [Classification]
   737 E C0439507:/month [Temporal Concept]

Phrase: "(median,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0549183:Median [Spatial Concept]
  1000   C0876920:Median [Quantitative Concept]
  1000   C2347635:Median [Quantitative Concept]
  1000   C2348144:Median [Quantitative Concept]
  1000   C2939193:Median [Spatial Concept]

Phrase: "2.5 months"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   913   C1442456:2 Months [Temporal Concept]
   827   C0439231:months [Temporal Concept]
   793 E C0439507:/month [Temporal Concept]
   734   C0450346:2 5 [Quantitative Concept]

Phrase: ")"

Phrase: "after the development"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0243107:development [Physiologic Function]
  1000   C0678723:Development [Organism Function]
  1000   C1527148:Development [Functional Concept]
   928 E C0458003:Developmental [Qualitative Concept]

Phrase: "of hepatitis."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0019158:Hepatitis [Disease or Syndrome]
  1000   C0019159:hepatitis [Disease or Syndrome]
  1000   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.82: The primary cause of death was protracted acute hepatitis in two patients, and chronic hepatitis, causing irreversible liver failure, in two others. 

Phrase: "The primary cause of death"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   926   C3262229:Primary Cause of Death [Finding]
   926   C3537403:Primary cause of death [Finding]
   862   C0007465:Cause of Death [Finding]
           Death Cause
   862   C0804771:Cause of death [Clinical Attribute]
   760   C0015127:cause [Functional Concept]
   760   C0205225:Primary [Qualitative Concept]
   760   C0439631:Primary [Therapeutic or Preventive Procedure]
   760   C1524003:Cause [Conceptual Entity]

Phrase: "was"

Phrase: "protracted"

Phrase: "acute hepatitis in two patients,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   806   C0267797:Acute hepatitis [Disease or Syndrome]
   760   C0019158:Hepatitis [Disease or Syndrome]
   760   C0019159:hepatitis [Disease or Syndrome]
   760   C0205178:acute [Temporal Concept]
   760   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "and"

Phrase: "chronic hepatitis,"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0019189:Hepatitis, Chronic [Disease or Syndrome]
   861   C0019158:Hepatitis [Disease or Syndrome]
   861   C0019159:hepatitis [Disease or Syndrome]
   861   C0205191:chronic [Temporal Concept]
   861   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "causing"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0678227:Causing [Functional Concept]
   966 E C0015127:cause [Functional Concept]
   966 E C1524003:Cause [Conceptual Entity]

Phrase: "irreversible liver failure,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0085605:Liver Failure [Disease or Syndrome]
   827   C0231174:Failure [Functional Concept]
   827   C0680095:failure [Individual Behavior]

Phrase: "in two others."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1955473:Others [Finding]
Processing 00000000.tx.83: Liver disease was a significant contributory cause of death in the remaining two cases. 

Phrase: "Liver disease"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
  1000   C0023895:Liver disease [Disease or Syndrome]
   861   C0012634:Disease [Disease or Syndrome]
   861   C0023884:Liver [Body Part, Organ, or Organ Component]
   861   C0736268:LIVER [Body Part, Organ, or Organ Component]
   861   C1278929:Liver [Body Part, Organ, or Organ Component]
   861   C2346688:LIVER [Food]
   805 E C0205054:Hepatic [Body Location or Region]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "was"

Phrase: "a significant contributory cause of death"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0007465:Cause of Death [Finding]
           Death Cause
   833   C0804771:Cause of death [Clinical Attribute]
   753   C0015127:cause [Functional Concept]
   753   C1524003:Cause [Conceptual Entity]

Phrase: "in the remaining two cases."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   827   C0868928:Cases [Functional Concept]
   827   C1533148:Cases [Quantitative Concept]
   793 E C1706255:CASE [Medical Device]
   793 E C1706256:Case [Conceptual Entity]
Processing 00000000.tx.84: HCV infection was considered the main cause of hepatic disease in all cases. 

Phrase: "HCV infection"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   923   C0019196:Hepatitis C Infection [Disease or Syndrome]
   861   C0042769:virus infection [Disease or Syndrome]
   812   C0009450:Infection, NOS [Disease or Syndrome]
   756   C0220847:Hepatitis C virus [Virus]
   741 E C0439663:Infected [Functional Concept]
   708   C0019186:Hepatitis virus [Virus]
   701 E C0030657:infectivity [Qualitative Concept]

Phrase: "was"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "the main cause of hepatic disease"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   783   C1314792:disease cause [Functional Concept]
   753   C0015127:cause [Functional Concept]
   753   C1524003:Cause [Conceptual Entity]

Phrase: "in all cases."
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0868928:Cases [Functional Concept]
  1000   C1533148:Cases [Quantitative Concept]
   966 E C1706255:CASE [Medical Device]
   966 E C1706256:Case [Conceptual Entity]
Processing 00000000.tx.85: Serologic studies excluded coinfection both with hepatitis B virus and human immunodeficiency virus in all cases. 

Phrase: "Serologic studies"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   964   C0036743:Serology studies [Laboratory Procedure]
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "excluded"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1554077:Excluded [Idea or Concept]
  1000   C2828389:Excluded [Activity]
   966 E C0332196:Exclude [Functional Concept]

Phrase: "coinfection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0275524:Co-infection [Disease or Syndrome]

Phrase: "both with hepatitis B virus"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   862   C0019169:Hepatitis B Virus [Virus]
   806   C0019163:Hepatitis B [Disease or Syndrome]
   806   C0019378:B Virus [Virus]
   797   C0019186:Hepatitis virus [Virus]
   797   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   760   C0019158:Hepatitis [Disease or Syndrome]
   760   C0019159:hepatitis [Disease or Syndrome]
   760   C0042776:Virus [Virus]
   760   C0238767:Both [Spatial Concept]
   760   C0319157:virus [Virus]
   760   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   760   C1706086:Both [Qualitative Concept]

Phrase: "and"

Phrase: "human immunodeficiency virus in all cases."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   833   C0019682:Virus, Human Immunodeficiency [Virus]
   790   C0682458:immunodeficiency virus [Virus]
   783   C0318356:Human virus [Virus]
   753   C0021051:IMMUNO-DEFICIENCY [Disease or Syndrome]
   753   C0042776:Virus [Virus]
   753   C0086418:Human [Human]
   753   C0319157:virus [Virus]
Processing 00000000.tx.86: Cytomegalovirus and Epstein-Barr virus coinfection was excluded in five and three ID patients, respectively. 

Phrase: "Cytomegalovirus"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010825:Cytomegalovirus [Virus]

Phrase: "and"

Phrase: "Epstein-Barr virus coinfection"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   812   C0275524:Co-infection [Disease or Syndrome]
   756   C0014644:Epstein-Barr Virus [Virus]

Phrase: "was"

Phrase: "excluded in five"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   790   C0205451:Five [Quantitative Concept]
   790   C1554077:Excluded [Idea or Concept]
   790   C2828389:Excluded [Activity]
   756 E C0332196:Exclude [Functional Concept]

Phrase: "and"

Phrase: "three ID patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "respectively."
Processing 00000000.tx.87: After IVIG therapy, the clinical course of the underlying hematologic disorder did not accelerate in any of the cases studied, nor were there any major changes in hematologic treatment, and none of the patients received cytostatic or immunosuppressive agents, which they had not received before IVIG (Table 1). 

Phrase: "After IVIG therapy,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C0455142:Intravenous therapy [Therapeutic or Preventive Procedure]
   884   C0021022:Immunoglobulin Therapy [Therapeutic or Preventive Procedure]
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C1363945:Therapy [Finding]
   734   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "the clinical course of the underlying hematologic disorder"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   793   C0242656:Course of disorder [Pathologic Function]
   770   C0449259:Clinical course [Temporal Concept]
   744   C0205210:Clinical [Qualitative Concept]
   744   C0750729:Course [Temporal Concept]
   731   C1274118:Clinical haematology [Biomedical Occupation or Discipline]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "accelerate in any of the cases"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   753   C0521110:accelerate [Functional Concept]
   753   C0868928:Cases [Functional Concept]
   753   C1533148:Cases [Quantitative Concept]
   719 E C1706255:CASE [Medical Device]
   719 E C1706256:Case [Conceptual Entity]

Phrase: "studied"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C0557651:Study [Manufactured Object]
   966   C2603343:Study [Research Activity]

Phrase: ","

Phrase: "nor"

Phrase: "were"

Phrase: "there"

Phrase: "any major changes in hematologic treatment,"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   753   C0392747:changes [Functional Concept]
   753   C0443172:changes [Quantitative Concept]
   719 E C1705241:Change [Quantitative Concept]

Phrase: "and"

Phrase: "none of the patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0456148:None [Quantitative Concept]
   770   C0549184:None [Quantitative Concept]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "cytostatic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0010858:cytostatic [Pharmacologic Substance]

Phrase: "or"

Phrase: "immunosuppressive agents,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
  1000   C0021081:Immunosuppressive Agents [Immunologic Factor,Pharmacologic Substance]
   827   C0450442:Agent [Chemical Viewed Functionally]
   827   C1254351:Agent [Pharmacologic Substance]
   827   C1521826:Agent [Intellectual Product]

Phrase: "which"

Phrase: "they"

Phrase: "had"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "received before IVIG"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   833   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   770   C0348016:Intravenous [Spatial Concept]
   770   C1514756:Received [Qualitative Concept]
   737 E C1621846:immunoglobulin [Molecular Function]

Phrase: "(Table 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.88: Comparison between ITP and ID patients. 

Phrase: "Comparison between ITP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C1707455:Comparison [Activity]

Phrase: "and"

Phrase: "ID patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.89: The two subgroups of patients did not show significant differences in age, performance status at the time of IVIG infusion, and frequency of corticosteroid therapy before and after IVIG. 

Phrase: "The two subgroups of patients"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C1079230:subgroups [Virus]
   726 E C1515021:Subgroup [Classification]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "significant differences in age,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   819   C0699810:age differences [Age Group]
   737   C1705241:*Difference [Quantitative Concept]
   737   C1705242:Difference [Qualitative Concept]

Phrase: "performance status at the time of IVIG infusion,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   764   C1518965:Performance Status [Clinical Attribute]
   742   C0449438:Status [Qualitative Concept]
   742   C0597198:Performance [Individual Behavior]
   742   C1882330:Performance [Activity]

Phrase: "and"

Phrase: "frequency of corticosteroid therapy"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   770   C0376249:frequency [Quantitative Concept]
   770   C0439603:Frequency [Temporal Concept]
   770   C0871396:Frequency [Quantitative Concept]
   770   C1561548:Frequency [Qualitative Concept]
   770   C1705502:Frequency [Quantitative Concept]

Phrase: "before"

Phrase: "and after IVIG."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   833   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   770   C0348016:Intravenous [Spatial Concept]
   770   C1515981:And [Idea or Concept]
   737 E C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.90: In the subgroup of ID patients, there was a predominance of males and patients received more cytostatic and/or immunosuppressive agents other than corticosteroids both before and after IVIG. 

Phrase: "In the subgroup"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1079230:subgroup [Virus]
  1000   C1515021:Subgroup [Classification]

Phrase: "of ID patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "there"

Phrase: "was"

Phrase: "a predominance of males"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   802   C1835590:Male predominance [Finding]

Phrase: "and"

Phrase: "patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "more cytostatic"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0010858:cytostatic [Pharmacologic Substance]

Phrase: "and/or"

Phrase: "immunosuppressive agents other than corticosteroids"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   806   C0021081:Immunosuppressive Agents [Immunologic Factor,Pharmacologic Substance]
   726   C0450442:Agent [Chemical Viewed Functionally]
   726   C1254351:Agent [Pharmacologic Substance]
   726   C1521826:Agent [Intellectual Product]

Phrase: "both before"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332152:Before [Temporal Concept]
  1000   C1705850:Before [Intellectual Product]

Phrase: "and after IVIG."
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   833   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   770   C0348016:Intravenous [Spatial Concept]
   770   C1515981:And [Idea or Concept]
   737 E C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.91: On the other hand, ITP patients were all females and three of them were splenectomized after IVIG (Table 1). 

Phrase: "On the"

Phrase: "other hand,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0018563:Hand [Body Part, Organ, or Organ Component]
  1000   C1281583:Hand [Body Part, Organ, or Organ Component]
  1000   C1552914:hand [Quantitative Concept]
   944 E C0024763:Manual [Intellectual Product,Manufactured Object]
   944 E C0175674:Manual [Functional Concept]

Phrase: "ITP patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0030705:Patients [Patient or Disabled Group]
   756   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura

Phrase: "were"

Phrase: "all females"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0015780:Females [Finding]
  1000   C0086287:Females [Population Group]
   966 E C0043210:female [Population Group]
   966 E C1705497:Female [Qualitative Concept]
   966 E C1705498:Female [Qualitative Concept]

Phrase: "and"

Phrase: "three of them"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0205449:Three [Quantitative Concept]

Phrase: "were"

Phrase: "splenectomized after IVIG"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   833   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   770   C0348016:Intravenous [Spatial Concept]
   737 E C1621846:immunoglobulin [Molecular Function]

Phrase: "(Table 1"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.92: The mean dose of IVIG received by the ITP patients was 88 g (SD  51), significantly higher than that of the ID patients (31.2 g; 

Phrase: "The mean dose of IVIG"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   753   C0178602:Dose [Quantitative Concept]
   753   C0444504:Mean [Quantitative Concept]
   753   C0869039:Dose [Quantitative Concept]
   753   C1114758:Dose # [Clinical Attribute]
   753   C2347634:Mean [Quantitative Concept]
   753   C2348143:Mean [Quantitative Concept]

Phrase: "received by the ITP patients"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   814   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   778   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   778   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   778   C1709850:Received By [Qualitative Concept]
   748   C0030705:Patients [Patient or Disabled Group]
   748   C0034150:Purpura [Disease or Syndrome]
   748   C0332240:Idiopathic [Functional Concept]
   748   C1514756:Received [Qualitative Concept]
   748   C3463943:Purpura [Eukaryote]

Phrase: "was"

Phrase: "88 g (SD  51"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0439267:g% [Quantitative Concept]

Phrase: ")"

Phrase: ","

Phrase: "significantly higher than that of the ID patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   711   C0205250:High [Qualitative Concept]
   711   C1299351:High [Qualitative Concept]
   711   C2700149:HIGH [Intellectual Product]

Phrase: "(31.2 g"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0439267:g% [Quantitative Concept]

Phrase: ";"
Processing 00000000.tx.93: SD: 9.8) (Student's t-test: P = .015). 

Phrase: "SD"

Phrase: ":"

Phrase: "9.8"

Phrase: ")"

Phrase: "(Student's t-test"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   827   C0022885:Test [Laboratory Procedure]
   827   C0038492:student [Professional or Occupational Group]
   827   C0039593:Test [Functional Concept]
   827   C0392366:test [Intellectual Product]
   827   C1551041:student [Idea or Concept]
   827   C1552573:student [Intellectual Product]

Phrase: ":"

Phrase: "P = .015"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.94: During acute infection, there were no significant differences in the duration of the incubation period as well as in ALT peak levels, although the highest levels were recorded among ITP patients whereas ALT never exceeded 1,000 U/dL in ID patients (Table 3). 

Phrase: "During acute infection,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0275518:Acute infection [Disease or Syndrome]
   861   C0009450:Infection, NOS [Disease or Syndrome]
   789 E C0439663:Infected [Functional Concept]
   750 E C0030657:infectivity [Qualitative Concept]

Phrase: "there"

Phrase: "were"

Phrase: "no significant differences in the duration of the incubation period"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   706   C1705241:*Difference [Quantitative Concept]
   706   C1705242:Difference [Qualitative Concept]

Phrase: "as well as in ALT peak levels,"
Meta Candidates (Total=8; Excluded=3; Pruned=0; Remaining=5)
   762   C0444505:Peak level [Quantitative Concept]
           Peak
   748   C0205170:Well [Qualitative Concept]
   748   C0441889:Levels [Qualitative Concept]
   748   C3146287:Well [Manufactured Object]
   714 E C0456079:Level [Classification]
   714 E C1547707:Level [Geographic Area]
   714 E C2946261:Level [Pharmacologic Substance]

Phrase: "although"

Phrase: "the highest levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "were"

Phrase: "recorded among ITP patients"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   833   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   790   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   790   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0034150:Purpura [Disease or Syndrome]
   753   C0332240:Idiopathic [Functional Concept]
   753   C3463943:Purpura [Eukaryote]
   719   C0034869:Record [Intellectual Product]

Phrase: "whereas"

Phrase: "ALT never"

Phrase: "exceeded"

Phrase: "1,000 U/dL in ID patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   778   C1532632:U/dL [Quantitative Concept]
   778   C1880520:U/dL [Quantitative Concept]
   748   C3642216:/dL [Quantitative Concept]

Phrase: "(Table 3"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039224:Table [Manufactured Object]
   861   C1706073:Table [Medical Device]
   861   C1706074:Table [Intellectual Product]

Phrase: ")."
Processing 00000000.tx.95: On the other hand, ID patients had more marked increases of bilirubin levels. 

Phrase: "On the"

Phrase: "other hand,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0018563:Hand [Body Part, Organ, or Organ Component]
  1000   C1281583:Hand [Body Part, Organ, or Organ Component]
  1000   C1552914:hand [Quantitative Concept]
   944 E C0024763:Manual [Intellectual Product,Manufactured Object]
   944 E C0175674:Manual [Functional Concept]

Phrase: "ID patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "had"

Phrase: "more marked increases of bilirubin levels."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0442805:increases [Functional Concept]
Processing 00000000.tx.96: A bilirubin level greater than 5 mg/dL occurred in 86% of ID patients compared with 33% of ITP patients. 

Phrase: "A bilirubin level"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0344395:Bilirubin level [Laboratory Procedure]
  1000   C1287365:Bilirubin level [Laboratory or Test Result]
   861   C0005437:Bilirubin [Biologically Active Substance,Organic Chemical]
   861   C0441889:Level [Qualitative Concept]
   861   C0456079:Level [Classification]
   861   C1547707:Level [Geographic Area]
   861   C2946261:Level [Pharmacologic Substance]

Phrase: "greater than 5 mg/dL"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   806   C0439093:Greater Than [Quantitative Concept]
   760   C0443228:greater [Quantitative Concept]
   760   C1704243:Greater [Quantitative Concept]
   726 E C0549177:Great [Quantitative Concept]

Phrase: "occurred in 86% of ID patients"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   753   C0021051:Immunodeficient [Disease or Syndrome]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C1709305:Occurred [Activity]
   719 E C2745955:OCCUR [Temporal Concept]

Phrase: "compared with 33% of ITP patients."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   800   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   770   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   770   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   744   C0030705:Patients [Patient or Disabled Group]
   744   C0034150:Purpura [Disease or Syndrome]
   744   C0332240:Idiopathic [Functional Concept]
   744   C1707455:Compared [Activity]
   744   C3463943:Purpura [Eukaryote]
Processing 00000000.tx.97: Chronic HCV hepatitis developed in all evaluable ID patients and in 5 of 6 ITP patients. 

Phrase: "Chronic HCV hepatitis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   717   C0220847:Hepatitis C virus [Virus]
   717   C0524910:Hepatitis C, Chronic [Disease or Syndrome]

Phrase: "developed in all evaluable ID patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   783   C2986511:evaluable patients [Patient or Disabled Group]
   753   C0021051:Immunodeficient [Disease or Syndrome]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C1516986:Evaluable [Disease or Syndrome]

Phrase: "and in 5 of 6 ITP patients."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   790   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   764   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   764   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   742   C0030705:Patients [Patient or Disabled Group]
   742   C0034150:Purpura [Disease or Syndrome]
   742   C0332240:Idiopathic [Functional Concept]
   742   C1515981:And [Idea or Concept]
   742   C3463943:Purpura [Eukaryote]
Processing 00000000.tx.98: Signs of liver failure developed in 71% of ID patients and in no ITP patient (Chi-square analysis with Yates's correction: P = .04). 

Phrase: "Signs of liver failure"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0220912:signs [Functional Concept]
   770   C0220913:signs [Manufactured Object]
   770   C0311392:SIGNS [Finding]
   737 E C1547188:Sign [Idea or Concept]

Phrase: "developed in 71% of ID patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0021051:Immunodeficient [Disease or Syndrome]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0450389:71 [Intellectual Product]

Phrase: "and in no ITP patient"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   814   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   778   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   778   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   748   C0030705:*^patient [Patient or Disabled Group]
   748   C0034150:Purpura [Disease or Syndrome]
   748   C0332240:Idiopathic [Functional Concept]
   748   C1515981:And [Idea or Concept]
   748   C3463943:Purpura [Eukaryote]

Phrase: "(Chi-square analysis with Yates's correction"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0002778:Analysis [Laboratory Procedure]
   753   C0936012:Analysis [Research Activity]
   753   C1524024:analysis [Functional Concept]

Phrase: ":"

Phrase: "P = .04"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.99: Two years after IVIG, only one ID patient was alive (14%) whereas all ITP patients were alive. 

Phrase: "Two years after IVIG,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0439234:years [Temporal Concept]
   726 E C0439508:/year [Temporal Concept]

Phrase: "only one ID patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0030705:*^patient [Patient or Disabled Group]

Phrase: "was"

Phrase: "alive"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0376558:Alive [Idea or Concept]
  1000   C2584946:Alive [Finding]

Phrase: "(14%"

Phrase: ")"

Phrase: "whereas"

Phrase: "all ITP patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0030705:Patients [Patient or Disabled Group]
   756   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura

Phrase: "were"

Phrase: "alive."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0376558:Alive [Idea or Concept]
  1000   C2584946:Alive [Finding]
Processing 00000000.tx.100: The median survival of ID patients was 12 months, significantly worse than that of ITP patients (Mantel-Cox analysis: P = .003).  

Phrase: "The median survival of ID patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0038952:Survival [Activity]
   753   C0220921:survival [Functional Concept]

Phrase: "was"

Phrase: "12 months,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   861   C0439231:months [Temporal Concept]
   827 E C0439507:/month [Temporal Concept]

Phrase: "significantly worse than that of ITP patients"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   742   C0332271:worse [Qualitative Concept]
   742   C1279889:Worse [Finding]
   742   C1457868:Worse [Qualitative Concept]
   708 E C0205169:Bad [Qualitative Concept]
   708 E C0231218:Ill [Sign or Symptom]

Phrase: "(Mantel-Cox analysis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0002778:Analysis [Laboratory Procedure]
   827   C0936012:Analysis [Research Activity]
   827   C1524024:analysis [Functional Concept]

Phrase: ":"

Phrase: "P = .003"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C2603361:P' [Clinical Attribute]

Phrase: ")."
Processing 00000000.tx.101: DISCUSSION Abstract Introduction Methods Results Discussion References The present study describes the development of HCV hepatitis in a small group of hematologic patients treated with a preparation of contaminated IVIG. 

Phrase: "DISCUSSION Abstract Introduction Methods Results Discussion"

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "The present study"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0150312:Present [Quantitative Concept]
   861   C0449450:Present [Idea or Concept]
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]

Phrase: "describes"

Phrase: "the development of HCV hepatitis"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   774   C0599615:virus development [Organism Function]
   748   C0243107:development [Physiologic Function]
   748   C0678723:Development [Organism Function]
   748   C1527148:Development [Functional Concept]

Phrase: "in a small group"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0679993:small group [Group Attribute]
   861   C0441833:Group [Idea or Concept]
   861   C0687744:group [Population Group]
   861   C1257890:Group [Population Group]
   861   C1552516:Group [Health Care Related Organization]
   861   C1705428:Group [Conceptual Entity]
   861   C1705429:Group [Population Group]

Phrase: "of hematologic patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "treated with a preparation of contaminated IVIG."
Meta Candidates (Total=15; Excluded=2; Pruned=0; Remaining=13)
   770   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   750   C0020835:Immunoglobulin A [Amino Acid, Peptide, or Protein,Immunologic Factor]
   750   C2825347:Immunoglobulin A [Immunologic Factor,Pharmacologic Substance]
   744   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   744   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   744   C0205279:Contaminated [Functional Concept]
   744   C0348016:Intravenous [Spatial Concept]
   744   C0455052:Preparation [Health Care Activity]
   744   C1521827:Preparation [Functional Concept]
   744   C1522326:Treated [Functional Concept]
   744   C2349974:CONTAMINATED [Idea or Concept]
   711 E C1292734:TREAT [Functional Concept]
   711 E C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.102: Because both a common source of infection and a common etiologic agent were detected in different patients, the influence of the patients' characteristics, particularly of their immune status, on the clinical course and prognosis of HCV infection could be analyzed in detail. 

Phrase: "Because"

Phrase: "both a common source of infection"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0449426:Source of infection [Finding]
           infection source
   753   C0449416:Source [Finding]
   753   C1705919:Source [Idea or Concept]

Phrase: "and"

Phrase: "a common etiologic agent"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C1254373:etiologic agent [Substance]
   827   C0450442:Agent [Chemical Viewed Functionally]
   827   C1254351:Agent [Pharmacologic Substance]
   827   C1521826:Agent [Intellectual Product]

Phrase: "were"

Phrase: "detected in different patients,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0442726:Detected [Finding]
   770   C1511790:Detected [Therapeutic or Preventive Procedure]
   770   C1705242:Different [Qualitative Concept]

Phrase: "the influence of the patients' characteristics,"

Phrase: "particularly of their immune status,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0020964:Immune status [Physiologic Function]
   760   C0439662:Immune [Functional Concept]
   760   C0449438:Status [Qualitative Concept]

Phrase: "on the clinical course"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0449259:Clinical course [Temporal Concept]
   861   C0205210:Clinical [Qualitative Concept]
   861   C0750729:Course [Temporal Concept]

Phrase: "and"

Phrase: "prognosis of HCV infection"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0033325:Prognosis [Health Care Activity]

Phrase: "could"

Phrase: "be"

Phrase: "analyzed in detail."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0936012:Analyzed [Research Activity]
   790   C1522508:Detail [Qualitative Concept]
   790   C1561567:detail [Functional Concept]
Processing 00000000.tx.103: Both epidemiological and clinical data closely linked the IVIG therapy received by all patients to subsequent development of HCV hepatitis. 

Phrase: "Both epidemiological"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0014507:Epidemiological [Biomedical Occupation or Discipline]
   928 E C0014508:epidemiology [Functional Concept]
   928 E C0699910:epidemiology [Health Care Activity]

Phrase: "and"

Phrase: "clinical data closely"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C1516606:Clinical Data [Intellectual Product]
   827   C1511726:Data [Idea or Concept]
   827   C3245479:data [Medical Device]

Phrase: "linked"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   966   C1517892:Link [Intellectual Product]
   966   C1704666:Link [Intellectual Product]

Phrase: "the IVIG therapy"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C0455142:Intravenous therapy [Therapeutic or Preventive Procedure]
   884   C0021022:Immunoglobulin Therapy [Therapeutic or Preventive Procedure]
   827   C0039798:therapy [Functional Concept]
   827   C0087111:Therapy [Therapeutic or Preventive Procedure]
   827   C1363945:Therapy [Finding]
   734   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "received by all patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   833   C1709850:Received By [Qualitative Concept]
   770   C0030705:Patients [Patient or Disabled Group]
   770   C1514756:Received [Qualitative Concept]

Phrase: "to subsequent development"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   861   C0243107:development [Physiologic Function]
   861   C0678723:Development [Organism Function]
   861   C1527148:Development [Functional Concept]
   789 E C0458003:Developmental [Qualitative Concept]

Phrase: "of HCV hepatitis."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   756   C0220847:Hepatitis C virus [Virus]
   708   C0019186:Hepatitis virus [Virus]
Processing 00000000.tx.104: In addition, virologic studies strongly suggested that patients were infected by at least one identical strain of HCV, consistent with the hypothesis of a single infection source. 

Phrase: "In addition,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1883712:Addition [Functional Concept]
   928 E C1524062:Additional [Functional Concept]

Phrase: "virologic studies strongly"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   827   C0947630:studies [Laboratory Procedure]
   793 E C0557651:Study [Manufactured Object]
   793 E C2603343:Study [Research Activity]

Phrase: "suggested"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "that patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "infected by"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   833   C0439663:Infected [Functional Concept]

Phrase: "at least one identical strain"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0080194:Strain [Injury or Poisoning]
   812   C0456178:strain [Intellectual Product]
   812   C1518614:Strain [Organism]
   812   C2987481:Strain [Mental Process]

Phrase: "of HCV,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   913   C0019186:Hepatitis virus [Virus]
   901   C0019196:Hepatitis C [Disease or Syndrome]
   827   C0019158:Hepatitis [Disease or Syndrome]
   827   C0019159:hepatitis [Disease or Syndrome]
   827   C0042776:Virus [Virus]
   827   C0319157:virus [Virus]
   827   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "consistent with the hypothesis of a single infection source."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   764   C0332290:Consistent with [Idea or Concept]
           Consistent
Processing 00000000.tx.105: The same HCV genotype 1 was shown in all the patients tested. 

Phrase: "The same HCV genotype 1"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   947   C3532919:Hepatitis C virus genotype 1 [Virus]
   901   C1148363:Hepatitis C virus genotype [Finding]
   901   C1533728:Hepatitis C virus genotype [Laboratory Procedure]
   861   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   839   C0019186:Hepatitis virus [Virus]
   827   C0019196:Hepatitis C [Disease or Syndrome]
   799   C0017431:Genotype [Organism Attribute]
   799   C0019158:Hepatitis [Disease or Syndrome]
   799   C0019159:hepatitis [Disease or Syndrome]
   799   C0042776:Virus [Virus]
   799   C0319157:virus [Virus]
   799   C0445247:Same [Qualitative Concept]
   799   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "was"

Phrase: "shown in all"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   756   C1547282:Show [Intellectual Product]

Phrase: "the patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "tested."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392366:tested [Intellectual Product]
   966 E C0022885:Test [Laboratory Procedure]
   966 E C0039593:Test [Functional Concept]
Processing 00000000.tx.106: More importantly, a high degree of homology was demonstrated among the HVR1 sequences derived from the four patients tested. 

Phrase: "More importantly,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205172:More [Functional Concept]

Phrase: "a high degree of homology"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   760   C0441889:Degree [Qualitative Concept]
   760   C0449286:Degree [Quantitative Concept]
   760   C0542560:Degree [Intellectual Product]
   760   C1561545:degree [Quantitative Concept]
   760   C2348088:Degree [Quantitative Concept]

Phrase: "was"

Phrase: "demonstrated among the HVR1 sequences"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   748   C0017446:Region [Geographic Area]
   748   C0162326:Sequences [Nucleotide Sequence]
   748   C0205147:Region [Spatial Concept]
   714 E C0004793:Sequence [Nucleotide Sequence]
   714 E C0162327:Sequence [Nucleotide Sequence]
   714 E C1519249:Sequence [Functional Concept]

Phrase: "derived from the four patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0205450:Four [Quantitative Concept]
   760   C1441547:Derived [Qualitative Concept]
   760   C3245521:derived [Idea or Concept]

Phrase: "tested."
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0392366:tested [Intellectual Product]
   966 E C0022885:Test [Laboratory Procedure]
   966 E C0039593:Test [Functional Concept]
Processing 00000000.tx.107: Because the HVR1 region is extremely variable among different isolates, and because distinct sequences can be identified even in a single patient,14 sequence analysis further strengthens the possibility of a common infectious source. 

Phrase: "Because"

Phrase: "the HVR1 region"

Phrase: "is"

Phrase: "extremely variable among different isolates,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0439828:Variable [Qualitative Concept]

Phrase: "and"

Phrase: "because"

Phrase: "distinct sequences"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
   861   C0162326:Sequences [Nucleotide Sequence]
   827 E C0004793:Sequence [Nucleotide Sequence]
   827 E C0162327:Sequence [Nucleotide Sequence]
   827 E C1519249:Sequence [Functional Concept]
   777 E C1548958:Sequential [Idea or Concept]
   777 E C1705294:Sequential [Qualitative Concept]

Phrase: "can"

Phrase: "be"

Phrase: "identified"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]

Phrase: "even in a single patient,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   760   C0030705:*^patient [Patient or Disabled Group]
   760   C0037179:Single [Population Group]
   760   C0087136:single [Finding]
   760   C0205171:Single [Quantitative Concept]

Phrase: "14 sequence analysis further"
Meta Candidates (Total=10; Excluded=2; Pruned=0; Remaining=8)
   861   C0162801:Sequence Analysis [Laboratory Procedure,Molecular Biology Research Technique]
   812   C0002778:Analysis [Laboratory Procedure]
   812   C0004793:Sequence [Nucleotide Sequence]
   812   C0162326:Sequence [Nucleotide Sequence]
   812   C0162327:Sequence [Nucleotide Sequence]
   812   C0936012:Analysis [Research Activity]
   812   C1519249:Sequence [Functional Concept]
   812   C1524024:analysis [Functional Concept]
   741 E C1548958:Sequential [Idea or Concept]
   741 E C1705294:Sequential [Qualitative Concept]

Phrase: "strengthens"

Phrase: "the possibility of a common infectious source."
Processing 00000000.tx.108: In one patient a second independent HVR1 sequence belonging to a different genotype was identified. 

Phrase: "In one patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "a second independent HVR1 sequence belonging to a different genotype"

Phrase: "was"

Phrase: "identified."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0205396:Identified [Qualitative Concept]
  1000   C1550043:Identified [Finding]
  1000   C1551388:Identified [Functional Concept]
Processing 00000000.tx.109: Because the original batches of IVIG were not available for study, it was impossible to assess whether double infection derived from IVIG or from different sources. 

Phrase: "Because"

Phrase: "the original batches of IVIG"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1550176:Batch [Idea or Concept]
   753   C1948031:Batch [Quantitative Concept]

Phrase: "were"

Phrase: "not available for study,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   833   C1548671:Not available [Idea or Concept]
   770   C0470187:Available [Functional Concept]

Phrase: "it"

Phrase: "was"

Phrase: "impossible to"

Phrase: "assess"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1516048:Assess [Activity]

Phrase: "whether"

Phrase: "double infection"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
   861   C0009450:Infection, NOS [Disease or Syndrome]
   789 E C0439663:Infected [Functional Concept]
   750 E C0030657:infectivity [Qualitative Concept]

Phrase: "derived from IVIG"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   833   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   770   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   770   C0348016:Intravenous [Spatial Concept]
   770   C1441547:Derived [Qualitative Concept]
   770   C3245521:derived [Idea or Concept]
   737 E C1621846:immunoglobulin [Molecular Function]

Phrase: "or from different sources."
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   770   C0449416:sources [Finding]
   770   C1705242:Different [Qualitative Concept]
   737 E C1705919:Source [Idea or Concept]
Processing 00000000.tx.110: Subdividing patients in two subgroups according to their underlying disease enabled us to analyze the relationship between HCV infection and the host's immune status. 

Phrase: "Subdividing patients in two subgroups"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0030705:Patients [Patient or Disabled Group]

Phrase: "according to their underlying disease"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "enabled"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0562342:Enabled [Mental Process]
   966 E C1171285:enable [Mental Process]

Phrase: "us to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "analyze"

Phrase: "the relationship between HCV infection"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   748   C0439849:Relationship [Qualitative Concept]
   748   C1705630:Relationship [Idea or Concept]
   748   C1706279:Relationship [Idea or Concept]
   748   C3540605:Relationship [Intellectual Product]

Phrase: "and"

Phrase: "the host's immune status."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   901   C0020964:Immune status [Physiologic Function]
   827   C0449438:Status [Qualitative Concept]
Processing 00000000.tx.111: The six patients with ITP were considered immunocompetent, whereas the remaining seven patients were considered ID, since they had hypogammaglobulinemia, either primary or secondary to chronic lymphoid malignancies, or graft-versus-host disease after bone marrow transplantation, a condition in which immune reconstitution is markedly impaired. 

Phrase: "The six patients with ITP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "immunocompetent,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1512656:Immunocompetent [Clinical Attribute]
   928 E C0020987:Immunocompetence [Cell Function]

Phrase: "whereas"

Phrase: "the remaining seven patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0030705:Patients [Patient or Disabled Group]

Phrase: "were"

Phrase: "considered"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0750591:considered [Idea or Concept]

Phrase: "ID,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021051:Immunodeficient [Disease or Syndrome]

Phrase: "since"

Phrase: "they"

Phrase: "had"

Phrase: "hypogammaglobulinemia,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0086438:Hypogammaglobulinaemia [Disease or Syndrome]

Phrase: "either primary"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205225:Primary [Qualitative Concept]
   861   C0439631:Primary [Therapeutic or Preventive Procedure]

Phrase: "or"

Phrase: "secondary to chronic lymphoid malignancies,"
Meta Candidates (Total=8; Excluded=2; Pruned=0; Remaining=6)
   806   C0175668:Secondary to [Temporal Concept]
           Secondary
   797   C0027627:secondary malignancies [Neoplastic Process]
           secondary
   797   C2939419:Secondary malignancies [Neoplastic Process]
   781 E C1558148:SECONDARY MALIGNANCY [Finding]
   781 E C3266877:Secondary Malignancy [Neoplastic Process]
   760   C0205436:Secondary [Quantitative Concept]

Phrase: "or"

Phrase: "graft-versus-host disease after bone marrow transplantation,"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   833   C0018133:Graft-Versus-Host Disease [Disease or Syndrome]
   833   C2984293:Graft-versus-host disease [Functional Concept]
   793   C0005956:Bone Marrow Disease [Disease or Syndrome]
   793   C0005961:Bone marrow graft [Therapeutic or Preventive Procedure]
   767   C0005940:Bone disease [Disease or Syndrome]
   767   C0005976:Bone graft [Therapeutic or Preventive Procedure]
   767   C0181075:Bone graft [Biomedical or Dental Material]
   744   C0012634:Disease [Disease or Syndrome]
   744   C0181074:{Graft} [Biomedical or Dental Material]
   744   C0332835:Graft [Tissue]
   744   C1167395:Host [Organism]
   744   C1961139:Graft, NOS [Therapeutic or Preventive Procedure]

Phrase: "a condition in which immune reconstitution"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C0012634:condition [Disease or Syndrome]
   753   C0348080:Condition [Qualitative Concept]
   753   C1705253:Condition [Conceptual Entity]

Phrase: "is"

Phrase: "markedly"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0522501:Markedly [Qualitative Concept]

Phrase: "impaired."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0221099:Impaired [Functional Concept]
  1000   C0684336:Impaired [Pathologic Function]
Processing 00000000.tx.112: The demonstration of the contact with HCV was difficult in ID patients. 

Phrase: "The demonstration of the contact"

Phrase: "with HCV"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   913   C0019186:Hepatitis virus [Virus]
   901   C0019196:Hepatitis C [Disease or Syndrome]
   827   C0019158:Hepatitis [Disease or Syndrome]
   827   C0019159:hepatitis [Disease or Syndrome]
   827   C0042776:Virus [Virus]
   827   C0319157:virus [Virus]
   827   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "was"

Phrase: "difficult in ID patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0332218:Difficult [Qualitative Concept]
Processing 00000000.tx.113: Serum anti-HCV Ab testing was not sufficient and had to be complemented with HCV-RNA detection by PCR, because only two of the seven patients developed antibodies to HCV after IVIG. 

Phrase: "Serum anti-HCV Ab testing"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0201472:hepatitis testing [Laboratory Procedure]
   818   C0580327:antibody testing [Laboratory Procedure]
   795   C0039593:Testing [Functional Concept]
   795   C0392366:testing [Intellectual Product]
   710   C0166049:Hepatitis C virus antibody [Immunologic Factor]
   710   C0201487:Hepatitis C Virus Antibody [Laboratory Procedure]

Phrase: "was"

Phrase: "not sufficient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0205410:Sufficient [Qualitative Concept]

Phrase: "and"

Phrase: "had"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "complemented with HCV-RNA detection"
Meta Candidates (Total=18; Excluded=0; Pruned=0; Remaining=18)
   853   C0369335:Hepatitis C virus RNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   814   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   804   C0855840:hepatitis c rna [Laboratory Procedure]
   778   C0019196:Hepatitis C [Disease or Syndrome]
   778   C0035691:Virus-RNA [Virus]
   778   C0035736:virus RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   774   C0019186:Hepatitis virus [Virus]
   774   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   774   C1294356:virus detection [Laboratory Procedure]
   748   C0019158:Hepatitis [Disease or Syndrome]
   748   C0019159:hepatitis [Disease or Syndrome]
   748   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   748   C0042776:Virus [Virus]
   748   C0319157:virus [Virus]
   748   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   748   C1511790:Detection [Therapeutic or Preventive Procedure]
   714   C0009498:Complement [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "by PCR,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0032520:Polymerase Chain Reaction [Laboratory Procedure,Molecular Biology Research Technique]
   827   C0337112:Chain [Manufactured Object]
   827   C0443286:Reaction [Functional Concept]
   827   C1114821:Reaction [Clinical Attribute]
   827   C1335439:Polymerase [Amino Acid, Peptide, or Protein,Enzyme]
   827   C1524075:Chain [Idea or Concept]

Phrase: "because"

Phrase: "only two of the seven patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0205448:Two [Quantitative Concept]

Phrase: "developed"

Phrase: "antibodies to HCV"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   988   C0166049:Antibody to hepatitis C virus [Immunologic Factor]
           Antibody to hepatitis C
           Hepatitis C Virus Antibodies
           Hepatitis C Antibodies
   883 E C0201487:Hepatitis C Virus Antibody [Laboratory Procedure]
   797   C0019161:Hepatitis Antibodies [Amino Acid, Peptide, or Protein,Immunologic Factor]
   797   C0368815:antibodies c [Amino Acid, Peptide, or Protein,Immunologic Factor]
   760   C0003241:Antibodies [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   726 E C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "after IVIG."
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
  1000   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   861   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   861   C0348016:Intravenous [Spatial Concept]
   827 E C1621846:immunoglobulin [Molecular Function]
Processing 00000000.tx.114: Similarly, low rates (53% to 66%) of anti-HCV Ab positivity were reported in HCV-infected patients with immunodeficiency disorders and with malignant hematologic diseases,9,15 but when the search for HCV-RNA was performed, HCV infection could be documented in 85% to 100% of patients with primary hypogammaglobulinemia5 or after bone marrow transplants from HCV-RNA-positive donors.16 On the other hand, anti-HCV Ab positivity developed in all ITP patients. 

Phrase: "Similarly,"

Phrase: "low rates"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0871208:Rate [Activity]
   827   C1521828:Rate [Quantitative Concept]

Phrase: "(53% to 66%"

Phrase: ")"

Phrase: "of anti-HCV Ab positivity"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   791   C0741132:antibody positive [Laboratory or Test Result]
   734   C0166049:Hepatitis C virus antibody [Immunologic Factor]
           Hepatitis C antibody
   734   C0201487:Hepatitis C Virus Antibody [Laboratory Procedure]
   727   C0439178:% Positive [Quantitative Concept]
   727   C1446409:Positive [Qualitative Concept]
   727   C1514241:Positive [Finding]
   727   C2825490:Positive [Qualitative Concept]
   712   C0051967:anti-c antibody [Immunologic Factor]
   709   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "were"

Phrase: "reported in HCV-infected patients"
Meta Candidates (Total=17; Excluded=1; Pruned=0; Remaining=16)
   814   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   778   C0019196:Hepatitis C [Disease or Syndrome]
   774   C0019186:Hepatitis virus [Virus]
   774   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   757   C0747307:patients report [Intellectual Product]
   748   C0019158:Hepatitis [Disease or Syndrome]
   748   C0019159:hepatitis [Disease or Syndrome]
   748   C0030705:Patients [Patient or Disabled Group]
   748   C0042776:Virus [Virus]
   748   C0319157:virus [Virus]
   748   C0439663:Infected [Functional Concept]
   748   C0684224:Reported [Intellectual Product]
   748   C0700287:Reported [Health Care Activity]
   748   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   748   C3496591:Reported [Clinical Attribute]
   714 E C3273238:Report [Intellectual Product]

Phrase: "with immunodeficiency disorders"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C0021051:Immunodeficiency disorder [Disease or Syndrome]
           IMMUNO-DEFICIENCY
   861   C0012634:Disorders [Disease or Syndrome]

Phrase: "and with malignant hematologic diseases,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   806   C0018939:Hematologic Diseases [Disease or Syndrome]
   781   C0442867:Malignant disease [Disease or Syndrome]
   760   C0012634:Diseases [Disease or Syndrome]
   760   C0018943:Hematologic [Biomedical Occupation or Discipline]
   760   C0205282:Malignant [Qualitative Concept]
   760   C0205488:Haematologic [Functional Concept]
   760   C0334590:MALIGNANT [Neoplastic Process]
   760   C1515981:And [Idea or Concept]
   760   C1533592:MALIGNANT [Neoplastic Process]

Phrase: "9,"

Phrase: "15"

Phrase: "but"

Phrase: "when"

Phrase: "the search for HCV-RNA"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C1552603:search [Intellectual Product]
   748   C1706202:Search [Activity]

Phrase: "was"

Phrase: "performed"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0884358:Performed [Functional Concept]
   966 E C2947996:Perform [Pharmacologic Substance]

Phrase: ","

Phrase: "HCV infection"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   923   C0019196:Hepatitis C Infection [Disease or Syndrome]
   861   C0042769:virus infection [Disease or Syndrome]
   812   C0009450:Infection, NOS [Disease or Syndrome]
   756   C0220847:Hepatitis C virus [Virus]
   741 E C0439663:Infected [Functional Concept]
   708   C0019186:Hepatitis virus [Virus]
   701 E C0030657:infectivity [Qualitative Concept]

Phrase: "could"

Phrase: "be"

Phrase: "documented in 85%"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   790   C1301725:Documented [Health Care Activity]
   790   C1609436:documented [Idea or Concept]
   756 E C1301746:document [Intellectual Product]
   756 E C1547673:Document [Intellectual Product]

Phrase: "to 100%"

Phrase: "of patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with primary hypogammaglobulinemia5"

Phrase: "or after bone marrow transplants"
Meta Candidates (Total=16; Excluded=5; Pruned=0; Remaining=11)
   862   C0005961:bone marrow transplants [Therapeutic or Preventive Procedure]
   806   C0005953:Bone Marrow [Tissue]
   797   C0005976:bone transplants [Therapeutic or Preventive Procedure]
   770 E C1708973:Medullary Bone [Tissue]
   760   C0086590:Marrow [Food]
   760   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   760   C0332835:Transplants [Tissue]
   760   C0376152:Marrow [Body Part, Organ, or Organ Component]
   760   C0391978:Bone [Tissue]
   760   C1266908:Bone [Body Part, Organ, or Organ Component]
   760   C1266909:Bone [Body System]
   760   C1546708:Marrow [Intellectual Product]
   726 E C0040732:Transplant [Therapeutic or Preventive Procedure]
   704 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   704 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   704 E C1550278:Medullary [Body Part, Organ, or Organ Component]

Phrase: "from HCV-RNA-positive donors.16"
Meta Candidates (Total=21; Excluded=1; Pruned=0; Remaining=20)
   877   C0369335:Hepatitis C virus RNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   852   C0855840:hepatitis c rna [Laboratory Procedure]
   845   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   829   C0019186:Hepatitis virus [Virus]
   818   C0019196:Hepatitis C [Disease or Syndrome]
   818   C0035691:Virus-RNA [Virus]
   818   C0035736:virus RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   795   C0013018:Donors [Population Group]
   795   C0019158:Hepatitis [Disease or Syndrome]
   795   C0019159:hepatitis [Disease or Syndrome]
   795   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   795   C0042776:Virus [Virus]
   795   C0319157:virus [Virus]
   795   C0439178:% Positive [Quantitative Concept]
   795   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   795   C1446409:Positive [Qualitative Concept]
   795   C1514241:Positive [Finding]
   795   C1527169:Donors [Finding]
   795   C2825490:Positive [Qualitative Concept]
   762 E C0040288:Donor [Population Group]

Phrase: "On the"

Phrase: "other hand,"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0018563:Hand [Body Part, Organ, or Organ Component]
  1000   C1281583:Hand [Body Part, Organ, or Organ Component]
  1000   C1552914:hand [Quantitative Concept]
   944 E C0024763:Manual [Intellectual Product,Manufactured Object]
   944 E C0175674:Manual [Functional Concept]

Phrase: "anti-HCV Ab positivity"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   791   C0741132:antibody positive [Laboratory or Test Result]
   734   C0166049:Hepatitis C virus antibody [Immunologic Factor]
           Hepatitis C antibody
   734   C0201487:Hepatitis C Virus Antibody [Laboratory Procedure]
   727   C0439178:% Positive [Quantitative Concept]
   727   C1446409:Positive [Qualitative Concept]
   727   C1514241:Positive [Finding]
   727   C2825490:Positive [Qualitative Concept]
   712   C0051967:anti-c antibody [Immunologic Factor]
   709   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]

Phrase: "developed in all ITP patients."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   814   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   778   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   778   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   748   C0030705:Patients [Patient or Disabled Group]
   748   C0034150:Purpura [Disease or Syndrome]
   748   C0332240:Idiopathic [Functional Concept]
   748   C3463943:Purpura [Eukaryote]
Processing 00000000.tx.115: The rate of HCV infection after IVIG infusion was 100% in our patients, indicating that the efficiency of transmission might not be influenced by the immune status. 

Phrase: "The rate of HCV infection"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   748   C0871208:Rate [Activity]
   748   C1521828:Rate [Quantitative Concept]

Phrase: "after IVIG infusion"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C0021440:Intravenous infusion [Therapeutic or Preventive Procedure]
   913   C1272892:Intravenous infusion [Biomedical or Dental Material]
   913   C1621368:Intravenous Infusion [Functional Concept]
   827   C0574032:Infusion [Therapeutic or Preventive Procedure]
   827   C1827465:Infusion [Functional Concept]
   734   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]

Phrase: "was"

Phrase: "100% in our patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0030705:Patients [Patient or Disabled Group]

Phrase: "indicating"

Phrase: "that"

Phrase: "the efficiency of transmission"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0013682:Efficiency [Quantitative Concept]

Phrase: "might"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "be"

Phrase: "influenced by the immune status."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   806   C0020964:Immune status [Physiologic Function]
   760   C0439662:Immune [Functional Concept]
   760   C0449438:Status [Qualitative Concept]
Processing 00000000.tx.116: An alternative explanation might be a high viral load in the infectious inoculum, or the high total doses of IVIG administered. 

Phrase: "An alternative explanation"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0681841:Explanation [Intellectual Product]

Phrase: "might"

Phrase: "be"

Phrase: "a high viral load in the infectious inoculum,"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   770   C0376705:Viral Load [Finding]
   770   C1261478:Viral load [Laboratory Procedure]
   744   C0205250:High [Qualitative Concept]
   744   C0521026:Viral [Functional Concept]
   744   C1299351:High [Qualitative Concept]
   744   C1550025:Load [Idea or Concept]
   744   C1704782:Load [Manufactured Object]
   744   C1708715:Load [Activity]
   744   C2700149:HIGH [Intellectual Product]
   731   C0042769:Viral Infections [Disease or Syndrome]

Phrase: "or"

Phrase: "the high total doses of IVIG"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   757   C0428539:Total immunoglobulin [Laboratory Procedure]
   757   C0443626:Total immunoglobulin [Laboratory or Test Result]
   757   C0444956:High dose [Quantitative Concept]
   748   C0178602:Doses [Quantitative Concept]
   748   C0439175:% total [Quantitative Concept]
   748   C0439810:Total [Qualitative Concept]
   745   C2986497:Total Dose [Conceptual Entity]
   714 E C0869039:Dose [Quantitative Concept]
   714 E C1114758:Dose # [Clinical Attribute]
   714 E C1428722:DOS [Gene or Genome]

Phrase: "administered."
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1521801:Administered [Functional Concept]
   966 E C1621583:Administer [Functional Concept]
Processing 00000000.tx.117: Notably, ITP patients received a significantly higher dose of IVIG, which may partially account for their high infection rate. 

Phrase: "Notably,"

Phrase: "ITP patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0030705:Patients [Patient or Disabled Group]
   756   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "a significantly higher dose of IVIG,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   762   C0444956:High dose [Quantitative Concept]
   748   C0178602:Dose [Quantitative Concept]
   748   C0869039:Dose [Quantitative Concept]
   748   C1114758:Dose # [Clinical Attribute]

Phrase: "which"

Phrase: "may"

Phrase: "partially"

Phrase: "account for their high infection rate."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   753   C0009450:Infection, NOS [Disease or Syndrome]
   753   C0205250:High [Qualitative Concept]
   753   C0871208:Rate [Activity]
   753   C1299351:High [Qualitative Concept]
   753   C1521828:Rate [Quantitative Concept]
   753   C1551359:account [Idea or Concept]
   753   C2700149:HIGH [Intellectual Product]
   753   C2741673:Account # [Clinical Attribute]
   753   C2981730:Account [Classification]
Processing 00000000.tx.118: A high infection rate (82%) was recently documented also among patients in the United Kingdom who received a contaminated batch of anti-HCV antibody-screened IVIG.17 Neither the timing nor the severity of acute infection seemed to be influenced by the immune status of patients. 

Phrase: "A high infection rate"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   827   C0009450:Infection, NOS [Disease or Syndrome]
   827   C0871208:Rate [Activity]
   827   C1521828:Rate [Quantitative Concept]
   755 E C0439663:Infected [Functional Concept]
   716 E C0030657:infectivity [Qualitative Concept]

Phrase: "(82%"

Phrase: ")"

Phrase: "was"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "documented"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C1301725:Documented [Health Care Activity]
  1000   C1609436:documented [Idea or Concept]
   966 E C1301746:document [Intellectual Product]
   966 E C1547673:Document [Intellectual Product]

Phrase: "also among patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0030705:Patients [Patient or Disabled Group]

Phrase: "in the United Kingdom"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0041700:United Kingdom [Geographic Area]
   861   C1708611:Kingdom [Classification]
   827   C0166872:unite [Biomedical or Dental Material]

Phrase: "who"

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "a contaminated batch"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1550176:Batch [Idea or Concept]
   861   C1948031:Batch [Quantitative Concept]

Phrase: "of anti-HCV antibody-screened IVIG.17"
Meta Candidates (Total=29; Excluded=1; Pruned=0; Remaining=28)
   849   C0166049:Hepatitis C virus antibody [Immunologic Factor]
           Hepatitis C antibody
   849   C0201487:Hepatitis C Virus Antibody [Laboratory Procedure]
   843   C0051967:anti-c antibody [Immunologic Factor]
   842   C0003242:anti antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   829   C0019161:Hepatitis antibody [Amino Acid, Peptide, or Protein,Immunologic Factor]
   829   C0948769:hepatitis C screen [Therapeutic or Preventive Procedure]
   827   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   817   C0019186:Hepatitis virus [Virus]
   817   C0432624:Anti C [Amino Acid, Peptide, or Protein,Immunologic Factor]
   817   C0432626:Anti c [Amino Acid, Peptide, or Protein,Immunologic Factor]
   807   C0019196:Hepatitis C [Disease or Syndrome]
   807   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   791   C0003241:Antibody [Amino Acid, Peptide, or Protein,Cell Component,Immunologic Factor]
   791   C0019158:Hepatitis [Disease or Syndrome]
   791   C0019159:hepatitis [Disease or Syndrome]
   791   C0021027:Antibody [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
           Immunoglobulins
   791   C0042776:Virus [Virus]
   791   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   791   C0319157:virus [Virus]
   791   C0348016:Intravenous [Spatial Concept]
   791   C0368676:Antibody screen [Laboratory Procedure]
   791   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   758   C0220908:screen [Health Care Activity]
   758   C1305399:screen [Functional Concept]
   758 E C1621846:immunoglobulin [Molecular Function]
   758   C1705053:Screen [Medical Device]

Phrase: "Neither the timing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0449243:Timing [Temporal Concept]
  1000   C1704250:Timing [Conceptual Entity]

Phrase: "nor"

Phrase: "the severity of acute infection"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   797   C0517627:Infection severity [Finding]
   760   C0439793:Severity [Qualitative Concept]
   760   C2983285:Severity [Intellectual Product]

Phrase: "seemed"

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "be"

Phrase: "influenced by the immune status of patients."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   778   C0020964:Immune status [Physiologic Function]
   757   C0449437:Patient status [Finding]
   748   C0030705:Patients [Patient or Disabled Group]
   748   C0439662:Immune [Functional Concept]
   748   C0449438:Status [Qualitative Concept]
Processing 00000000.tx.119: The incubation period of acute hepatitis was similar in ITP and in ID patients. 

Phrase: "The incubation period of acute hepatitis"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C1320226:Incubation period [Finding]
   753   C0439531:/period [Temporal Concept]
   753   C1948053:Period [Temporal Concept]

Phrase: "was"

Phrase: "similar in ITP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C2348205:Similar [Qualitative Concept]

Phrase: "and in ID patients."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0021051:Immunodeficient [Disease or Syndrome]
   770   C0030705:Patients [Patient or Disabled Group]
   770   C1515981:And [Idea or Concept]
Processing 00000000.tx.120: Peak ALT levels did not differ significantly between ITP and ID patients. 

Phrase: "Peak ALT levels"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   896   C0444505:Peak level [Quantitative Concept]
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "differ"

Phrase: "significantly between ITP"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   862   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   806   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   806   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   760   C0034150:Purpura [Disease or Syndrome]
   760   C0332240:Idiopathic [Functional Concept]
   760   C3463943:Purpura [Eukaryote]

Phrase: "and"

Phrase: "ID patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.121: Nevertheless, it should be noted that ID patients had particularly mild increases of ALT, whose peak levels never exceeded 1,000 IU/dL. 

Phrase: "Nevertheless,"

Phrase: "it"

Phrase: "should"

Phrase: "be"

Phrase: "noted"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   966   C1316572:Note [Clinical Attribute]
   966   C1317574:Note [Intellectual Product]
   966   C1369612:Note [Clinical Attribute]

Phrase: "that ID patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "had"

Phrase: "particularly mild increases of ALT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0442805:increases [Functional Concept]

Phrase: "whose peak levels never"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   884   C0444505:Peak level [Quantitative Concept]
   827   C0441889:Levels [Qualitative Concept]
   793 E C0456079:Level [Classification]
   793 E C1547707:Level [Geographic Area]
   793 E C2946261:Level [Pharmacologic Substance]

Phrase: "exceeded"

Phrase: "1,000 IU/dL."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1960947:IU/dL [Quantitative Concept]
   812   C3642216:/dL [Quantitative Concept]
Processing 00000000.tx.122: In most reported studies, immunosuppression does not appear to worsen the severity of acute hepatitis. 

Phrase: "In most reported studies,"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   966   C1317750:report study [Intellectual Product]
   861   C0947630:studies [Laboratory Procedure]
   827 E C0557651:Study [Manufactured Object]
   827 E C2603343:Study [Research Activity]

Phrase: "immunosuppression"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0021079:Immunosuppression [Therapeutic or Preventive Procedure]
  1000   C0021080:Immunosuppression [Organism Function]
  1000   C1373218:Immunosuppression [Pathologic Function]

Phrase: "does"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "appear"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0700364:APPEAR [Qualitative Concept]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "worsen"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0332271:worsen [Qualitative Concept]
  1000   C1279889:worsen [Finding]

Phrase: "the severity of acute hepatitis."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0439793:Severity [Qualitative Concept]
   760   C2983285:Severity [Intellectual Product]
Processing 00000000.tx.123: ALT levels decreased when corticosteroids or cytostatic drugs were given to patients with hepatitis,15,18,19 with some exceptions.20 However, during immunosuppressive therapy an increase in viremia has been reported by different investigators,19,21 even with no biochemical signs of hepatic necrosis. 

Phrase: "ALT levels"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   861   C0441889:Levels [Qualitative Concept]
   827 E C0456079:Level [Classification]
   827 E C1547707:Level [Geographic Area]
   827 E C2946261:Level [Pharmacologic Substance]

Phrase: "decreased"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C0205216:Decreased [Quantitative Concept]
  1000   C0392756:Decreased [Qualitative Concept]
  1000   C0442797:decreased [Qualitative Concept]
   966 E C0547047:Decrease [Quantitative Concept]

Phrase: "when"

Phrase: "corticosteroids"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0001617:Corticosteroids [Hormone,Pharmacologic Substance,Steroid]
   966 E C3536709:Corticosteroid [Pharmacologic Substance]

Phrase: "or"

Phrase: "cytostatic drugs"
Meta Candidates (Total=6; Excluded=4; Pruned=0; Remaining=2)
  1000   C0010858:Cytostatic Drugs [Pharmacologic Substance]
   861   C0013227:Drugs [Pharmacologic Substance]
   827 E C1254351:Drug [Pharmacologic Substance]
   789 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   789 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   761 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "were"

Phrase: "given to patients"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1442162:GIVEN [Conceptual Entity]
   790   C1550718:given [Idea or Concept]
   790   C3244317:given [Intellectual Product]
   756 E C1947971:Give [Functional Concept]

Phrase: "with hepatitis,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0019158:Hepatitis [Disease or Syndrome]
  1000   C0019159:hepatitis [Disease or Syndrome]
  1000   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "15,"

Phrase: "18,"

Phrase: "19 with some exceptions.20 However,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C1554961:exception [Idea or Concept]
   719   C1705847:Exception [Conceptual Entity]

Phrase: "during immunosuppressive therapy"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0021079:Immunosuppressive therapy [Therapeutic or Preventive Procedure]
   861   C0021081:immunosuppressive [Immunologic Factor,Pharmacologic Substance]
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]

Phrase: "an increase in viremia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0442805:Increase [Functional Concept]

Phrase: "has"

Phrase: "been"

Phrase: "reported by different investigators,"
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   833   C1709908:Reported By [Group]
   770   C0035173:Investigators [Professional or Occupational Group]
   770   C0684224:Reported [Intellectual Product]
   770   C0700287:Reported [Health Care Activity]
   770   C1705242:Different [Qualitative Concept]
   770   C3496591:Reported [Clinical Attribute]
   737 E C3273238:Report [Intellectual Product]

Phrase: "19,"

Phrase: "21 even with no biochemical signs of hepatic necrosis."
Meta Candidates (Total=10; Excluded=1; Pruned=0; Remaining=9)
   764   C0151798:Hepatic necrosis [Disease or Syndrome]
   764   C1963135:Hepatic necrosis [Finding]
   742   C0027540:Necrosis [Organ or Tissue Function]
   742   C0205054:Hepatic [Body Location or Region]
   742   C0205474:Biochemical [Functional Concept]
   742   C0220912:signs [Functional Concept]
   742   C0220913:signs [Manufactured Object]
   742   C0311392:SIGNS [Finding]
   742   C1334928:Necrosis [Finding]
   708 E C1547188:Sign [Idea or Concept]
Processing 00000000.tx.124: On suspending corticosteroid or cytostatic treatment, several cases of fulminant hepatitis C have been observed,16,22-25 as in patients infected with hepatitis B virus,26 suggesting a role of the immune system in the pathogenesis of acute hepatic necrosis. 

Phrase: "On suspending corticosteroid"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0001617:corticosteroid [Hormone,Pharmacologic Substance,Steroid]
   861   C3536709:Corticosteroid [Pharmacologic Substance]

Phrase: "or"

Phrase: "cytostatic treatment,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]

Phrase: "several cases of fulminant hepatitis C"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
   753   C0868928:Cases [Functional Concept]
   753   C1533148:Cases [Quantitative Concept]
   719 E C1706255:CASE [Medical Device]
   719 E C1706256:Case [Conceptual Entity]

Phrase: "have"

Phrase: "been"

Phrase: "observed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1441672:Observed [Functional Concept]

Phrase: ","

Phrase: "16,"

Phrase: "22-25"

Phrase: "as in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0030705:Patients [Patient or Disabled Group]

Phrase: "infected with hepatitis B virus,"
Meta Candidates (Total=11; Excluded=0; Pruned=0; Remaining=11)
   862   C0019169:Hepatitis B Virus [Virus]
   806   C0019163:Hepatitis B [Disease or Syndrome]
   806   C0019378:B Virus [Virus]
   797   C0019186:Hepatitis virus [Virus]
   797   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   760   C0019158:Hepatitis [Disease or Syndrome]
   760   C0019159:hepatitis [Disease or Syndrome]
   760   C0042776:Virus [Virus]
   760   C0319157:virus [Virus]
   760   C0439663:Infected [Functional Concept]
   760   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "26"

Phrase: "suggesting"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1705535:Suggest [Idea or Concept]

Phrase: "a role of the immune system"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "in the pathogenesis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0543483:pathogenesis [Functional Concept]
  1000   C0699748:Pathogenesis [Pathologic Function]

Phrase: "of acute hepatic necrosis."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0001364:Acute hepatic necrosis [Pathologic Function]
   913   C0333501:Acute necrosis [Pathologic Function]
   901   C0151798:Hepatic necrosis [Disease or Syndrome]
   901   C1963135:Hepatic necrosis [Finding]
   827   C0027540:Necrosis [Organ or Tissue Function]
   827   C1334928:Necrosis [Finding]
Processing 00000000.tx.125: In our study a trend toward a more marked elevation of bilirubin levels was shown in the subgroup of ID patients. 

Phrase: "In our"

Phrase: "study"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0557651:Study [Manufactured Object]
  1000   C2603343:Study [Research Activity]

Phrase: "a trend toward a more marked elevation of bilirubin levels"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   739   C1521798:trend [Temporal Concept]

Phrase: "was"

Phrase: "shown in the subgroup of ID patients."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   748   C0021051:Immunodeficient [Disease or Syndrome]
   748   C0030705:Patients [Patient or Disabled Group]
   748   C1079230:subgroup [Virus]
   748   C1515021:Subgroup [Classification]
   714   C1547282:Show [Intellectual Product]
Processing 00000000.tx.126: Jaundice developed in the majority (86%) of ID patients compared with 33% of ITP patients, and was the main cause of hospital admission. 

Phrase: "Jaundice"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022346:Jaundice [Pathologic Function]

Phrase: "developed in the majority"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0680220:majority [Social Behavior]

Phrase: "(86%"

Phrase: ")"

Phrase: "of ID patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "compared with 33% of ITP patients,"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   800   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   770   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   770   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   744   C0030705:Patients [Patient or Disabled Group]
   744   C0034150:Purpura [Disease or Syndrome]
   744   C0332240:Idiopathic [Functional Concept]
   744   C1707455:Compared [Activity]
   744   C3463943:Purpura [Eukaryote]

Phrase: "and"

Phrase: "was"

Phrase: "the main cause of hospital admission."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0015127:cause [Functional Concept]
   753   C1524003:Cause [Conceptual Entity]
Processing 00000000.tx.127: In patients with hematologic disorders an elevation of bilirubin levels during acute HCV hepatitis has been reported in 24% of cases.15 Both the type of the underlying disorder and the drugs used for its treatment may have contributed to the differences in the incidence and severity of jaundice in ID patients. 

Phrase: "In patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with hematologic disorders"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0018939:HEMATOLOGIC DISORDERS [Disease or Syndrome]
   861   C0012634:Disorders [Disease or Syndrome]

Phrase: "an elevation of bilirubin levels"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   760   C0439775:Elevation [Therapeutic or Preventive Procedure]
   760   C0702240:Elevation [Spatial Concept]

Phrase: "during acute HCV hepatitis"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   717   C0220847:Hepatitis C virus [Virus]
   717   C0400914:Acute hepatitis C [Disease or Syndrome]

Phrase: "has"

Phrase: "been"

Phrase: "reported in 24% of cases.15"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   767   C0007320:case reported [Intellectual Product]
   753   C0684224:Reported [Intellectual Product]
   753   C0700287:Reported [Health Care Activity]
   753   C0868928:Cases [Functional Concept]
   753   C1533148:Cases [Quantitative Concept]
   753   C3496591:Reported [Clinical Attribute]
   750 E C0085973:Case Report [Intellectual Product]
   719 E C1706255:CASE [Medical Device]
   719 E C1706256:Case [Conceptual Entity]
   719 E C3273238:Report [Intellectual Product]

Phrase: "Both the type of the underlying disorder"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   774   C0457464:disorder type [Intellectual Product]
   748   C0332307:Type [Qualitative Concept]
   748   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "the drugs"
Meta Candidates (Total=5; Excluded=4; Pruned=0; Remaining=1)
  1000   C0013227:Drugs [Pharmacologic Substance]
   966 E C1254351:Drug [Pharmacologic Substance]
   928 E C0031336:Pharmaceutical [Biomedical Occupation or Discipline]
   928 E C1135440:pharmaceutical [Therapeutic or Preventive Procedure]
   900 E C0456386:Medicament [Pharmacologic Substance]

Phrase: "used for its treatment"
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   770   C0039798:treatment [Functional Concept]
   770   C0087111:Treatment [Therapeutic or Preventive Procedure]
   770   C1273517:used [Finding]
   770   C1522326:Treatment [Functional Concept]
   770   C1533734:Treatment [Therapeutic or Preventive Procedure]
   770   C1705169:Treatment [Conceptual Entity]
   770   C3538994:TREATMENT [Research Activity]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]

Phrase: "may"

Phrase: "have"

Phrase: "contributed to the differences"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   737   C1705241:*Difference [Quantitative Concept]
   737   C1705242:Difference [Qualitative Concept]
   737   C1880177:Contribute [Activity]

Phrase: "in the incidence"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0021149:Incidence [Quantitative Concept]
  1000   C0220856:incidence [Functional Concept]
   928 E C1551358:incident [Idea or Concept]

Phrase: "and"

Phrase: "severity of jaundice"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
   790   C0439793:Severity [Qualitative Concept]
   790   C2983285:Severity [Intellectual Product]
   718 E C0205082:Severe [Qualitative Concept]

Phrase: "in ID patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]
Processing 00000000.tx.128: A severe cholestatic form of liver disease, which finally leads to death from liver failure, has also been observed in patients with heart and liver transplantation as well as in patients with hypogammaglobulinemia.3 The course of HCV hepatitis was strikingly different between ITP and ID patients and hepatic disease severely affected the overall prognosis of ID patients. 

Phrase: "A severe cholestatic form of liver disease,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   748   C0348078:Form [Qualitative Concept]
   748   C0376315:Form [Manufactured Object]
   748   C1522492:Form [Functional Concept]

Phrase: "which finally"

Phrase: "leads to death"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   790   C0011065:Death [Organism Function]
   790   C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   790   C0181586:leads [Medical Device]
   790   C1306577:Death, NOS [Finding]
   790   C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   790   C1522538:Lead [Functional Concept]
   790   C2348269:Lead [Element, Ion, or Isotope]
   790   C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "from liver failure,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0085605:Liver Failure [Disease or Syndrome]
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "has"

Phrase: "also"

Phrase: "been"

Phrase: "observed in patients"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0030705:Patients [Patient or Disabled Group]
   790   C1441672:Observed [Functional Concept]

Phrase: "with heart"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0018787:Heart [Body Part, Organ, or Organ Component]
  1000   C1281570:Heart [Body Part, Organ, or Organ Component]

Phrase: "and"

Phrase: "liver transplantation"
Meta Candidates (Total=9; Excluded=1; Pruned=0; Remaining=8)
  1000   C0023911:Liver Transplantation [Therapeutic or Preventive Procedure]
   861   C0023884:Liver [Body Part, Organ, or Organ Component]
   861   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   861   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   861   C0040733:transplantation [Functional Concept]
   861   C0736268:LIVER [Body Part, Organ, or Organ Component]
   861   C1278929:Liver [Body Part, Organ, or Organ Component]
   861   C2346688:LIVER [Food]
   805 E C0205054:Hepatic [Body Location or Region]

Phrase: "as well as in patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   760   C0030705:Patients [Patient or Disabled Group]
   760   C0205170:Well [Qualitative Concept]
   760   C3146287:Well [Manufactured Object]

Phrase: "with hypogammaglobulinemia.3"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0086438:Hypogammaglobulinaemia [Disease or Syndrome]

Phrase: "The course of HCV hepatitis"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0750729:Course [Temporal Concept]

Phrase: "was"

Phrase: "strikingly different between ITP"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1705242:Different [Qualitative Concept]

Phrase: "and"

Phrase: "ID patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "and"

Phrase: "hepatic disease severely"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   901   C0023895:HEPATIC DISEASE (NOS) [Disease or Syndrome]
   827   C0012634:Disease [Disease or Syndrome]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: "affected"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0392760:Affected [Functional Concept]
  1000   C1314939:Affected [Functional Concept]
   966 E C0001721:Affect [Mental Process]

Phrase: "the overall prognosis of ID patients."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C0033325:Prognosis [Health Care Activity]
Processing 00000000.tx.129: Among ITP patients, resolution of HCV infection occurred in one case and chronicization occurred in five patients (83%), a rate that is only marginally higher than that of normal individuals after HCV infection.9,27 Moreover, chronic infection was clinically mild and no patients have shown signs of liver failure. 

Phrase: "Among ITP patients,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0030705:Patients [Patient or Disabled Group]
   756   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura

Phrase: "resolution of HCV infection"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   753   C1514893:Resolution [Idea or Concept]
   753   C1706463:Resolution [Quantitative Concept]
   753   C2699488:Resolution [Conceptual Entity]

Phrase: "occurred in one case"
Meta Candidates (Total=6; Excluded=1; Pruned=0; Remaining=5)
   770   C0205447:One [Quantitative Concept]
   770   C0868928:Case [Functional Concept]
   770   C1706255:CASE [Medical Device]
   770   C1706256:Case [Conceptual Entity]
   770   C1709305:Occurred [Activity]
   737 E C2745955:OCCUR [Temporal Concept]

Phrase: "and"

Phrase: "chronicization"

Phrase: "occurred in five patients"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C0205451:Five [Quantitative Concept]
   770   C1709305:Occurred [Activity]
   737 E C2745955:OCCUR [Temporal Concept]

Phrase: "(83%"

Phrase: ")"

Phrase: ","

Phrase: "a rate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0871208:Rate [Activity]
  1000   C1521828:Rate [Quantitative Concept]

Phrase: "that"

Phrase: "is"

Phrase: "only marginally higher than that of normal individuals"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   725   C0587053:Normal height [Finding]
   711   C0205250:High [Qualitative Concept]
   711   C1299351:High [Qualitative Concept]
   711   C2700149:HIGH [Intellectual Product]

Phrase: "after HCV infection.9,"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   888   C0019196:Hepatitis C Infection [Disease or Syndrome]
           Hepatitis C
   884   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   853   C0019186:Hepatitis virus [Virus]
   840   C0042769:virus infection [Disease or Syndrome]
   804   C0009450:Infection, NOS [Disease or Syndrome]
   804   C0019158:Hepatitis [Disease or Syndrome]
   804   C0019159:hepatitis [Disease or Syndrome]
   804   C0042776:Virus [Virus]
   804   C0319157:virus [Virus]
   804   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   733 E C0439663:Infected [Functional Concept]

Phrase: "27 Moreover,"

Phrase: "chronic infection"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
  1000   C0151317:Chronic infection [Disease or Syndrome]
   861   C0009450:Infection, NOS [Disease or Syndrome]
   861   C0205191:chronic [Temporal Concept]
   789 E C0439663:Infected [Functional Concept]
   750 E C0030657:infectivity [Qualitative Concept]

Phrase: "was"

Phrase: "clinically mild"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2945599:Mild [Qualitative Concept]

Phrase: "and"

Phrase: "no patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "have"

Phrase: "shown"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1547282:Show [Intellectual Product]

Phrase: "signs of liver failure."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0220912:signs [Functional Concept]
   770   C0220913:signs [Manufactured Object]
   770   C0311392:SIGNS [Finding]
   737 E C1547188:Sign [Idea or Concept]
Processing 00000000.tx.130: Conversely, among ID patients, liver failure developed in 71% of cases and proved irreversible in 80% of them. 

Phrase: "Conversely,"

Phrase: "among ID patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "liver failure"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0085605:Liver Failure [Disease or Syndrome]
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "developed in 71% of cases"
Meta Candidates (Total=5; Excluded=2; Pruned=0; Remaining=3)
   760   C0450389:71 [Intellectual Product]
   760   C0868928:Cases [Functional Concept]
   760   C1533148:Cases [Quantitative Concept]
   726 E C1706255:CASE [Medical Device]
   726 E C1706256:Case [Conceptual Entity]

Phrase: "and"

Phrase: "proved irreversible in 80% of them."
Processing 00000000.tx.131: It is noteworthy that this occurred in the absence of signs of hyperacute hepatic necrosis, as shown by only moderate ALT elevation, throughout the clinical course of the disease. 

Phrase: "It"

Phrase: "is"

Phrase: "noteworthy"

Phrase: "that"

Phrase: "this"

Phrase: "occurred in the absence of signs of hyperacute hepatic necrosis,"
Meta Candidates (Total=15; Excluded=2; Pruned=0; Remaining=13)
   782   C0277791:Absence of signs [Finding]
   777   C2749404:Absence of necrosis [Finding]
   760   C0151798:Hepatic necrosis [Disease or Syndrome]
   760   C1963135:Hepatic necrosis [Finding]
   739   C0027540:Necrosis [Organ or Tissue Function]
   739   C0205054:Hepatic [Body Location or Region]
   739   C0220912:signs [Functional Concept]
   739   C0220913:signs [Manufactured Object]
   739   C0311392:SIGNS [Finding]
   739   C0332197:absence [Quantitative Concept]
   739   C1334928:Necrosis [Finding]
   739   C1689985:Absence [Anatomical Abnormality]
   739   C1709305:Occurred [Activity]
   706 E C1547188:Sign [Idea or Concept]
   706 E C2745955:OCCUR [Temporal Concept]

Phrase: "as"

Phrase: "shown by only"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0205171:Only [Quantitative Concept]
   790   C1720467:Only [Intellectual Product]
   756   C1547282:Show [Intellectual Product]

Phrase: "moderate"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0205081:Moderate [Qualitative Concept]
  1000   C1881878:Moderate [Qualitative Concept]
   944 E C1553901:Mitigate [Idea or Concept]

Phrase: "ALT elevation,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439775:Elevation [Therapeutic or Preventive Procedure]
   861   C0702240:Elevation [Spatial Concept]

Phrase: "throughout the clinical course"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0449259:Clinical course [Temporal Concept]
   861   C0205210:Clinical [Qualitative Concept]
   861   C0750729:Course [Temporal Concept]

Phrase: "of the disease."
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0012634:Disease [Disease or Syndrome]
   944 E C1836721:MALS [Finding]
   944 E C3538764:MALS [Gene or Genome]
   944 E C3540595:MAL [Gene or Genome]
Processing 00000000.tx.132: Apoptosis has been recently identified as a mechanism of programmed cell death in many tissues, including the liver.28 As opposed to necrosis, apoptosis is not associated with inflammatory signs. 

Phrase: "Apoptosis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "has"

Phrase: "been"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "identified as a mechanism of programmed cell death"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
   819   C1708951:Mechanism of Cell Death [Cell Function]
   800   C0162638:Programmed Cell Death [Cell Function]
   770   C0007587:Cell Death [Cell Function]
   744   C0007634:Cell [Cell]
   744   C0011065:Death [Organism Function]
   744   C0205396:Identified [Qualitative Concept]
   744   C0441712:Mechanism [Functional Concept]
   744   C1269647:Cell [Cell]
   744   C1306577:Death, NOS [Finding]
   744   C1550043:Identified [Finding]
   744   C1551388:Identified [Functional Concept]
   744   C1704653:Cell [Medical Device]
   744   C1706376:Mechanism [Manufactured Object]
   744   C1948049:Cell [Spatial Concept]

Phrase: "in many tissues,"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0040300:Tissues [Tissue]
   966 E C1547928:Tissue [Intellectual Product]

Phrase: "including"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332257:Including [Functional Concept]
   966 E C1552866:include [Idea or Concept]
   966 E C2700399:Include [Activity]

Phrase: "the liver.28"
Meta Candidates (Total=5; Excluded=1; Pruned=0; Remaining=4)
   861   C0023884:Liver [Body Part, Organ, or Organ Component]
   861   C0736268:LIVER [Body Part, Organ, or Organ Component]
   861   C1278929:Liver [Body Part, Organ, or Organ Component]
   861   C2346688:LIVER [Food]
   805 E C0205054:Hepatic [Body Location or Region]

Phrase: "As"

Phrase: "opposed to necrosis,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0027540:Necrosis [Organ or Tissue Function]
   790   C1334928:Necrosis [Finding]

Phrase: "apoptosis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "is"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "associated with inflammatory signs."
Meta Candidates (Total=10; Excluded=3; Pruned=0; Remaining=7)
   833   C0332281:Associated with [Qualitative Concept]
           Associated
   802   C0521990:Associated sign [Sign or Symptom]
   770   C0220912:signs [Functional Concept]
   770   C0220913:signs [Manufactured Object]
   770   C0311392:SIGNS [Finding]
   770   C0333348:Inflammatory [Functional Concept]
   737 E C0750490:Associate [Idea or Concept]
   737 E C1547188:Sign [Idea or Concept]
   737 E C1706221:Associate [Professional or Occupational Group]
Processing 00000000.tx.133: It may be postulated that since apoptosis has been shown in hepatitis C, it may be one of the mechanisms involved in hepatocellular injury in patients with immunodeficiency. 

Phrase: "It"

Phrase: "may"

Phrase: "be"

Phrase: "postulated"

Phrase: "that"

Phrase: "since"

Phrase: "apoptosis"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C0162638:Apoptosis [Cell Function]
   928 E C1516044:Apoptotic [Qualitative Concept]

Phrase: "has"

Phrase: "been"

Phrase: "shown in hepatitis C,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   833   C0019196:Hepatitis C [Disease or Syndrome]
   833   C0220847:Hepatitis C [Virus]
   770   C0019158:Hepatitis [Disease or Syndrome]
   770   C0019159:hepatitis [Disease or Syndrome]
   770   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   737   C1547282:Show [Intellectual Product]

Phrase: "it"

Phrase: "may"

Phrase: "be"

Phrase: "one of the mechanisms"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0205447:One [Quantitative Concept]

Phrase: "involved in hepatocellular injury"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   833   C0151763:Hepatocellular Injury [Pathologic Function]
   770   C1314939:Involved [Functional Concept]
   770   C2697585:Hepatocellular [Qualitative Concept]
   770   C3263722:Injury [Injury or Poisoning]
   770   C3263723:Injury [Injury or Poisoning]

Phrase: "in patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:Patients [Patient or Disabled Group]

Phrase: "with immunodeficiency."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0021051:IMMUNO-DEFICIENCY [Disease or Syndrome]
Processing 00000000.tx.134: Hepatic disease was the most important factor in determining the very poor outcome of ID patients, whose 2-year survival rate was only 12%. 

Phrase: "Hepatic disease"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
  1000   C0023895:HEPATIC DISEASE (NOS) [Disease or Syndrome]
   861   C0012634:Disease [Disease or Syndrome]
   805 E C1836721:MALS [Finding]
   805 E C3538764:MALS [Gene or Genome]
   805 E C3540595:MAL [Gene or Genome]

Phrase: "was"

Phrase: "the most important factor in determining"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1521761:Factor [Functional Concept]
   753   C2827422:Factor [Conceptual Entity]

Phrase: "the very poor outcome of ID patients,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   757   C1547647:Patient Outcome [Idea or Concept]
   748   C1274040:Outcome [Functional Concept]

Phrase: "whose 2-year survival rate"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   861   C0038954:Survival Rate [Quantitative Concept]
   812   C0038952:Survival [Activity]
   812   C0220921:survival [Functional Concept]
   812   C0439234:year [Temporal Concept]
   812   C0439508:/year [Temporal Concept]
   812   C0871208:Rate [Activity]
   812   C1521828:Rate [Quantitative Concept]

Phrase: "was"

Phrase: "only 12%."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0205171:Only [Quantitative Concept]
   861   C1720467:Only [Intellectual Product]
Processing 00000000.tx.135: In addition to their immune status, other differences between ITP and ID patients, such as their underlying disorders, the possibility of coinfection with other unidentified viral agents, or the treatments received, may be advocated to explain the different course of hepatic disease. 

Phrase: "In addition to their immune status,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0020964:Immune status [Physiologic Function]
   861   C0449438:Status [Qualitative Concept]

Phrase: "other differences between ITP"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   719   C1705241:*Difference [Quantitative Concept]
   719   C1705242:Difference [Qualitative Concept]

Phrase: "and"

Phrase: "ID patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "such as their underlying disorders,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012634:Disorders [Disease or Syndrome]

Phrase: "the possibility of coinfection"

Phrase: "with other unidentified viral agents,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   793   C0450442:Agent [Chemical Viewed Functionally]
   793   C1254351:Agent [Pharmacologic Substance]
   793   C1521826:Agent [Intellectual Product]

Phrase: "or"

Phrase: "the treatments"
Meta Candidates (Total=6; Excluded=5; Pruned=0; Remaining=1)
  1000   C0087111:Treatments [Therapeutic or Preventive Procedure]
   966 E C0039798:treatment [Functional Concept]
   966 E C1522326:Treatment [Functional Concept]
   966 E C1533734:Treatment [Therapeutic or Preventive Procedure]
   966 E C1705169:Treatment [Conceptual Entity]
   966 E C3538994:TREATMENT [Research Activity]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: ","

Phrase: "may"

Phrase: "be"

Phrase: "advocated"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C1510823:Advocate [Occupation or Discipline]

Phrase: "to"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1883351:To [Qualitative Concept]

Phrase: "explain"

Phrase: "the different course of hepatic disease."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   783   C0242656:disease course [Pathologic Function]
   753   C0750729:Course [Temporal Concept]
Processing 00000000.tx.136: However, ID patients lacked signs of liver involvement by their underlying disorder before HCV infection and did not show a progressive course thereafter. 

Phrase: "However,"

Phrase: "ID patients"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "lacked"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0332268:lack [Qualitative Concept]

Phrase: "signs of liver involvement"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   770   C0220912:signs [Functional Concept]
   770   C0220913:signs [Manufactured Object]
   770   C0311392:SIGNS [Finding]
   737 E C1547188:Sign [Idea or Concept]

Phrase: "by their underlying disorder"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012634:Disorder [Disease or Syndrome]

Phrase: "before HCV infection"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   923   C0019196:Hepatitis C Infection [Disease or Syndrome]
   861   C0042769:virus infection [Disease or Syndrome]
   812   C0009450:Infection, NOS [Disease or Syndrome]
   756   C0220847:Hepatitis C virus [Virus]
   741 E C0439663:Infected [Functional Concept]
   708   C0019186:Hepatitis virus [Virus]
   701 E C0030657:infectivity [Qualitative Concept]

Phrase: "and"

Phrase: "did"

Phrase: "not"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1518422:Not [Functional Concept]

Phrase: "show"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1547282:Show [Intellectual Product]

Phrase: "a progressive course thereafter."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0750729:Course [Temporal Concept]
Processing 00000000.tx.137: Moreover, hepatic histology, in the cases analyzed, further confirmed that HCV infection was the only cause of hepatic disease, as recently observed in a patient with chronic lymphocytic leukemia treated with HCV-infected IVIG.17 Immunosuppressive therapy was given both to ITP and ID patients, but only ID patients also received cytostatic agents before and after HCV infection. 

Phrase: "Moreover,"

Phrase: "hepatic histology,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0019638:Histology [Biomedical Occupation or Discipline]
   861   C0205462:histology [Functional Concept]
   861   C0344441:Histology [Laboratory Procedure]

Phrase: "in the cases"
Meta Candidates (Total=4; Excluded=2; Pruned=0; Remaining=2)
  1000   C0868928:Cases [Functional Concept]
  1000   C1533148:Cases [Quantitative Concept]
   966 E C1706255:CASE [Medical Device]
   966 E C1706256:Case [Conceptual Entity]

Phrase: "analyzed"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0936012:Analyzed [Research Activity]

Phrase: ","

Phrase: "further"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
  1000   C1517331:Further [Spatial Concept]
   966 E C0205108:far [Spatial Concept]

Phrase: "confirmed"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C0521093:confirmed [Qualitative Concept]
  1000   C0750484:Confirmed [Idea or Concept]
   966 E C1456348:Confirm [Qualitative Concept]

Phrase: "that HCV infection"
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
   923   C0019196:Hepatitis C Infection [Disease or Syndrome]
   861   C0042769:virus infection [Disease or Syndrome]
   812   C0009450:Infection, NOS [Disease or Syndrome]
   756   C0220847:Hepatitis C virus [Virus]
   741 E C0439663:Infected [Functional Concept]
   708   C0019186:Hepatitis virus [Virus]
   701 E C0030657:infectivity [Qualitative Concept]

Phrase: "was"

Phrase: "the only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "cause of hepatic disease,"
Meta Candidates (Total=9; Excluded=3; Pruned=0; Remaining=6)
   833   C0023895:HEPATIC DISEASE (NOS) [Disease or Syndrome]
   819   C1314792:disease cause [Functional Concept]
   770   C0012634:Disease [Disease or Syndrome]
   770   C0015127:cause [Functional Concept]
   770   C0205054:Hepatic [Body Location or Region]
   770   C1524003:Cause [Conceptual Entity]
   715 E C1836721:MALS [Finding]
   715 E C3538764:MALS [Gene or Genome]
   715 E C3540595:MAL [Gene or Genome]

Phrase: "as"

Phrase: "recently"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332185:Recently [Temporal Concept]

Phrase: "observed in a patient"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0030705:*^patient [Patient or Disabled Group]
   770   C1441672:Observed [Functional Concept]

Phrase: "with chronic lymphocytic leukemia"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0023434:Chronic Lymphocytic Leukemia [Neoplastic Process]
   913   C1279296:Chronic leukaemia [Neoplastic Process]
   901   C0023448:Lymphocytic Leukemia [Neoplastic Process]
   827   C0023418:Leukaemia [Neoplastic Process]
   827   C0024264:Lymphocytic [Cell]
   827   C0205191:chronic [Temporal Concept]
   827   C2939172:Lymphocytic [Qualitative Concept]

Phrase: "treated with HCV-infected IVIG.17 Immunosuppressive therapy"
Meta Candidates (Total=27; Excluded=2; Pruned=0; Remaining=25)
   775   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   756   C0019196:Hepatitis C [Disease or Syndrome]
   756   C0021079:Immunosuppressive therapy [Therapeutic or Preventive Procedure]
   756   C0085297:Immunoglobulins, Intravenous [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   756   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   754   C0019186:Hepatitis virus [Virus]
   754   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   754   C0455142:Intravenous therapy [Therapeutic or Preventive Procedure]
   738   C0019158:Hepatitis [Disease or Syndrome]
   738   C0019159:hepatitis [Disease or Syndrome]
   738   C0021027:Immunoglobulins [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   738   C0021081:immunosuppressive [Immunologic Factor,Pharmacologic Substance]
   738   C0039798:therapy [Functional Concept]
   738   C0042776:Virus [Virus]
   738   C0087111:Therapy [Therapeutic or Preventive Procedure]
   738   C0202081:Immunoglobulins NOS [Laboratory Procedure]
   738   C0319157:virus [Virus]
   738   C0348016:Intravenous [Spatial Concept]
   738   C0439663:Infected [Functional Concept]
   738   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   738   C1363945:Therapy [Finding]
   738   C1522326:Treated [Functional Concept]
   737   C0021022:Immunoglobulin Therapy [Therapeutic or Preventive Procedure]
   704 E C1292734:TREAT [Functional Concept]
   704 E C1621846:immunoglobulin [Molecular Function]

Phrase: "was"

Phrase: "given"
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
  1000   C1442162:GIVEN [Conceptual Entity]
  1000   C1550718:given [Idea or Concept]
  1000   C3244317:given [Intellectual Product]
   966 E C1947971:Give [Functional Concept]

Phrase: "both to ITP"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
   862   C0043117:Purpura, Thrombocytopenic, Idiopathic [Disease or Syndrome]
           Idiopathic purpura
   806   C0034153:thrombocytopenic purpura [Pharmacologic Substance]
   806   C0857305:Thrombocytopenic purpura [Disease or Syndrome]
   760   C0034150:Purpura [Disease or Syndrome]
   760   C0238767:Both [Spatial Concept]
   760   C0332240:Idiopathic [Functional Concept]
   760   C1706086:Both [Qualitative Concept]
   760   C3463943:Purpura [Eukaryote]

Phrase: "and"

Phrase: "ID patients,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:Patients [Patient or Disabled Group]

Phrase: "but"

Phrase: "only ID patients also"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C0030705:Patients [Patient or Disabled Group]

Phrase: "received"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1514756:Received [Qualitative Concept]

Phrase: "cytostatic agents before"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   882   C0010858:Cytostatic Agents [Pharmacologic Substance]
           cytostatic
   756   C0450442:Agent [Chemical Viewed Functionally]
   756   C1254351:Agent [Pharmacologic Substance]
   756   C1521826:Agent [Intellectual Product]

Phrase: "and after HCV infection."
Meta Candidates (Total=17; Excluded=0; Pruned=0; Remaining=17)
   833   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   820   C0019196:Hepatitis C Infection [Disease or Syndrome]
           Hepatitis C
   791   C0019160:Hepatitis Virus, Infectious [Virus]
   791   C0376325:Infectious hepatitis virus [Virus]
   790   C0042769:virus infection [Disease or Syndrome]
   783   C0019186:Hepatitis virus [Virus]
   783   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   753   C0009450:Infection, NOS [Disease or Syndrome]
   753   C0019158:Hepatitis [Disease or Syndrome]
   753   C0019159:hepatitis [Disease or Syndrome]
           Hepatitis, Infectious
   753   C0042776:Virus [Virus]
   753   C0319157:virus [Virus]
   753   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   753   C1515981:And [Idea or Concept]
Processing 00000000.tx.138: Therefore, it cannot be excluded that preceding or concomitant chemotherapy may predispose patients to subacute or chronic HCV-mediated liver damage in the presence of immunodeficiency. 

Phrase: "Therefore,"

Phrase: "it"

Phrase: "cannot"

Phrase: "be"

Phrase: "excluded"
Meta Candidates (Total=3; Excluded=1; Pruned=0; Remaining=2)
  1000   C1554077:Excluded [Idea or Concept]
  1000   C2828389:Excluded [Activity]
   966 E C0332196:Exclude [Functional Concept]

Phrase: "that preceding"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0332152:Preceding [Temporal Concept]

Phrase: "or"

Phrase: "concomitant chemotherapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   861   C0013217:chemotherapy [Functional Concept]
   861   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]

Phrase: "may"

Phrase: "predispose"

Phrase: "patients to subacute"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   790   C0030705:Patients [Patient or Disabled Group]

Phrase: "or"

Phrase: "chronic HCV-mediated liver damage in the presence of immunodeficiency."
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   753   C0151763:Liver damage [Pathologic Function]
   736   C0010957:Damage [Injury or Poisoning]
   736   C0023884:Liver [Body Part, Organ, or Organ Component]
   736   C0736268:LIVER [Body Part, Organ, or Organ Component]
   736   C1278929:Liver [Body Part, Organ, or Organ Component]
   736   C1883709:Damage [Functional Concept]
   736   C2346688:LIVER [Food]
   723   C0341439:chronic hepatic [Disease or Syndrome]
Processing 00000000.tx.139: Indeed, liver failure developed rapidly in the two ID patients who continued cytostatic treatment after IVIG, whereas the only surviving ID patient has never been treated with chemotherapy. 

Phrase: "Indeed,"

Phrase: "liver failure"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0085605:Liver Failure [Disease or Syndrome]
   861   C0231174:Failure [Functional Concept]
   861   C0680095:failure [Individual Behavior]

Phrase: "developed"

Phrase: "rapidly in the two ID patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   753   C0021051:Immunodeficient [Disease or Syndrome]
   753   C0030705:Patients [Patient or Disabled Group]
   753   C0205448:Two [Quantitative Concept]
   753   C1637379:Rapidly [Qualitative Concept]

Phrase: "who"

Phrase: "continued"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0549178:Continued [Idea or Concept]

Phrase: "cytostatic treatment after IVIG,"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   760   C0039798:treatment [Functional Concept]
   760   C0087111:Treatment [Therapeutic or Preventive Procedure]
   760   C1522326:Treatment [Functional Concept]
   760   C1533734:Treatment [Therapeutic or Preventive Procedure]
   760   C1705169:Treatment [Conceptual Entity]
   760   C3538994:TREATMENT [Research Activity]

Phrase: "whereas"

Phrase: "the only"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0205171:Only [Quantitative Concept]
  1000   C1720467:Only [Intellectual Product]

Phrase: "surviving"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C0310255:SURVIVE [Pharmacologic Substance]

Phrase: "ID patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0030705:*^patient [Patient or Disabled Group]

Phrase: "has"

Phrase: "never"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C2003901:Never [Temporal Concept]

Phrase: "been"

Phrase: "treated with chemotherapy."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   882   C0332293:Treated with [Therapeutic or Preventive Procedure]
           treated
   790   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
   790   C0013217:chemotherapy [Functional Concept]
   790   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]
   790   C1522326:Treated [Functional Concept]
   756 E C1292734:TREAT [Functional Concept]
Processing 00000000.tx.140: However, because the type of drugs and the dosages used in our patients are unlikely to be associated with a significant drug-induced liver toxicity, it is possible that chemotherapy plays its negative role by further impairing the immune status of ID patients.  

Phrase: "However,"

Phrase: "because"

Phrase: "the type of drugs"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   898   C0457591:Type of drug [Qualitative Concept]
           drugs type
   770   C0332307:Type [Qualitative Concept]
   770   C1547052:*Type [Quantitative Concept]

Phrase: "and"

Phrase: "the dosages"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0178602:Dosages [Quantitative Concept]

Phrase: "used in our patients"
Meta Candidates (Total=5; Excluded=3; Pruned=0; Remaining=2)
   770   C0030705:Patients [Patient or Disabled Group]
   770   C1273517:used [Finding]
   737 E C0042153:use [Functional Concept]
   737 E C0457083:Use [Functional Concept]
   737 E C1947944:Use [Intellectual Product]

Phrase: "are"

Phrase: "unlikely to"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0750558:Unlikely [Conceptual Entity]
   861   C1710571:Unlikely [Qualitative Concept]

Phrase: "be"

Phrase: "associated with a significant drug-induced liver toxicity,"
Meta Candidates (Total=18; Excluded=2; Pruned=0; Remaining=16)
   770   C0332281:Associated with [Qualitative Concept]
           Associated
   770   C0458082:Drug-induced [Functional Concept]
   767   C0013221:Drug toxicity [Injury or Poisoning]
   744   C0013227:Drug [Pharmacologic Substance]
   744   C0023884:Liver [Body Part, Organ, or Organ Component]
   744   C0040539:toxicity [Qualitative Concept]
   744   C0205263:Induced [Functional Concept]
   744   C0237881:significant [Quantitative Concept]
   744   C0600688:Toxicity [Injury or Poisoning]
   744   C0736268:LIVER [Body Part, Organ, or Organ Component]
   744   C0750502:Significant [Idea or Concept]
   744   C1254351:Drug [Pharmacologic Substance]
   744   C1278929:Liver [Body Part, Organ, or Organ Component]
   744   C1546944:Significant [Qualitative Concept]
   744   C2346688:LIVER [Food]
   711 E C0750490:Associate [Idea or Concept]
   711 E C1706221:Associate [Professional or Occupational Group]

Phrase: "it"

Phrase: "is"

Phrase: "possible"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0332149:Possible [Qualitative Concept]
  1000   C1705910:Possible [Qualitative Concept]
  1000   C2362652:Possible [Qualitative Concept]

Phrase: "that chemotherapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0013216:Chemotherapy [Therapeutic or Preventive Procedure]
  1000   C0013217:chemotherapy [Functional Concept]
  1000   C0392920:Chemotherapy [Therapeutic or Preventive Procedure]

Phrase: "plays"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0032214:Play [Daily or Recreational Activity]
  1000   C0600138:Plays [Finding]

Phrase: "its negative role by further impairing"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C0035820:Role [Social Behavior]
   753   C1705810:Role [Conceptual Entity]

Phrase: "the immune status of ID patients."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   790   C0020964:Immune status [Physiologic Function]
   767   C0449437:Patient status [Finding]
   753   C0449438:Status [Qualitative Concept]
Processing 00000000.tx.141: FOOTNOTES  Submitted October 3, 1996; 

Phrase: "FOOTNOTES"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   966   C2825232:Footnote [Intellectual Product]

Phrase: "Submitted"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1515023:Submitted [Functional Concept]

Phrase: "October 3,"

Phrase: "1996"

Phrase: ";"
Processing 00000000.tx.142: accepted March 26, 1997.  

Phrase: "accepted March 26,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1272684:Accepted [Qualitative Concept]
   827   C1548435:Accepted [Idea or Concept]

Phrase: "1997."
Processing 00000000.tx.143: Address reprint requests to Giuseppe Rossi, MD, Sezione Ematologia, Spedali Civili, p.le Spedali Civili, 1, 25100 Brescia, Italy.  

Phrase: "Address reprint"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3273171:Reprint [Intellectual Product]

Phrase: "requests to Giuseppe Rossi,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0686900:request [Functional Concept]
   770   C1272683:Request [Functional Concept]
   770   C1522634:Request [Intellectual Product]

Phrase: "MD,"

Phrase: "Sezione Ematologia,"

Phrase: "Spedali Civili,"

Phrase: "p.le Spedali Civili,"

Phrase: "1,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]

Phrase: "25100 Brescia,"

Phrase: "Italy."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]
Processing 00000000.tx.144: The publication costs of this article were defrayed in part by page charge payment. 

Phrase: "The publication"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0034036:Publication [Intellectual Product,Manufactured Object]
  1000   C0034037:Publication [Occupational Activity]
  1000   C1704324:Publication [Intellectual Product]

Phrase: "costs of this article"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0010186:Cost [Quantitative Concept]
   770   C0220812:Costs [Quantitative Concept]
   770   C1706852:Article [Intellectual Product]

Phrase: "were"

Phrase: "defrayed in part"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C0449719:Part [Spatial Concept]
   790   C1709471:Part [Quantitative Concept]

Phrase: "by page charge payment."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0220808:payment [Quantitative Concept]
   827   C0680264:payment [Quantitative Concept]
Processing 00000000.tx.145: This article must therefore be hearly marked ``advertisment'' in accordance with 18 U.S.C. section 1734 solely to indicate this fact.  

Phrase: "This article"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1706852:Article [Intellectual Product]

Phrase: "must"

Phrase: "therefore"

Phrase: "be"

Phrase: "hearly"

Phrase: "marked"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0522501:Marked [Qualitative Concept]
  1000   C1706089:Marked [Qualitative Concept]

Phrase: "``advertisment''"

Phrase: "in accordance with 18 U.S.C. section 1734 solely to"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   812   C0041703:U S [Geographic Area]
   793   C0205155:Section [Spatial Concept]
   793   C1293097:Section, NOS [Therapeutic or Preventive Procedure]
   793   C1522472:Section [Substance]
   793   C1552923:Section [Quantitative Concept]
   793   C1705191:Section [Physical Object]

Phrase: "indicate"

Phrase: "this fact."
Processing 00000000.tx.146: REFERENCES Abstract Introduction Methods Results Discussion References 1. 

Phrase: "REFERENCES"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "Abstract Introduction Methods Results Discussion"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   804   C0557061:Discussion [Therapeutic or Preventive Procedure]
   804   C2584313:Discussion [Social Behavior]

Phrase: "References"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1514811:Reference [Idea or Concept]
  1000   C1706462:Reference [Conceptual Entity]

Phrase: "1."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2827734:1+ [Quantitative Concept]
  1000   C2981698:1+ [Classification]
Processing 00000000.tx.147: Seeff LB, Buskell-Bales Z, Wright EC, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, Stevens CE, Hollingsworth CG, the National Hearth, Lung and Blood Institute Study Group: Long-term mortality after transfusion-associated non-A, non-B hepatitis. 

Phrase: "Seeff LB,"

Phrase: "Buskell-Bales Z,"

Phrase: "Wright EC,"

Phrase: "Wright EC,"

Phrase: "Durako SJ,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1515101:SJ [Geographic Area]
   861   C2986905:SJ [Idea or Concept]

Phrase: "Alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "HJ,"

Phrase: "Iber FL,"

Phrase: "Hollinger FB,"

Phrase: "Gitnick G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Knodell RG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412999:RG [Gene or Genome]

Phrase: "Perrillo RP,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1538326:RP [Gene or Genome]
   861   C3541325:RP [Idea or Concept]

Phrase: "Stevens CE,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2827664:CE [Idea or Concept]

Phrase: "Hollingsworth CG,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0054868:CG [Amino Acid, Peptide, or Protein,Enzyme]
   861   C3540479:CG [Gene or Genome]

Phrase: "the National Hearth,"

Phrase: "Lung"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
  1000   C0024109:Lung [Body Part, Organ, or Organ Component]
  1000   C0819757:LUNG [Tissue]
  1000   C1278908:Lung [Body Part, Organ, or Organ Component]
   944 E C2707265:Pulmonary [Clinical Attribute]
   944 E C2709248:Pulmonary [Qualitative Concept]
   907 E C0032285:Pneumonia [Disease or Syndrome]

Phrase: "and"

Phrase: "Blood Institute Study Group"
Meta Candidates (Total=10; Excluded=0; Pruned=0; Remaining=10)
   902   C0005810:Blood Group [Classification]
   902   C0600103:Blood group [Laboratory or Test Result]
   812   C0441833:Group [Idea or Concept]
   812   C0557651:Study [Manufactured Object]
   812   C0687744:group [Population Group]
   812   C1257890:Group [Population Group]
   812   C1552516:Group [Health Care Related Organization]
   812   C1705428:Group [Conceptual Entity]
   812   C1705429:Group [Population Group]
   812   C2603343:Study [Research Activity]

Phrase: ":"

Phrase: "Long-term mortality"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   901   C0443252:Long-term [Temporal Concept]
   827   C0026565:Mortality [Quantitative Concept]
   827   C0026566:mortality [Quantitative Concept]
   827   C0205166:Long [Qualitative Concept]
   827   C1515273:Term [Temporal Concept]
   827   C1705313:Term [Idea or Concept]
   827   C1706317:Long [Qualitative Concept]
   827   C2826302:TERM [Intellectual Product]

Phrase: "after transfusion-associated non-A, non-B hepatitis."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   913   C0019196:Non-A, non-B hepatitis [Disease or Syndrome]
           non b hepatitis
   893   C0520788:Transfusion hepatitis [Disease or Syndrome]
   795   C0019158:Hepatitis [Disease or Syndrome]
   795   C0019159:hepatitis [Disease or Syndrome]
   795   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.148: N Engl J Med 327:1906, 1992[Abstract] 2. 

Phrase: "N Engl J Med 327"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ":"

Phrase: "1906,"

Phrase: "1992"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 2."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0740116:+2 [Quantitative Concept]
  1000   C2827735:2+ [Quantitative Concept]
  1000   C2981700:2+ [Classification]
Processing 00000000.tx.149: Tong MJ, El-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion-associated hepatitis C. 

Phrase: "Tong MJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: "El-Farra NS,"

Phrase: "Reikes AR,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2986463:AR+ [Finding]

Phrase: "Co RL"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1419337:RL [Gene or Genome]
   861   C3539667:RL [Gene or Genome]

Phrase: ":"

Phrase: "Clinical outcomes after transfusion-associated hepatitis C."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   714   C1274040:Outcome [Functional Concept]
Processing 00000000.tx.150: N Engl J Med 332:1463, 1995[Abstract/Free FullText] 3. 

Phrase: "N Engl J Med 332"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ":"

Phrase: "1463,"

Phrase: "1995"

Phrase: "[Abstract/Free FullText"

Phrase: "] 3."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0439086:<3 [Quantitative Concept]
  1000   C2827736:3+ [Quantitative Concept]
  1000   C2981702:3+ [Classification]
Processing 00000000.tx.151: Spengler U, Lechmann M, Irrgang B, Dumoulin FL, Sauerbruch T: Immune responses in hepatitis C virus infection. 

Phrase: "Spengler U,"

Phrase: "Lechmann M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Irrgang B,"

Phrase: "Dumoulin FL,"

Phrase: "Sauerbruch T"

Phrase: ":"

Phrase: "Immune responses in hepatitis C virus infection."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   778   C0301872:immune responses [Organ or Tissue Function]
   774   C0744855:hepatitis immune [Disease or Syndrome]
   748   C0439662:Immune [Functional Concept]
   748   C0871261:responses [Organism Attribute]
   714 E C1704632:Response [Finding]
   714 E C1706817:Response [Intellectual Product]
   714 E C2911692:Response [Mental Process]
Processing 00000000.tx.152: J Hepatol 24:20, 1996 (suppl 2) 4. 

Phrase: "J Hepatol 24"

Phrase: ":"

Phrase: "20,"

Phrase: "1996"

Phrase: "(suppl 2"

Phrase: ")"

Phrase: "4."
Processing 00000000.tx.153: Gonzales-Peralta RP, Davis GL, Lau JYN: Pathogenetic mechanisms of hepatocellular damage in chronic hepatitis C virus infection. 

Phrase: "Gonzales-Peralta RP,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C1538326:RP [Gene or Genome]
   827   C3541325:RP [Idea or Concept]

Phrase: "Davis GL,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0018229:GL [Geographic Area]
   861   C1423073:GL [Gene or Genome]
   861   C1427674:GL [Gene or Genome]

Phrase: "Lau JYN"

Phrase: ":"

Phrase: "Pathogenetic mechanisms of hepatocellular damage"
Meta Candidates (Total=2; Excluded=1; Pruned=0; Remaining=1)
   760   C0441712:Mechanisms [Functional Concept]
   726 E C1706376:Mechanism [Manufactured Object]

Phrase: "in chronic hepatitis C virus infection."
Meta Candidates (Total=7; Excluded=1; Pruned=0; Remaining=6)
   897   C0151317:Chronic infection [Disease or Syndrome]
   888   C0019196:Hepatitis C Infection [Disease or Syndrome]
   840   C0042769:virus infection [Disease or Syndrome]
   804   C0009450:Infection, NOS [Disease or Syndrome]
   733 E C0439663:Infected [Functional Concept]
   717   C0220847:Hepatitis C virus [Virus]
   717   C0524910:Hepatitis C, Chronic [Disease or Syndrome]
Processing 00000000.tx.154: J Hepatol 21:255, 1994[Medline] [OrderarticleviaInfotrieve] 5. 

Phrase: "J Hepatol 21"

Phrase: ":"

Phrase: "255,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 5."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C0439084:>5 [Quantitative Concept]
  1000   C0728893:+5 [Quantitative Concept]
Processing 00000000.tx.155: Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T: Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. 

Phrase: "Bjoro K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Froland SS,"

Phrase: "Yun Z,"

Phrase: "Samdal HH,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0062941:HH [Organic Chemical,Pharmacologic Substance]
   861   C1384665:HH [Gene or Genome]
   861   C1414862:Hh [Gene or Genome]

Phrase: "Haaland T"

Phrase: ":"

Phrase: "Hepatitis C infection in patients"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   862   C0019196:Hepatitis C Infection [Disease or Syndrome]
   762   C0019159:Hepatitis, Infectious [Disease or Syndrome]
   760   C0009450:Infection, NOS [Disease or Syndrome]

Phrase: "with primary hypogammaglobulinemia"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0086438:Hypogammaglobulinaemia [Disease or Syndrome]

Phrase: "after treatment"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
  1000   C0039798:treatment [Functional Concept]
  1000   C0087111:Treatment [Therapeutic or Preventive Procedure]
  1000   C1522326:Treatment [Functional Concept]
  1000   C1533734:Treatment [Therapeutic or Preventive Procedure]
  1000   C1705169:Treatment [Conceptual Entity]
  1000   C3538994:TREATMENT [Research Activity]

Phrase: "with contaminated immune globulin."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   901   C0021027:immune globulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   827   C0017649:Globulin [Amino Acid, Peptide, or Protein,Biologically Active Substance]
   827   C0439662:Immune [Functional Concept]
Processing 00000000.tx.156: N Engl J Med 331:1607, 1994[Abstract/Free FullText] 6. 

Phrase: "N Engl J Med 331"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   804   C0369718:N NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   804   C0441922:N+ [Intellectual Product]
   804   C1414400:ENGL [Gene or Genome]
   804   C1553036:[n] [Quantitative Concept]

Phrase: ":"

Phrase: "1607,"

Phrase: "1994"

Phrase: "[Abstract/Free FullText"

Phrase: "] 6."
Processing 00000000.tx.157: Lim HL, Lau GKK, Davis GL, Dolson DJ, Lau JYN: Cholestatic hepatitis leading to hepatic failure in a patient with organ-transmitted hepatitis C virus infection. 

Phrase: "Lim HL,"

Phrase: "Lau GKK,"

Phrase: "Davis GL,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0018229:GL [Geographic Area]
   861   C1423073:GL [Gene or Genome]
   861   C1427674:GL [Gene or Genome]

Phrase: "Dolson DJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0012836:DJ [Geographic Area]

Phrase: "Lau JYN"

Phrase: ":"

Phrase: "Cholestatic hepatitis"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0149904:Cholestatic hepatitis [Disease or Syndrome]
   861   C0019158:Hepatitis [Disease or Syndrome]
   861   C0019159:hepatitis [Disease or Syndrome]
   861   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   789   C0008370:Cholestases [Disease or Syndrome]

Phrase: "leading to hepatic failure"
Meta Candidates (Total=10; Excluded=4; Pruned=0; Remaining=6)
   833   C0085605:Hepatic Failure [Disease or Syndrome]
   770   C0205054:Hepatic [Body Location or Region]
   770   C0231174:Failure [Functional Concept]
   770   C0332152:Leading [Temporal Concept]
   770   C0680095:failure [Individual Behavior]
   770   C1522538:Leading [Functional Concept]
   737 E C0023175:???lead [Element, Ion, or Isotope,Hazardous or Poisonous Substance]
   737 E C1442948:lead [Inorganic Chemical,Pharmacologic Substance]
   737 E C2348269:Lead [Element, Ion, or Isotope]
   737 E C3275067:LEAD [Therapeutic or Preventive Procedure]

Phrase: "in a patient"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0030705:*^patient [Patient or Disabled Group]

Phrase: "with organ-transmitted hepatitis C virus infection."
Meta Candidates (Total=4; Excluded=1; Pruned=0; Remaining=3)
   867   C0019196:Hepatitis C Infection [Disease or Syndrome]
   827   C0042769:virus infection [Disease or Syndrome]
   799   C0009450:Infection, NOS [Disease or Syndrome]
   727 E C0439663:Infected [Functional Concept]
Processing 00000000.tx.158: Gastroenterology 106:248, 1994[Medline] [OrderarticleviaInfotrieve] 7. 

Phrase: "Gastroenterology 106"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017163:Gastroenterology [Biomedical Occupation or Discipline]

Phrase: ":"

Phrase: "248,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 7."
Processing 00000000.tx.159: Martin P, Di Bisceglie AM, Kassianides C, Lisker-Melman M, Hoofnagle JH: Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. 

Phrase: "Martin P,"

Phrase: "Di Bisceglie"

Phrase: "AM"

Phrase: ","

Phrase: "Kassianides C,"

Phrase: "Lisker-Melman M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C0441923:M+ [Intellectual Product]

Phrase: "Hoofnagle JH"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0268060:JH [Disease or Syndrome]
   861   C1415529:JH [Gene or Genome]

Phrase: ":"

Phrase: "Rapidly progressive non-A, non-B hepatitis in patients"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   849   C0019196:Non-A, non-B hepatitis [Disease or Syndrome]
           non b hepatitis
   762   C0019159:Hepatitis A [Disease or Syndrome]
           hepatitis
   762   C0019163:Hepatitis B [Disease or Syndrome]
   742   C0019158:Hepatitis [Disease or Syndrome]
   742   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "with human immunodeficiency virus infection."
Meta Candidates (Total=7; Excluded=2; Pruned=0; Remaining=5)
  1000   C0019693:Human immunodeficiency virus infection [Disease or Syndrome]
   861   C0042769:virus infection [Disease or Syndrome]
   812   C0009450:Infection, NOS [Disease or Syndrome]
   756   C0019682:Virus, Human Immunodeficiency [Virus]
   741 E C0439663:Infected [Functional Concept]
   708   C0318356:Human virus [Virus]
   701 E C0030657:infectivity [Qualitative Concept]
Processing 00000000.tx.160: Gastroenterology 97:1559, 1989[Medline] [OrderarticleviaInfotrieve] 8. 

Phrase: "Gastroenterology 97"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0017163:Gastroenterology [Biomedical Occupation or Discipline]
   861   C0439073:97 [Intellectual Product]
   861   C0439082:>97 [Quantitative Concept]

Phrase: ":"

Phrase: "1559,"

Phrase: "1989"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 8."
Processing 00000000.tx.161: Eyster ME, Diamondstone LS, Lien J, Christopher Ehmann W, Quan S, Goedert JJ for the Multicenter Hemophilia Cohort Study: Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. 

Phrase: "Eyster"

Phrase: "ME,"

Phrase: "Diamondstone LS,"

Phrase: "Lien J,"

Phrase: "Christopher Ehmann W,"

Phrase: "Quan S,"

Phrase: "Goedert JJ for the Multicenter Hemophilia Cohort Study"

Phrase: ":"

Phrase: "Natural history of hepatitis C virus infection"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   778   C0175860:Natural History [Occupation or Discipline]
   748   C0019664:History [Occupation or Discipline]
   748   C0019665:history [Intellectual Product]
   748   C0205296:Natural [Functional Concept]
   748   C0262512:History, NOS [Organism Attribute]
   748   C0262926:History [Finding]
   748   C1705255:History [Conceptual Entity]
   748   C2004062:History [Finding]

Phrase: "in multitransfused hemophiliacs"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0259931:Hemophiliacs [Patient or Disabled Group]

Phrase: ":"

Phrase: "Effect of coinfection"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   790   C1280500:Effect [Qualitative Concept]
   790   C2348382:Effect [Qualitative Concept]

Phrase: "with human immunodeficiency virus."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0019682:Virus, Human Immunodeficiency [Virus]
   913   C0318356:Human virus [Virus]
   901   C0682458:immunodeficiency virus [Virus]
   827   C0021051:IMMUNO-DEFICIENCY [Disease or Syndrome]
   827   C0042776:Virus [Virus]
   827   C0086418:Human [Human]
   827   C0319157:virus [Virus]
Processing 00000000.tx.162: J AIDS 6:602, 1993[Medline] [OrderarticleviaInfotrieve] 9. 

Phrase: "J AIDS 6"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   827   C0001175:AIDS [Disease or Syndrome]
   793 E C0018896:Aid [Social Behavior]
   793 E C0449435:Aid [Manufactured Object]
   793 E C3540469:AID [Gene or Genome]

Phrase: ":"

Phrase: "602,"

Phrase: "1993"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 9."
Processing 00000000.tx.163: Meeks EL, Beach MJ: Outbreak of hepatitis C associated with intravenous immunoglobulin administration United States, October 1993-June 1994. 

Phrase: "Meeks EL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C1416870:EL [Gene or Genome]
   861   C1823249:EL [Gene or Genome]

Phrase: "Beach MJ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439254:MJ [Medical Device]

Phrase: ":"

Phrase: "Outbreak of hepatitis C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   770   C0012652:outbreak [Phenomenon or Process]

Phrase: "associated with intravenous immunoglobulin administration United States,"
Meta Candidates (Total=17; Excluded=4; Pruned=0; Remaining=13)
   778   C0041703:United States [Geographic Area]
   778   C0085297:Intravenous immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   778   C0332281:Associated with [Qualitative Concept]
           Associated
   774   C0013125:intravenous administration [Spatial Concept]
   774   C0021440:intravenous administration [Therapeutic or Preventive Procedure]
   748   C0001554:Administration [Occupational Activity]
   748   C0021027:Immunoglobulin [Amino Acid, Peptide, or Protein,Immunologic Factor,Pharmacologic Substance]
   748   C0348016:Intravenous [Spatial Concept]
   748   C1301808:states [Geographic Area]
   748   C1533734:Administration [Therapeutic or Preventive Procedure]
   748   C1621846:immunoglobulin [Molecular Function]
   714   C0166872:unite [Biomedical or Dental Material]
   714 E C0750490:Associate [Idea or Concept]
   714 E C1442792:State [Functional Concept]
   714 E C1706221:Associate [Professional or Occupational Group]
   714 E C3148680:State [Geographic Area]

Phrase: "October 1993-June 1994."
Processing 00000000.tx.164: Morb Mortal Wkly Rep 43:505, 1994[Medline] [OrderarticleviaInfotrieve] 10. 

Phrase: "Morb Mortal Wkly Rep 43"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   804   C1744664:REP [Molecular Function]

Phrase: ":"

Phrase: "505,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 10."
Processing 00000000.tx.165: Puoti M, Zonaro A, Ravaggi A, Marin MG, Castelnuovo F, Cariani E: Hepatitis C virus RNA and antibody response in the clinical course of acute hepatitis C virus infection. 

Phrase: "Puoti M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Zonaro A,"

Phrase: "Ravaggi A,"

Phrase: "Marin MG,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439269:mg% [Quantitative Concept]
   861   C1960952:mg % [Quantitative Concept]
   861   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "Castelnuovo F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Cariani E"

Phrase: ":"

Phrase: "Hepatitis C virus RNA"
Meta Candidates (Total=14; Excluded=0; Pruned=0; Remaining=14)
  1000   C0369335:Hepatitis C virus RNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   923   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   923   C0855840:hepatitis c rna [Laboratory Procedure]
   875   C0019186:Hepatitis virus [Virus]
   861   C0019196:Hepatitis C [Disease or Syndrome]
   861   C0035691:Virus-RNA [Virus]
   861   C0035736:virus RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0019158:Hepatitis [Disease or Syndrome]
   812   C0019159:hepatitis [Disease or Syndrome]
   812   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   812   C0042776:Virus [Virus]
   812   C0319157:virus [Virus]
   812   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "and"

Phrase: "antibody response in the clinical course of acute hepatitis C virus infection."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   753   C0003261:Antibody Response [Biologic Function]
   736   C0871261:Response [Organism Attribute]
   736   C1704632:Response [Finding]
   736   C1706817:Response [Intellectual Product]
   736   C2911692:Response [Mental Process]
Processing 00000000.tx.166: Hepatology 16:877, 1992[Medline] [OrderarticleviaInfotrieve] 11. 

Phrase: "Hepatology 16"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0086403:Hepatology [Biomedical Occupation or Discipline]
   861   C1555763:Hepatology [Professional or Occupational Group]

Phrase: ":"

Phrase: "877,"

Phrase: "1992"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 11."
Processing 00000000.tx.167: Ravaggi A, Zonaro A, Marin MG, Puoti M, Albertini A, Cariani E: Distribution of viral genotypes in Italy determined by hepatitis C virus typing by DNA immunoassay. 

Phrase: "Ravaggi A,"

Phrase: "Zonaro A,"

Phrase: "Marin MG,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439269:mg% [Quantitative Concept]
   861   C1960952:mg % [Quantitative Concept]
   861   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "Puoti M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Albertini A,"

Phrase: "Cariani E"

Phrase: ":"

Phrase: "Distribution of viral genotypes"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C0520511:distribution [Idea or Concept]
   770   C1704711:Distribution [Functional Concept]

Phrase: "in Italy"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0022277:Italy [Geographic Area]

Phrase: "determined by hepatitis C virus typing"
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   833   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   790   C0019196:Hepatitis C [Disease or Syndrome]
   783   C0019186:Hepatitis virus [Virus]
   783   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   753   C0019158:Hepatitis [Disease or Syndrome]
   753   C0019159:hepatitis [Disease or Syndrome]
   753   C0042776:Virus [Virus]
   753   C0319157:virus [Virus]
   753   C0441704:Typing [Health Care Activity]
   753   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   753   C0872404:typing [Occupational Activity]

Phrase: "by DNA immunoassay."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0020980:Immunoassay [Laboratory Procedure]
   861   C0021060:immunoassay [Laboratory Procedure]
Processing 00000000.tx.168: J Clin Microbiol 32:2280, 1994[Abstract] 12. 

Phrase: "J Clin Microbiol 32"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1315013:CLIN [Intellectual Product]

Phrase: ":"

Phrase: "2280,"

Phrase: "1994"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 12."
Processing 00000000.tx.169: Ravaggi A, Rossini A, Mazza C, Puoti M, Marin MG, Cariani E: HCV genotypes in northern Italy: Clinical and virological features. 

Phrase: "Ravaggi A,"

Phrase: "Rossini A,"

Phrase: "Mazza C,"

Phrase: "Puoti M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Marin MG,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0439269:mg% [Quantitative Concept]
   861   C1960952:mg % [Quantitative Concept]
   861   C2346927:Mg++ [Element, Ion, or Isotope,Pharmacologic Substance]

Phrase: "Cariani E"

Phrase: ":"

Phrase: "HCV genotypes in northern Italy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   837   C1148363:Hepatitis C virus genotype [Finding]
   837   C1533728:Hepatitis C virus genotype [Laboratory Procedure]
   748   C0017431:Genotypes [Organism Attribute]

Phrase: ":"

Phrase: "Clinical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205210:Clinical [Qualitative Concept]

Phrase: "and"

Phrase: "virological features."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   827   C1521970:Feature [Qualitative Concept]
   827   C1706388:Feature [Conceptual Entity]
   827   C2346469:Feature [Qualitative Concept]
   827   C2348519:Feature [Qualitative Concept]
Processing 00000000.tx.170: J Clin Microbiol 34:2822, 1996[Abstract] 13. 

Phrase: "J Clin Microbiol 34"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1315013:CLIN [Intellectual Product]

Phrase: ":"

Phrase: "2822,"

Phrase: "1996"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 13."
Processing 00000000.tx.171: Bukh J, Purcell RH, Miller RH: At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. 

Phrase: "Bukh J,"

Phrase: "Purcell RH,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035493:Rh [Element, Ion, or Isotope]
   861   C2699077:Rh- [Classification]
   861   C2699078:Rh+ [Classification]

Phrase: "Miller RH"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035493:Rh [Element, Ion, or Isotope]
   861   C2699077:Rh- [Classification]
   861   C2699078:Rh+ [Classification]

Phrase: ":"

Phrase: "At least 12 genotypes"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0017431:Genotypes [Organism Attribute]

Phrase: "of hepatitis C virus"
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   913   C0019186:Hepatitis virus [Virus]
   901   C0019196:Hepatitis C [Disease or Syndrome]
   827   C0019158:Hepatitis [Disease or Syndrome]
   827   C0019159:hepatitis [Disease or Syndrome]
   827   C0042776:Virus [Virus]
   827   C0319157:virus [Virus]
   827   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "predicted by sequence analysis of the putative E1 gene of isolates"
Meta Candidates (Total=13; Excluded=1; Pruned=0; Remaining=12)
   756   C0162801:Sequence Analysis [Laboratory Procedure,Molecular Biology Research Technique]
   738   C0002778:Analysis [Laboratory Procedure]
   738   C0004793:Sequence [Nucleotide Sequence]
   738   C0017337:Gene [Gene or Genome]
   738   C0162326:Sequence [Nucleotide Sequence]
   738   C0162327:Sequence [Nucleotide Sequence]
   738   C0370215:isolates [Substance]
   738   C0681842:Predicted [Idea or Concept]
   738   C0936012:Analysis [Research Activity]
   738   C1519249:Sequence [Functional Concept]
   738   C1524024:analysis [Functional Concept]
   738   C1882327:%{Predicted} [Quantitative Concept]
   704 E C1875400:ISOLATE [Pharmacologic Substance]

Phrase: "collected"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C1516695:Collected [Idea or Concept]
  1000   C1516698:Collected [Functional Concept]

Phrase: "worldwide."
Processing 00000000.tx.172: Proc Natl Acad Sci USA 90:8234, 1993[Abstract/Free FullText] 14. 

Phrase: "Proc Natl Acad Sci USA 90"
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
   799   C0041703:USA [Geographic Area]
   799   C0268596:ACAD [Disease or Syndrome]
   799   C0439083:>90 [Quantitative Concept]
   799   C0439087:<90 [Quantitative Concept]
   799   C1418943:PROC [Gene or Genome]
   799   C2700624:ACAD [Cell Function]
   799   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "8234,"

Phrase: "1993"

Phrase: "[Abstract/Free FullText"

Phrase: "] 14."
Processing 00000000.tx.173: Weiner AJ, Geysen HM, Christopherson C, Hall JE, Mason TJ, Saracco G, Bonino F, Crawford K, Marion CD, Crawford KA, Brunetto M, Barr PJ, Miyamura T, McHutchinson J, Houghton M: Evidence for immune selection of hepatitis C virus putative envelope glycoprotein variants: Potential role in chronic HCV infections. 

Phrase: "Weiner AJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0230613:AJ [Cell Component]

Phrase: "Geysen HM,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0262500:hm [Health Care Activity]
   861   C1512358:HM [Geographic Area]
   861   C3538713:HM [Idea or Concept]

Phrase: "Christopherson C,"

Phrase: "Hall JE,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0454673:JE [Geographic Area]
   861   C1550752:JE [Temporal Concept]

Phrase: "Mason TJ,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0039247:TJ [Geographic Area]

Phrase: "Saracco G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Bonino F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Crawford K,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: "Marion CD,"

Phrase: "Crawford KA,"

Phrase: "Brunetto M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Barr PJ,"

Phrase: "Miyamura T,"

Phrase: "McHutchinson J,"

Phrase: "Houghton M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "Evidence for immune selection of hepatitis C virus putative envelope glycoprotein variants"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   751   C0332120:Evidence of [Functional Concept]
           Evidence

Phrase: ":"

Phrase: "Potential role in chronic HCV infections."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   744   C0035820:Role [Social Behavior]
   744   C1705810:Role [Conceptual Entity]
Processing 00000000.tx.174: Proc Natl Acad Sci USA 89:3468, 1992[Abstract] 15. 

Phrase: "Proc Natl Acad Sci USA 89"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   799   C0041703:USA [Geographic Area]
   799   C0268596:ACAD [Disease or Syndrome]
   799   C1418943:PROC [Gene or Genome]
   799   C2700624:ACAD [Cell Function]
   799   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "3468,"

Phrase: "1992"

Phrase: "[Abstract"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0000857:Abstract [Occupational Activity]
  1000   C0600678:Abstract [Intellectual Product]
  1000   C1552863:Abstract [Idea or Concept]

Phrase: "] 15."
Processing 00000000.tx.175: Gruber A, Grillner L, Norder H, Magnius L, Rubio C, Bjoerkholm M: Hepatitis C virus infection in patients with malignant haematologic disease, in Becker Y, Darai G (eds): PCR Protocols for Diagnosis of Human and Animal Virus Disease. 

Phrase: "Gruber"

Phrase: "A,"

Phrase: "Grillner L,"

Phrase: "Norder H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Magnius L,"

Phrase: "Rubio C,"

Phrase: "Bjoerkholm M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "Hepatitis C virus infection in patients"
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   820   C0019196:Hepatitis C Infection [Disease or Syndrome]
   791   C0019160:Hepatitis Virus, Infectious [Virus]
   791   C0376325:Infectious hepatitis virus [Virus]
   790   C0042769:virus infection [Disease or Syndrome]
   753   C0009450:Infection, NOS [Disease or Syndrome]
   748   C0019159:Hepatitis, Infectious [Disease or Syndrome]

Phrase: "with malignant haematologic disease,"
Meta Candidates (Total=6; Excluded=3; Pruned=0; Remaining=3)
   913   C0442867:Malignant disease [Disease or Syndrome]
   901   C0018939:Haematologic disease [Disease or Syndrome]
   827   C0012634:Disease [Disease or Syndrome]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]

Phrase: "in Becker Y,"

Phrase: "Darai G (eds"

Phrase: ")"

Phrase: ":"

Phrase: "PCR Protocols for Diagnosis of Human"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
   744   C0442711:Protocols [Intellectual Product]
   711 E C1507394:Protocol [Intellectual Product]
   711 E C1522729:Protocol [Intellectual Product]
   711 E C2348563:Protocol [Intellectual Product]

Phrase: "and"

Phrase: "Animal Virus Disease."
Meta Candidates (Total=7; Excluded=3; Pruned=0; Remaining=4)
   913   C0003047:animal disease [Disease or Syndrome]
   901   C0042769:Virus Disease [Disease or Syndrome]
   827   C0012634:Disease [Disease or Syndrome]
   771 E C1836721:MALS [Finding]
   771 E C3538764:MALS [Gene or Genome]
   771 E C3540595:MAL [Gene or Genome]
   734   C0003060:Animal virus [Virus]
Processing 00000000.tx.176: Heidelberg, Germany, Springer Verlag, 1995, p 107 16. 

Phrase: "Heidelberg,"

Phrase: "Germany,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0017480:Germany [Geographic Area]

Phrase: "Springer Verlag,"

Phrase: "1995,"

Phrase: "p 107 16."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   827   C0369773:P NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   827   C2603361:P' [Clinical Attribute]
Processing 00000000.tx.177: Shuhart MC, Myerson D, Childs BH, Childs BH, Fingeroth JD, Perry JJ, Snyder DS, Spurgeon CL, Bevan CA, McDonald GB: Marrow transplantation from hepatitis C virus seropositive donors: Transmission rate and clinical course. 

Phrase: "Shuhart MC,"

Phrase: "Myerson D,"

Phrase: "Childs BH,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0004684:BH [Geographic Area]
   861   C1412800:BH [Gene or Genome]
   861   C2986890:BH [Idea or Concept]

Phrase: "Childs BH,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0004684:BH [Geographic Area]
   861   C1412800:BH [Gene or Genome]
   861   C2986890:BH [Idea or Concept]

Phrase: "Fingeroth JD,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1549972:JD [Intellectual Product]

Phrase: "Perry JJ,"

Phrase: "Snyder DS,"

Phrase: "Spurgeon CL,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0596019:Cl - [Element, Ion, or Isotope]

Phrase: "Bevan CA,"

Phrase: "McDonald GB"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0041700:GB [Geographic Area]
   861   C1551090:Gb [Quantitative Concept]

Phrase: ":"

Phrase: "Marrow transplantation from hepatitis C virus seropositive donors"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0005961:Marrow Transplantation [Therapeutic or Preventive Procedure]
   744   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   744   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   744   C0040733:transplantation [Functional Concept]

Phrase: ":"

Phrase: "Transmission rate"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0871208:Rate [Activity]
   861   C1521828:Rate [Quantitative Concept]

Phrase: "and"

Phrase: "clinical course."
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0449259:Clinical course [Temporal Concept]
   861   C0205210:Clinical [Qualitative Concept]
   861   C0750729:Course [Temporal Concept]
Processing 00000000.tx.178: Blood 84:3229, 1994[Abstract/Free FullText] 17. 

Phrase: "Blood 84"
Meta Candidates (Total=10; Excluded=7; Pruned=0; Remaining=3)
   861   C0005767:Blood [Tissue]
   861   C0005768:blood [Body Substance]
   861   C0229664:Blood [Body Substance]
   789 E C0333275:Bloody [Qualitative Concept]
   777 E C0005847:Blood Vessel [Body Part, Organ, or Organ Component]
   777 E C0392895:Bloods [Population Group]
   777 E C1283786:Blood vessel [Body Part, Organ, or Organ Component]
   777 E C1511228:VESSEL, BLOOD [Tissue]
   761 E C1558950:VASCULAR [Finding]
   761 E C1801960:Vascular [Qualitative Concept]

Phrase: ":"

Phrase: "3229,"

Phrase: "1994"

Phrase: "[Abstract/Free FullText"

Phrase: "] 17."
Processing 00000000.tx.179: Healey CJ, Sabharwal NK, Daub J, Davidson F, Yap PL, Fleming KA, Chapman RWG, Simmonds P, Chapel H: Outbreak of acute hepatitis C following the use of anti hepatitis C virus-screened intravenous immunoglobulin therapy. 

Phrase: "Healey CJ,"

Phrase: "Sabharwal NK,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0022688:NK [Cell]

Phrase: "Daub J,"

Phrase: "Davidson F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Yap PL,"

Phrase: "Fleming KA,"

Phrase: "Chapman RWG,"

Phrase: "Simmonds P,"

Phrase: "Chapel H"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: ":"

Phrase: "Outbreak of acute hepatitis C"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C0012652:outbreak [Phenomenon or Process]

Phrase: "following"
Meta Candidates (Total=3; Excluded=2; Pruned=0; Remaining=1)
  1000   C0332282:Following [Temporal Concept]
   966 E C0332283:follow [Temporal Concept]
   966 E C1719822:Follow [Intellectual Product]

Phrase: "the use of anti hepatitis C virus-screened intravenous immunoglobulin therapy."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   756   C1524063:Use of [Functional Concept]
   754   C1522726:Intravenous use [Functional Concept]
   738   C0042153:use [Functional Concept]
   738   C0457083:Use [Functional Concept]
   738   C1947944:Use [Intellectual Product]
Processing 00000000.tx.180: Gastroenterology 110:1120, 1996[Medline] [OrderarticleviaInfotrieve] 18. 

Phrase: "Gastroenterology 110"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017163:Gastroenterology [Biomedical Occupation or Discipline]

Phrase: ":"

Phrase: "1120,"

Phrase: "1996"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 18."
Processing 00000000.tx.181: Fong TL, Valinluck B, Govindarajan S, Charboneau F, Adkins RH, Redeker AG: Short-term prednisone therapy affects aminotransferase activity and hepatitis C virus RNA levels in chronic hepatitis C. 

Phrase: "Fong TL,"

Phrase: "Valinluck B,"

Phrase: "Govindarajan S,"

Phrase: "Charboneau F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Adkins RH,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0035493:Rh [Element, Ion, or Isotope]
   861   C2699077:Rh- [Classification]
   861   C2699078:Rh+ [Classification]

Phrase: "Redeker AG"

Phrase: ":"

Phrase: "Short-term prednisone therapy"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   812   C0039798:therapy [Functional Concept]
   812   C0087111:Therapy [Therapeutic or Preventive Procedure]
   812   C1363945:Therapy [Finding]

Phrase: "affects"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0001721:Affect [Mental Process]

Phrase: "aminotransferase activity"
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C1152208:aminotransferase activity [Molecular Function]
   861   C0205177:Activity [Functional Concept]
   861   C0439167:% activity [Quantitative Concept]
   861   C0441655:Activity [Activity]
   861   C1561536:*Activity [Idea or Concept]

Phrase: "and"

Phrase: "hepatitis C virus RNA levels in chronic hepatitis C."
Meta Candidates (Total=19; Excluded=3; Pruned=0; Remaining=16)
   818   C0369335:Hepatitis C virus RNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]
   790   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   784   C0855840:hepatitis c rna [Laboratory Procedure]
   764   C0019196:Hepatitis C [Disease or Syndrome]
   764   C0035691:Virus-RNA [Virus]
   764   C0035736:virus RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   762   C0019186:Hepatitis virus [Virus]
   762   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   742   C0019158:Hepatitis [Disease or Syndrome]
   742   C0019159:hepatitis [Disease or Syndrome]
   742   C0035668:RNA [Nucleic Acid, Nucleoside, or Nucleotide]
   742   C0042776:Virus [Virus]
   742   C0319157:virus [Virus]
   742   C0441889:Levels [Qualitative Concept]
   742   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
   708 E C0456079:Level [Classification]
   708 E C1547707:Level [Geographic Area]
   708 E C2946261:Level [Pharmacologic Substance]
Processing 00000000.tx.182: Gastroenterology 104:196, 1994[Medline] [OrderarticleviaInfotrieve] 19. 

Phrase: "Gastroenterology 104"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017163:Gastroenterology [Biomedical Occupation or Discipline]

Phrase: ":"

Phrase: "196,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 19."
Processing 00000000.tx.183: Magrin S, Craxi A, Fabiano C, Scimonetti RG, Fiorentino G, Marino L, Diquattro O, Di Marco V, Loiacono O, Volpes R, Almasio P, Urdea MS, Neuwald P, Sanchez-Prescador R, Detmer J, Wilber JC, Pagliaro L: Hepatitis C viremia in chronic liver disease: Relationship to interferon-alfa or corticosteroid treatment. 

Phrase: "Magrin S,"

Phrase: "Craxi A,"

Phrase: "Fabiano C,"

Phrase: "Scimonetti RG,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1412999:RG [Gene or Genome]

Phrase: "Fiorentino G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0439267:g% [Quantitative Concept]

Phrase: "Marino L,"

Phrase: "Diquattro O,"

Phrase: "Di Marco V,"

Phrase: "Loiacono O,"

Phrase: "Volpes R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Almasio P,"

Phrase: "Urdea MS,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0039676:MS [Amino Acid, Peptide, or Protein,Enzyme]
   861   C2349943:Ms. [Conceptual Entity]
   861   C3539704:MS [Gene or Genome]

Phrase: "Neuwald P,"

Phrase: "Sanchez-Prescador R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0205090:R- [Spatial Concept]
   827   C0684010:R. [Professional or Occupational Group]
   827   C2603358:R' [Clinical Attribute]

Phrase: "Detmer J,"

Phrase: "Wilber JC,"

Phrase: "Pagliaro L"

Phrase: ":"

Phrase: "Hepatitis C viremia in chronic liver disease"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   748   C0042749:Viraemia [Disease or Syndrome]

Phrase: ":"

Phrase: "Relationship to interferon-alfa"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   770   C0439849:Relationship [Qualitative Concept]
   770   C1705630:Relationship [Idea or Concept]
   770   C1706279:Relationship [Idea or Concept]
   770   C3540605:Relationship [Intellectual Product]

Phrase: "or"

Phrase: "corticosteroid treatment."
Meta Candidates (Total=6; Excluded=0; Pruned=0; Remaining=6)
   861   C0039798:treatment [Functional Concept]
   861   C0087111:Treatment [Therapeutic or Preventive Procedure]
   861   C1522326:Treatment [Functional Concept]
   861   C1533734:Treatment [Therapeutic or Preventive Procedure]
   861   C1705169:Treatment [Conceptual Entity]
   861   C3538994:TREATMENT [Research Activity]
Processing 00000000.tx.184: Hepatology 19:273, 1994[Medline] [OrderarticleviaInfotrieve] 20. 

Phrase: "Hepatology 19"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0086403:Hepatology [Biomedical Occupation or Discipline]
   861   C1555763:Hepatology [Professional or Occupational Group]

Phrase: ":"

Phrase: "273,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 20."
Processing 00000000.tx.185: Brink NS, Chopra R, Perrons CJ, Ring CIA, Garson JA, Briggs EM, Goldstone AH, Linch DC, Tedder RS: Acute hepatitis C infection in patients undergoing therapy for haematological malignancies: A clinical and virological study. 

Phrase: "Brink NS,"

Phrase: "Chopra R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0205090:R- [Spatial Concept]
   861   C0684010:R. [Professional or Occupational Group]
   861   C2603358:R' [Clinical Attribute]

Phrase: "Perrons CJ,"

Phrase: "Ring CIA,"

Phrase: "Garson JA,"

Phrase: "Briggs EM,"

Phrase: "Goldstone AH,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C1836672:AH [Disease or Syndrome]

Phrase: "Linch DC,"

Phrase: "Tedder RS"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3539879:RS [Idea or Concept]

Phrase: ":"

Phrase: "Acute hepatitis C infection in patients"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   833   C0019196:Hepatitis C Infection [Disease or Syndrome]
   783   C0275518:Acute infection [Disease or Syndrome]
   753   C0009450:Infection, NOS [Disease or Syndrome]
   748   C0019159:Hepatitis, Infectious [Disease or Syndrome]

Phrase: "undergoing"

Phrase: "therapy for haematological malignancies"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   770   C0039798:therapy [Functional Concept]
   770   C0087111:Therapy [Therapeutic or Preventive Procedure]
   770   C1363945:Therapy [Finding]

Phrase: ":"

Phrase: "A clinical"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0205210:Clinical [Qualitative Concept]

Phrase: "and"

Phrase: "virological study."
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0557651:Study [Manufactured Object]
   861   C2603343:Study [Research Activity]
Processing 00000000.tx.186: Br J Haematol 83:498, 1993[Medline] [OrderarticleviaInfotrieve] 21. 

Phrase: "Br J Haematol 83"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1704648:Br. [Conceptual Entity]

Phrase: ":"

Phrase: "498,"

Phrase: "1993"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 21."
Processing 00000000.tx.187: Chazouilleres O, Kim M, Combs C, Ferrel L, Baccheti P, Roberts J, Asher NL, Neuwald P, Wilber J, Quan S, Sanchez-Pescador R, Wright TL: Quantitation of hepatitis C virus RNA in liver transplant recipients. 

Phrase: "Chazouilleres O,"

Phrase: "Kim M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Combs C,"

Phrase: "Ferrel L,"

Phrase: "Baccheti P,"

Phrase: "Roberts J,"

Phrase: "Asher NL,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0027778:NL [Geographic Area]
   861   C0560008:nL [Quantitative Concept]

Phrase: "Neuwald P,"

Phrase: "Wilber J,"

Phrase: "Quan S,"

Phrase: "Sanchez-Pescador R,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   827   C0205090:R- [Spatial Concept]
   827   C0684010:R. [Professional or Occupational Group]
   827   C2603358:R' [Clinical Attribute]

Phrase: "Wright TL"

Phrase: ":"

Phrase: "Quantitation of hepatitis C virus RNA"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   753   C1709793:Quantitation [Quantitative Concept]
   716   C0369335:Hepatitis C virus RNA [Biologically Active Substance,Nucleic Acid, Nucleoside, or Nucleotide]

Phrase: "in liver transplant recipients."
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   901   C0376387:Transplant Recipients [Patient or Disabled Group]
   793   C1709854:Recipient [Human]
   734   C0023911:Liver Transplant [Therapeutic or Preventive Procedure]
   734   C0040746:Liver transplant [Body Part, Organ, or Organ Component]
Processing 00000000.tx.188: Gastroenterology 106:994, 1994[Medline] [OrderarticleviaInfotrieve] 22. 

Phrase: "Gastroenterology 106"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017163:Gastroenterology [Biomedical Occupation or Discipline]

Phrase: ":"

Phrase: "994,"

Phrase: "1994"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 22."
Processing 00000000.tx.189: Vento S, Cainelli F, Mirandola F, Cosco L, Di Perri G, Solbiati M, Ferraro T, Concia E: Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus. 

Phrase: "Vento S,"

Phrase: "Cainelli F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Mirandola F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Cosco L,"

Phrase: "Di Perri G,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   827   C0439267:g% [Quantitative Concept]

Phrase: "Solbiati M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Ferraro T,"

Phrase: "Concia E"

Phrase: ":"

Phrase: "Fulminant hepatitis on withdrawal of chemotherapy"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   790   C0302809:Fulminant hepatitis [Disease or Syndrome]
   753   C0019158:Hepatitis [Disease or Syndrome]
   753   C0019159:hepatitis [Disease or Syndrome]
   753   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "in carriers"
Meta Candidates (Total=4; Excluded=3; Pruned=0; Remaining=1)
  1000   C0007294:carriers [Finding]
   966 E C0560175:Carrier [Finding]
   966 E C1706209:Carrier [Medical Device]
   966 E C3273162:Carrier [Intellectual Product]

Phrase: "of hepatitis C virus."
Meta Candidates (Total=9; Excluded=0; Pruned=0; Remaining=9)
  1000   C0220847:Hepatitis C virus [Virus]
           Hepatitis C
   913   C0019186:Hepatitis virus [Virus]
   901   C0019196:Hepatitis C [Disease or Syndrome]
   827   C0019158:Hepatitis [Disease or Syndrome]
   827   C0019159:hepatitis [Disease or Syndrome]
   827   C0042776:Virus [Virus]
   827   C0319157:virus [Virus]
   827   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]
Processing 00000000.tx.190: Lancet 347:92, 1996[Medline] [OrderarticleviaInfotrieve] 23. 

Phrase: "Lancet 347"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0777169:Lancet [Medical Device]

Phrase: ":"

Phrase: "92,"

Phrase: "1996"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 23."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0450348:23 [Quantitative Concept]
Processing 00000000.tx.191: Fan FS, Tzeng CH, Hsiao KI, Hu ST, Lin WT, Chen PM: Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C. 

Phrase: "Fan FS,"

Phrase: "Tzeng CH,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0558269:Ch. [Professional or Occupational Group]
   861   C1552984:[Ch] [Quantitative Concept]

Phrase: "Hsiao KI,"

Phrase: "Hu ST,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C3272372:ST [Intellectual Product]

Phrase: "Lin WT,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C2700323:WT [Fish]

Phrase: "Chen"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0999213:Chen [Bird]

Phrase: "PM"

Phrase: ":"

Phrase: "Withdrawal of immunosuppressive therapy"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   770   C2349954:Withdrawal [Activity]
   770   C2825032:Withdrawal [Mental or Behavioral Dysfunction]

Phrase: "in allogeneic bone marrow transplantation"
Meta Candidates (Total=22; Excluded=5; Pruned=0; Remaining=17)
  1000   C0149615:Allogeneic bone marrow transplantation [Therapeutic or Preventive Procedure]
   923   C0005961:Bone Marrow Transplantation [Therapeutic or Preventive Procedure]
           Marrow Transplantation
   902   C0040739:Transplantation, Allogeneic [Therapeutic or Preventive Procedure]
   875   C0005976:Bone Transplantation [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   812   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   812   C0040733:transplantation [Functional Concept]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1515895:Allogeneic [Qualitative Concept]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]

Phrase: "reactivates"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0521123:reactivate [Functional Concept]

Phrase: "chronic viral hepatitis C."
Meta Candidates (Total=7; Excluded=0; Pruned=0; Remaining=7)
  1000   C0524910:Chronic viral hepatitis C [Disease or Syndrome]
           Hepatitis C, Chronic
   923   C0019196:Viral hepatitis C [Disease or Syndrome]
           Hepatitis C
   861   C0220847:Hepatitis C [Virus]
   756   C0276623:Chronic viral hepatitis [Disease or Syndrome]
   708   C0019189:Hepatitis, Chronic [Disease or Syndrome]
Processing 00000000.tx.192: Bone Marrow Transplant 8:417, 1991[Medline] [OrderarticleviaInfotrieve] 24. 

Phrase: "Bone Marrow Transplant 8"
Meta Candidates (Total=17; Excluded=5; Pruned=0; Remaining=12)
   923   C0005961:Bone Marrow Transplant [Therapeutic or Preventive Procedure]
   875   C0005976:Bone transplant [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0040732:Transplant [Therapeutic or Preventive Procedure]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0332835:Transplant [Tissue]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]

Phrase: ":"

Phrase: "417,"

Phrase: "1991"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 24."
Processing 00000000.tx.193: Gruber A, Lundberg LG, Bjoerkholm M: Reactivation of chronic hepatitis C after withdrawal of immunosuppressive therapy. 

Phrase: "Gruber"

Phrase: "A,"

Phrase: "Lundberg LG,"

Phrase: "Bjoerkholm M"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: ":"

Phrase: "Reactivation of chronic hepatitis C"

Phrase: "after withdrawal"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
  1000   C2349954:Withdrawal [Activity]
  1000   C2825032:Withdrawal [Mental or Behavioral Dysfunction]

Phrase: "of immunosuppressive therapy."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
  1000   C0021079:Immunosuppressive therapy [Therapeutic or Preventive Procedure]
   861   C0021081:immunosuppressive [Immunologic Factor,Pharmacologic Substance]
   861   C0039798:therapy [Functional Concept]
   861   C0087111:Therapy [Therapeutic or Preventive Procedure]
   861   C1363945:Therapy [Finding]
Processing 00000000.tx.194: J Intern Med 234:223, 1993[Medline] [OrderarticleviaInfotrieve] 25. 

Phrase: "J Intern Med 234"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C1144859:INTERN [Professional or Occupational Group]

Phrase: ":"

Phrase: "223,"

Phrase: "1993"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 25."
Processing 00000000.tx.195: Kanamori H, Fukawa H, Maruta A, Harano H, Kodama F, Matzuzaki M, Miyashita H, Motomura S, Okubo T, Yoshiba M, Sekiyama K: Case report: Fulminant hepatitis C viral infection after allogeneic bone marrow transplantation. 

Phrase: "Kanamori H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Fukawa H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Maruta A,"

Phrase: "Harano H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Kodama F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Matzuzaki M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Miyashita H,"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   861   C0033727:H+ [Element, Ion, or Isotope]
   861   C0369286:H NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441932:H+ [Classification]
   861   C0564385:/h [Quantitative Concept]

Phrase: "Motomura S,"

Phrase: "Okubo T,"

Phrase: "Yoshiba M,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0369637:M NOS [Amino Acid, Peptide, or Protein,Immunologic Factor]
   861   C0441923:M+ [Intellectual Product]

Phrase: "Sekiyama K"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0597277:K+ [Element, Ion, or Isotope,Pharmacologic Substance]
   861   C1708601:K' [Quantitative Concept]

Phrase: ":"

Phrase: "Case report"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
  1000   C0007320:case report [Intellectual Product]
  1000   C0085973:Case Report [Intellectual Product]
   861   C0684224:Report [Intellectual Product]
   861   C0700287:Report [Health Care Activity]
   861   C0868928:Case [Functional Concept]
   861   C1706255:CASE [Medical Device]
   861   C1706256:Case [Conceptual Entity]
   861   C3273238:Report [Intellectual Product]

Phrase: ":"

Phrase: "Fulminant hepatitis C viral infection after allogeneic bone marrow transplantation."
Meta Candidates (Total=12; Excluded=0; Pruned=0; Remaining=12)
   777   C0019196:Hepatitis C Infection [Disease or Syndrome]
           Viral hepatitis C
   760   C0042769:Viral infection [Disease or Syndrome]
   757   C0029443:bone infection [Disease or Syndrome]
   757   C0042721:Viral hepatitis [Disease or Syndrome]
   757   C1537065:transplantation infection [Pathologic Function]
   757   C1963279:Viral hepatitis [Finding]
   757   C2242472:Bone infection [Disease or Syndrome]
   751   C0019159:Infectious Viral Hepatitis [Disease or Syndrome]
           Hepatitis, Infectious
   739   C0009450:Infection, NOS [Disease or Syndrome]
   739   C0521026:Viral [Functional Concept]
Processing 00000000.tx.196: Am J Med Sci 303:109, 1992[Medline] [OrderarticleviaInfotrieve] 26. 

Phrase: "Am"

Phrase: "J Med Sci 303"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   812   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "109,"

Phrase: "1992"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 26."
Processing 00000000.tx.197: Pariente EA, Goudeau A, Dubois F, Degott C, Gluckman E, Devergie A, Brechot C, Schenmetzler C, Bernuau J: Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation. 

Phrase: "Pariente EA,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0014963:EA [Organic Chemical,Pharmacologic Substance]
   861   C1457900:EA [Quantitative Concept]

Phrase: "Goudeau A,"

Phrase: "Dubois F,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
   861   C0016327:F- [Inorganic Chemical,Pharmacologic Substance]
   861   C0439133:(f) [Intellectual Product]
   861   C1553038:[f] [Quantitative Concept]

Phrase: "Degott C,"

Phrase: "Gluckman E,"

Phrase: "Devergie A,"

Phrase: "Brechot C,"

Phrase: "Schenmetzler C,"

Phrase: "Bernuau J"

Phrase: ":"

Phrase: "Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection"
Meta Candidates (Total=13; Excluded=0; Pruned=0; Remaining=13)
   792   C0400894:Hepatitis due to infection [Disease or Syndrome]
   772   C0019169:Hepatitis B Virus [Virus]
   770   C0019163:Hepatitis B infection [Disease or Syndrome]
           Hepatitis B
   756   C0302809:Fulminant hepatitis [Disease or Syndrome]
   754   C0019186:Hepatitis virus [Virus]
   754   C0042721:VIRUS HEPATITIS [Disease or Syndrome]
   746   C0019160:Hepatitis Virus, Infectious [Virus]
   746   C0376325:Infectious hepatitis virus [Virus]
   738   C0019158:Hepatitis [Disease or Syndrome]
   738   C0019159:hepatitis [Disease or Syndrome]
           Hepatitis, Infectious
   738   C0795623:hepatitis [Immunologic Factor,Pharmacologic Substance]

Phrase: "after allogeneic bone marrow transplantation."
Meta Candidates (Total=22; Excluded=5; Pruned=0; Remaining=17)
  1000   C0149615:Allogeneic bone marrow transplantation [Therapeutic or Preventive Procedure]
   923   C0005961:Bone Marrow Transplantation [Therapeutic or Preventive Procedure]
           Marrow Transplantation
   902   C0040739:Transplantation, Allogeneic [Therapeutic or Preventive Procedure]
   875   C0005976:Bone Transplantation [Therapeutic or Preventive Procedure]
   861   C0005953:Bone Marrow [Tissue]
   812   C0029216:Transplantation [Therapeutic or Preventive Procedure]
   812   C0040732:Transplantation [Therapeutic or Preventive Procedure]
   812   C0040733:transplantation [Functional Concept]
   812   C0086590:Marrow [Food]
   812   C0262950:Bone, NOS [Body Part, Organ, or Organ Component]
   812   C0376152:Marrow [Body Part, Organ, or Organ Component]
   812   C0391978:Bone [Tissue]
   812   C1266908:Bone [Body Part, Organ, or Organ Component]
   812   C1266909:Bone [Body System]
   812   C1515895:Allogeneic [Qualitative Concept]
   812   C1546708:Marrow [Intellectual Product]
   756 E C0001629:Medullary [Body Part, Organ, or Organ Component]
   756 E C0025148:Medullary [Body Part, Organ, or Organ Component]
   756 E C1550278:Medullary [Body Part, Organ, or Organ Component]
   741 E C0443157:Bony [Functional Concept]
   729 E C0330477:Marrows [Plant]
Processing 00000000.tx.198: Dig Dis Sci 33:1185, 1988[Medline] [OrderarticleviaInfotrieve] 27. 

Phrase: "Dig Dis Sci 33"
Meta Candidates (Total=4; Excluded=0; Pruned=0; Remaining=4)
   812   C0451119:DIS [Intellectual Product]
   812   C1321878:DIG [Neoplastic Process]
   812   C1444662:DIS [Finding]
   812   C3642273:SCI [Professional or Occupational Group]

Phrase: ":"

Phrase: "1185,"

Phrase: "1988"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 27."
Processing 00000000.tx.199: Alter MJ: The detection, transmission, and outcome of hepatitis C virus infection. 

Phrase: "Alter"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   916   C0392747:Altered [Functional Concept]

Phrase: "MJ"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0439254:MJ [Medical Device]

Phrase: ":"

Phrase: "The detection,"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C1511790:Detection [Therapeutic or Preventive Procedure]

Phrase: "transmission,"
Meta Candidates (Total=3; Excluded=0; Pruned=0; Remaining=3)
  1000   C0040722:transmission [Idea or Concept]
  1000   C0242781:Transmission [Pathologic Function]
  1000   C1521797:Transmission [Natural Phenomenon or Process]

Phrase: "and"

Phrase: "outcome of hepatitis C virus infection."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   753   C1274040:Outcome [Functional Concept]
Processing 00000000.tx.200: Infectious Agents Dis 2:155, 1993[Medline] [OrderarticleviaInfotrieve] 28. 

Phrase: "Infectious Agents Dis 2"
Meta Candidates (Total=9; Excluded=2; Pruned=0; Remaining=7)
   861   C0314732:Infectious Agents [Organism]
   812   C0451119:DIS [Intellectual Product]
   812   C1444662:DIS [Finding]
   779   C0450442:Agent [Chemical Viewed Functionally]
   779   C1254351:Agent [Pharmacologic Substance]
   779   C1521826:Agent [Intellectual Product]
   741   C0009450:Infection, NOS [Disease or Syndrome]
   719 E C0030657:infectivity [Qualitative Concept]
   712 E C0439663:Infected [Functional Concept]

Phrase: ":"

Phrase: "155,"

Phrase: "1993"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "] 28."
Processing 00000000.tx.201: Que FG, Gores GJ: Cell death by apoptosis: Basic concepts and disease relevance for the gastroenterologist. 

Phrase: "Que FG,"
Meta Candidates (Total=2; Excluded=0; Pruned=0; Remaining=2)
   861   C0439214:fg [Quantitative Concept]
   861   C2348814:FG [Quantitative Concept]

Phrase: "Gores GJ"

Phrase: ":"

Phrase: "Cell death by apoptosis"
Meta Candidates (Total=8; Excluded=0; Pruned=0; Remaining=8)
   846   C0162638:apoptotic cell death [Cell Function]
   833   C0007587:Cell Death [Cell Function]
   770   C0007634:Cell [Cell]
   770   C0011065:Death [Organism Function]
   770   C1269647:Cell [Cell]
   770   C1306577:Death, NOS [Finding]
   770   C1704653:Cell [Medical Device]
   770   C1948049:Cell [Spatial Concept]

Phrase: ":"

Phrase: "Basic concepts"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0178566:concepts [Idea or Concept]

Phrase: "and"

Phrase: "disease relevance for the gastroenterologist."
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   760   C2347946:Relevance [Qualitative Concept]
Processing 00000000.tx.202: Gastroenterology 110:1238, 1996[Medline] [OrderarticleviaInfotrieve]  1997 by The American Society of Hematology.

Phrase: "Gastroenterology 110"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
   861   C0017163:Gastroenterology [Biomedical Occupation or Discipline]

Phrase: ":"

Phrase: "1238,"

Phrase: "1996"

Phrase: "[Medline"
Meta Candidates (Total=1; Excluded=0; Pruned=0; Remaining=1)
  1000   C0025141:MEDLINE [Intellectual Product]

Phrase: "]"

Phrase: "[OrderarticleviaInfotrieve"

Phrase: "]  1997 by The American Society of Hematology."
Meta Candidates (Total=5; Excluded=0; Pruned=0; Remaining=5)
   853   C1515949:American Society of Hematology [Professional Society]
   748   C0018943:Haematology NOS [Biomedical Occupation or Discipline]
   748   C0037455:society [Organization]
   748   C0200627:HEMATOLOGY [Laboratory Procedure]
   748   C0596070:American [Population Group]

